WO2004072080A1 - Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of hsp90 complex activity - Google Patents
Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of hsp90 complex activity Download PDFInfo
- Publication number
- WO2004072080A1 WO2004072080A1 PCT/US2004/003922 US2004003922W WO2004072080A1 WO 2004072080 A1 WO2004072080 A1 WO 2004072080A1 US 2004003922 W US2004003922 W US 2004003922W WO 2004072080 A1 WO2004072080 A1 WO 2004072080A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- phenyl
- amino
- alkoxy
- compound
- Prior art date
Links
- 230000000694 effects Effects 0.000 title claims abstract description 31
- 101100016370 Danio rerio hsp90a.1 gene Proteins 0.000 title 1
- 101100285708 Dictyostelium discoideum hspD gene Proteins 0.000 title 1
- 101100071627 Schizosaccharomyces pombe (strain 972 / ATCC 24843) swo1 gene Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 242
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 claims abstract description 111
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 claims abstract description 110
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 70
- 238000000034 method Methods 0.000 claims abstract description 56
- 201000010099 disease Diseases 0.000 claims abstract description 38
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 33
- 208000035475 disorder Diseases 0.000 claims abstract description 32
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 29
- 201000011510 cancer Diseases 0.000 claims abstract description 26
- 241000282414 Homo sapiens Species 0.000 claims abstract description 13
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 9
- 239000003937 drug carrier Substances 0.000 claims abstract description 8
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 8
- 230000004770 neurodegeneration Effects 0.000 claims abstract description 7
- 230000001363 autoimmune Effects 0.000 claims abstract description 4
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 157
- 229910052736 halogen Inorganic materials 0.000 claims description 84
- 150000002367 halogens Chemical class 0.000 claims description 84
- -1 hydroxy, amino Chemical group 0.000 claims description 77
- 125000001424 substituent group Chemical group 0.000 claims description 74
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 71
- 239000000203 mixture Substances 0.000 claims description 62
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 42
- 239000001257 hydrogen Substances 0.000 claims description 40
- 229910052739 hydrogen Inorganic materials 0.000 claims description 40
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 36
- 125000000217 alkyl group Chemical group 0.000 claims description 36
- 108090000623 proteins and genes Proteins 0.000 claims description 36
- 102000004169 proteins and genes Human genes 0.000 claims description 35
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 33
- YVXDYWWLMNAMST-UHFFFAOYSA-N azanylidyne-[hydroxysulfamoyl(nitro)amino]methane Chemical compound ONS(=O)(=O)N(C#N)[N+]([O-])=O YVXDYWWLMNAMST-UHFFFAOYSA-N 0.000 claims description 30
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 27
- 210000004027 cell Anatomy 0.000 claims description 26
- 239000004202 carbamide Substances 0.000 claims description 23
- 125000003545 alkoxy group Chemical group 0.000 claims description 21
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 21
- 239000000758 substrate Substances 0.000 claims description 21
- 229910052760 oxygen Inorganic materials 0.000 claims description 20
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 16
- 125000001072 heteroaryl group Chemical group 0.000 claims description 16
- 229910052717 sulfur Inorganic materials 0.000 claims description 16
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 15
- 125000005842 heteroatom Chemical group 0.000 claims description 14
- 125000004076 pyridyl group Chemical group 0.000 claims description 14
- 125000002883 imidazolyl group Chemical group 0.000 claims description 13
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 12
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 12
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 12
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 12
- 150000002431 hydrogen Chemical class 0.000 claims description 11
- 125000004043 oxo group Chemical group O=* 0.000 claims description 11
- 210000004881 tumor cell Anatomy 0.000 claims description 11
- 125000002541 furyl group Chemical group 0.000 claims description 10
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 10
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 10
- 125000002971 oxazolyl group Chemical group 0.000 claims description 10
- 125000001544 thienyl group Chemical group 0.000 claims description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 9
- 241000124008 Mammalia Species 0.000 claims description 9
- 125000001246 bromo group Chemical group Br* 0.000 claims description 9
- 230000004663 cell proliferation Effects 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 239000001301 oxygen Substances 0.000 claims description 8
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 8
- XAFVEIHYUUZMEN-UHFFFAOYSA-N azanylidyne-[nitro(sulfamoyl)amino]methane Chemical compound NS(=O)(=O)N(C#N)[N+]([O-])=O XAFVEIHYUUZMEN-UHFFFAOYSA-N 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims description 7
- 229940124530 sulfonamide Drugs 0.000 claims description 7
- 150000003456 sulfonamides Chemical class 0.000 claims description 7
- 239000006188 syrup Substances 0.000 claims description 7
- 235000020357 syrup Nutrition 0.000 claims description 7
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 5
- 125000001153 fluoro group Chemical group F* 0.000 claims description 5
- 241000282326 Felis catus Species 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 238000000099 in vitro assay Methods 0.000 claims description 4
- 125000004193 piperazinyl group Chemical group 0.000 claims description 4
- 125000003386 piperidinyl group Chemical group 0.000 claims description 4
- 239000011593 sulfur Substances 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 125000002757 morpholinyl group Chemical group 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- 206010067484 Adverse reaction Diseases 0.000 claims description 2
- 230000006838 adverse reaction Effects 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 229940054534 ophthalmic solution Drugs 0.000 claims description 2
- 239000002997 ophthalmic solution Substances 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 4
- BFWQPZLWSXUQIV-UHFFFAOYSA-N 1-(2-methylphenyl)-3-[3-[8-(4-phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea Chemical compound CC1=CC=CC=C1NC(=O)NC1=CC=CC(C=2N=C(C3=NC=CN3C=2)N2C=C(N=C2)C=2C=CC=CC=2)=C1 BFWQPZLWSXUQIV-UHFFFAOYSA-N 0.000 claims 1
- CZJFIQQNYDNLJX-UHFFFAOYSA-N 1-(2-methylsulfanylphenyl)-3-[3-[8-(2-phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea Chemical compound CSC1=CC=CC=C1NC(=O)NC1=CC=CC(C=2N=C(C3=NC=CN3C=2)N2C(=NC=C2)C=2C=CC=CC=2)=C1 CZJFIQQNYDNLJX-UHFFFAOYSA-N 0.000 claims 1
- BVDHVYCJDLKKDR-UHFFFAOYSA-N 1-(3-chloro-4-fluorophenyl)-3-[3-[8-(2-phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea Chemical compound C1=C(Cl)C(F)=CC=C1NC(=O)NC1=CC=CC(C=2N=C(C3=NC=CN3C=2)N2C(=NC=C2)C=2C=CC=CC=2)=C1 BVDHVYCJDLKKDR-UHFFFAOYSA-N 0.000 claims 1
- QHXFNKDAQBHEHR-UHFFFAOYSA-N 1-(3-chloro-4-fluorophenyl)-3-[3-[8-(2-propan-2-ylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea Chemical compound CC(C)C1=NC=CN1C1=NC(C=2C=C(NC(=O)NC=3C=C(Cl)C(F)=CC=3)C=CC=2)=CN2C1=NC=C2 QHXFNKDAQBHEHR-UHFFFAOYSA-N 0.000 claims 1
- JHYPMLPMNJONNA-UHFFFAOYSA-N 1-(4-chlorophenyl)-3-[3-[8-(4-phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea Chemical compound C1=CC(Cl)=CC=C1NC(=O)NC1=CC=CC(C=2N=C(C3=NC=CN3C=2)N2C=C(N=C2)C=2C=CC=CC=2)=C1 JHYPMLPMNJONNA-UHFFFAOYSA-N 0.000 claims 1
- PRLTWINTDFQCBM-UHFFFAOYSA-N 1-(4-chlorophenyl)-3-[3-[8-[2-(2-fluorophenyl)imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]urea Chemical compound FC1=CC=CC=C1C1=NC=CN1C1=NC(C=2C=C(NC(=O)NC=3C=CC(Cl)=CC=3)C=CC=2)=CN2C1=NC=C2 PRLTWINTDFQCBM-UHFFFAOYSA-N 0.000 claims 1
- KZDQBZCZNHWOLY-UHFFFAOYSA-N 1-(4-chlorophenyl)-3-[3-[8-[2-(2-methoxyphenyl)imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]urea Chemical compound COC1=CC=CC=C1C1=NC=CN1C1=NC(C=2C=C(NC(=O)NC=3C=CC(Cl)=CC=3)C=CC=2)=CN2C1=NC=C2 KZDQBZCZNHWOLY-UHFFFAOYSA-N 0.000 claims 1
- UQVAZHKOTSHRBK-UHFFFAOYSA-N 1-[3-[8-[2-(2-fluorophenyl)imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-[3-(trifluoromethyl)phenyl]urea Chemical compound FC1=CC=CC=C1C1=NC=CN1C1=NC(C=2C=C(NC(=O)NC=3C=C(C=CC=3)C(F)(F)F)C=CC=2)=CN2C1=NC=C2 UQVAZHKOTSHRBK-UHFFFAOYSA-N 0.000 claims 1
- BAGAKUYRXQBKJB-UHFFFAOYSA-N 1-[3-[8-[2-(4-chlorophenyl)imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-[(4-chlorophenyl)methyl]urea Chemical compound C1=CC(Cl)=CC=C1CNC(=O)NC1=CC=CC(C=2N=C(C3=NC=CN3C=2)N2C(=NC=C2)C=2C=CC(Cl)=CC=2)=C1 BAGAKUYRXQBKJB-UHFFFAOYSA-N 0.000 claims 1
- DOUBMQHIWJGGLT-UHFFFAOYSA-N 1-[3-[8-[2-(4-chlorophenyl)imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-[4-(morpholin-4-ylmethyl)phenyl]urea Chemical compound C1=CC(Cl)=CC=C1C1=NC=CN1C1=NC(C=2C=C(NC(=O)NC=3C=CC(CN4CCOCC4)=CC=3)C=CC=2)=CN2C1=NC=C2 DOUBMQHIWJGGLT-UHFFFAOYSA-N 0.000 claims 1
- LVSDARIOPLJDHJ-UHFFFAOYSA-N 1-[3-[8-[4-(4-chlorophenyl)imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(2-methylphenyl)urea Chemical compound CC1=CC=CC=C1NC(=O)NC1=CC=CC(C=2N=C(C3=NC=CN3C=2)N2C=C(N=C2)C=2C=CC(Cl)=CC=2)=C1 LVSDARIOPLJDHJ-UHFFFAOYSA-N 0.000 claims 1
- MCJUPAGPFFOYKX-UHFFFAOYSA-N 2,6-dimethyl-n-[3-[8-(2-phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]benzamide Chemical compound CC1=CC=CC(C)=C1C(=O)NC1=CC=CC(C=2N=C(C3=NC=CN3C=2)N2C(=NC=C2)C=2C=CC=CC=2)=C1 MCJUPAGPFFOYKX-UHFFFAOYSA-N 0.000 claims 1
- 208000036647 Medication errors Diseases 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- CRYLBQFUJDWANW-UHFFFAOYSA-N n-[3-[8-[2-(4-chlorophenyl)imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]-2-[3-(trifluoromethyl)phenyl]acetamide Chemical compound FC(F)(F)C1=CC=CC(CC(=O)NC=2C=C(C=CC=2)C=2N=C(C3=NC=CN3C=2)N2C(=NC=C2)C=2C=CC(Cl)=CC=2)=C1 CRYLBQFUJDWANW-UHFFFAOYSA-N 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract description 48
- 102000020233 phosphotransferase Human genes 0.000 abstract description 48
- 239000013543 active substance Substances 0.000 abstract description 17
- 208000024891 symptom Diseases 0.000 abstract description 9
- 239000003814 drug Substances 0.000 abstract description 8
- 241001465754 Metazoa Species 0.000 abstract description 7
- 208000037765 diseases and disorders Diseases 0.000 abstract description 7
- 239000003085 diluting agent Substances 0.000 abstract description 5
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 abstract description 4
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 abstract description 4
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 abstract description 4
- 206010033128 Ovarian cancer Diseases 0.000 abstract description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract description 4
- 206010060862 Prostate cancer Diseases 0.000 abstract description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract description 4
- 206010006187 Breast cancer Diseases 0.000 abstract description 3
- 208000026310 Breast neoplasm Diseases 0.000 abstract description 3
- 206010009944 Colon cancer Diseases 0.000 abstract description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract description 3
- 244000144972 livestock Species 0.000 abstract description 3
- 206010005003 Bladder cancer Diseases 0.000 abstract description 2
- 208000003174 Brain Neoplasms Diseases 0.000 abstract description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 abstract description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract description 2
- 210000004556 brain Anatomy 0.000 abstract description 2
- 210000000481 breast Anatomy 0.000 abstract description 2
- 208000019622 heart disease Diseases 0.000 abstract description 2
- 201000001441 melanoma Diseases 0.000 abstract description 2
- 230000002611 ovarian Effects 0.000 abstract description 2
- 210000002307 prostate Anatomy 0.000 abstract description 2
- 208000023516 stroke disease Diseases 0.000 abstract description 2
- 229940124597 therapeutic agent Drugs 0.000 abstract description 2
- 201000002510 thyroid cancer Diseases 0.000 abstract description 2
- 210000001685 thyroid gland Anatomy 0.000 abstract description 2
- 201000005112 urinary bladder cancer Diseases 0.000 abstract description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 41
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 20
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 20
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 19
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 19
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 19
- 150000003839 salts Chemical group 0.000 description 18
- 229910052799 carbon Inorganic materials 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 230000033115 angiogenesis Effects 0.000 description 15
- 238000003556 assay Methods 0.000 description 15
- 238000009472 formulation Methods 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 125000003118 aryl group Chemical group 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 14
- 239000003112 inhibitor Substances 0.000 description 14
- 239000000725 suspension Substances 0.000 description 14
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 125000004429 atom Chemical group 0.000 description 11
- 125000006413 ring segment Chemical group 0.000 description 11
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- GXWNSJYVSIJRLS-UHFFFAOYSA-N 6-bromo-8-methylimidazo[1,2-a]pyrazine Chemical compound CC1=NC(Br)=CN2C=CN=C12 GXWNSJYVSIJRLS-UHFFFAOYSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 101100322915 Caenorhabditis elegans akt-1 gene Proteins 0.000 description 8
- 239000002246 antineoplastic agent Substances 0.000 description 8
- 239000000839 emulsion Substances 0.000 description 8
- 235000019441 ethanol Nutrition 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 230000037361 pathway Effects 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 239000003755 preservative agent Substances 0.000 description 8
- 102000001253 Protein Kinase Human genes 0.000 description 7
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 7
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 7
- 125000003342 alkenyl group Chemical group 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000005754 cellular signaling Effects 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 229960004063 propylene glycol Drugs 0.000 description 7
- 235000013772 propylene glycol Nutrition 0.000 description 7
- 108060006633 protein kinase Proteins 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 235000010356 sorbitol Nutrition 0.000 description 7
- 239000000600 sorbitol Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 6
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 125000000304 alkynyl group Chemical group 0.000 description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000013355 food flavoring agent Nutrition 0.000 description 6
- 235000003599 food sweetener Nutrition 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 125000004430 oxygen atom Chemical group O* 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- 239000000375 suspending agent Substances 0.000 description 6
- 239000003765 sweetening agent Substances 0.000 description 6
- 230000000699 topical effect Effects 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 239000000080 wetting agent Substances 0.000 description 6
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 5
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 5
- 108091008611 Protein Kinase B Proteins 0.000 description 5
- 125000002252 acyl group Chemical group 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 238000010256 biochemical assay Methods 0.000 description 5
- 150000001721 carbon Chemical group 0.000 description 5
- 238000001516 cell proliferation assay Methods 0.000 description 5
- 239000003086 colorant Substances 0.000 description 5
- 239000007859 condensation product Substances 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000002480 mineral oil Substances 0.000 description 5
- 235000010446 mineral oil Nutrition 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 4
- 241000416162 Astragalus gummifer Species 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- 235000019483 Peanut oil Nutrition 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 229920001615 Tragacanth Polymers 0.000 description 4
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 125000001188 haloalkyl group Chemical group 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000000021 kinase assay Methods 0.000 description 4
- 229940043355 kinase inhibitor Drugs 0.000 description 4
- 235000010445 lecithin Nutrition 0.000 description 4
- 239000000787 lecithin Substances 0.000 description 4
- 229940067606 lecithin Drugs 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- 239000004006 olive oil Substances 0.000 description 4
- 235000008390 olive oil Nutrition 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 239000000312 peanut oil Substances 0.000 description 4
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000008159 sesame oil Substances 0.000 description 4
- 235000011803 sesame oil Nutrition 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 125000004434 sulfur atom Chemical group 0.000 description 4
- 229910052722 tritium Inorganic materials 0.000 description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 3
- 108091006112 ATPases Proteins 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 3
- 239000005995 Aluminium silicate Substances 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 208000005623 Carcinogenesis Diseases 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 description 3
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 3
- 102100031983 Ephrin type-B receptor 4 Human genes 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 3
- 229930194542 Keto Natural products 0.000 description 3
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 102100037787 Protein-tyrosine kinase 2-beta Human genes 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 125000004414 alkyl thio group Chemical group 0.000 description 3
- 235000012211 aluminium silicate Nutrition 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000036952 cancer formation Effects 0.000 description 3
- 231100000504 carcinogenesis Toxicity 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000007960 cellular response to stress Effects 0.000 description 3
- 239000003240 coconut oil Substances 0.000 description 3
- 235000019864 coconut oil Nutrition 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 3
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 3
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
- 239000003974 emollient agent Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 3
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 229960004592 isopropanol Drugs 0.000 description 3
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 3
- 125000000468 ketone group Chemical group 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 102000027450 oncoproteins Human genes 0.000 description 3
- 108091008819 oncoproteins Proteins 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 3
- 230000012846 protein folding Effects 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 3
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- KJAXEBRGQOHHOY-VXRVIWLSSA-N (4s)-4-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s,3r)-2-[[(2s)-2-[[(2s)-1-[(2s)-2-[(2-aminoacetyl)amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropan Chemical compound N([C@@H](CCCN=C(N)N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)CN KJAXEBRGQOHHOY-VXRVIWLSSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- LILXDMFJXYAKMK-UHFFFAOYSA-N 2-bromo-1,1-diethoxyethane Chemical compound CCOC(CBr)OCC LILXDMFJXYAKMK-UHFFFAOYSA-N 0.000 description 2
- DTLBKXRFWUERQN-UHFFFAOYSA-N 3,5-dibromopyrazin-2-amine Chemical compound NC1=NC=C(Br)N=C1Br DTLBKXRFWUERQN-UHFFFAOYSA-N 0.000 description 2
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 2
- APRZHQXAAWPYHS-UHFFFAOYSA-N 4-[5-[3-(carboxymethoxy)phenyl]-3-(4,5-dimethyl-1,3-thiazol-2-yl)tetrazol-3-ium-2-yl]benzenesulfonate Chemical compound S1C(C)=C(C)N=C1[N+]1=NC(C=2C=C(OCC(O)=O)C=CC=2)=NN1C1=CC=C(S([O-])(=O)=O)C=C1 APRZHQXAAWPYHS-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 235000006491 Acacia senegal Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 102100032187 Androgen receptor Human genes 0.000 description 2
- 102100034608 Angiopoietin-2 Human genes 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 108010006519 Molecular Chaperones Proteins 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical group C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 230000003281 allosteric effect Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 125000004103 aminoalkyl group Chemical group 0.000 description 2
- 108010080146 androgen receptors Proteins 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 231100000590 oncogenic Toxicity 0.000 description 2
- 230000002246 oncogenic effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000012453 solvate Chemical group 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 2
- 239000002691 unilamellar liposome Substances 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- QBMHZZHJIBUPOX-UHFFFAOYSA-N (3-aminophenyl)boronic acid;hydron;chloride Chemical compound Cl.NC1=CC=CC(B(O)O)=C1 QBMHZZHJIBUPOX-UHFFFAOYSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- LGEZTMRIZWCDLW-UHFFFAOYSA-N 14-methylpentadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C LGEZTMRIZWCDLW-UHFFFAOYSA-N 0.000 description 1
- HDIFHQMREAYYJW-FMIVXFBMSA-N 2,3-dihydroxypropyl (e)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C\CCCCCCCC(=O)OCC(O)CO HDIFHQMREAYYJW-FMIVXFBMSA-N 0.000 description 1
- GXVUZYLYWKWJIM-UHFFFAOYSA-N 2-(2-aminoethoxy)ethanamine Chemical compound NCCOCCN GXVUZYLYWKWJIM-UHFFFAOYSA-N 0.000 description 1
- PNLVPDNPBLOPCP-UHFFFAOYSA-N 2-(4-chlorophenyl)-n-[3-[8-(2-phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]acetamide Chemical compound C1=CC(Cl)=CC=C1CC(=O)NC1=CC=CC(C=2N=C(C3=NC=CN3C=2)N2C(=NC=C2)C=2C=CC=CC=2)=C1 PNLVPDNPBLOPCP-UHFFFAOYSA-N 0.000 description 1
- UMQUIRYNOVNYPA-UHFFFAOYSA-N 2-(4-chlorophenyl)acetyl chloride Chemical compound ClC(=O)CC1=CC=C(Cl)C=C1 UMQUIRYNOVNYPA-UHFFFAOYSA-N 0.000 description 1
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
- 125000005273 2-acetoxybenzoic acid group Chemical group 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- OJIBJRXMHVZPLV-UHFFFAOYSA-N 2-methylpropyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(C)C OJIBJRXMHVZPLV-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000005925 3-methylpentyloxy group Chemical group 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- SINQIEAULQKUPD-UHFFFAOYSA-N 4-[4-(6-methoxy-2-naphthalenyl)-2-(4-methylsulfinylphenyl)-1H-imidazol-5-yl]pyridine Chemical compound C1=CC2=CC(OC)=CC=C2C=C1C=1N=C(C=2C=CC(=CC=2)S(C)=O)NC=1C1=CC=NC=C1 SINQIEAULQKUPD-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- CYGFZUOECZAJFD-UHFFFAOYSA-N 5-(4-methylphenyl)-1h-imidazole Chemical compound C1=CC(C)=CC=C1C1=CN=CN1 CYGFZUOECZAJFD-UHFFFAOYSA-N 0.000 description 1
- AMEMLELAMQEAIA-UHFFFAOYSA-N 6-(tert-butyl)thieno[3,2-d]pyrimidin-4(3H)-one Chemical compound N1C=NC(=O)C2=C1C=C(C(C)(C)C)S2 AMEMLELAMQEAIA-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 244000144927 Aloe barbadensis Species 0.000 description 1
- 235000002961 Aloe barbadensis Nutrition 0.000 description 1
- 102000009088 Angiopoietin-1 Human genes 0.000 description 1
- 108010048154 Angiopoietin-1 Proteins 0.000 description 1
- 102100022014 Angiopoietin-1 receptor Human genes 0.000 description 1
- 108010048036 Angiopoietin-2 Proteins 0.000 description 1
- 101100215673 Arabidopsis thaliana AGL11 gene Proteins 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 239000004358 Butane-1, 3-diol Substances 0.000 description 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 1
- 108091007914 CDKs Proteins 0.000 description 1
- 101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- OAJZORIMPKADIB-UHFFFAOYSA-N Cc(cc1)ccc1-c(nc1)c[n]1-c1nc(-c2cc(NC(Nc3ccccc3C)=O)ccc2)c[n]2c1ncc2 Chemical compound Cc(cc1)ccc1-c(nc1)c[n]1-c1nc(-c2cc(NC(Nc3ccccc3C)=O)ccc2)c[n]2c1ncc2 OAJZORIMPKADIB-UHFFFAOYSA-N 0.000 description 1
- LGJYYGPHRCIABN-UHFFFAOYSA-N Cc(cc1)ccc1-c(nc1)c[n]1-c1nc(-c2cccc(N)c2)c[n]2c1ncc2 Chemical compound Cc(cc1)ccc1-c(nc1)c[n]1-c1nc(-c2cccc(N)c2)c[n]2c1ncc2 LGJYYGPHRCIABN-UHFFFAOYSA-N 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102100038595 Estrogen receptor Human genes 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
- 102100033417 Glucocorticoid receptor Human genes 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 101710113864 Heat shock protein 90 Proteins 0.000 description 1
- CMBYOWLFQAFZCP-UHFFFAOYSA-N Hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 description 1
- 101000753291 Homo sapiens Angiopoietin-1 receptor Proteins 0.000 description 1
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 description 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 208000010038 Ischemic Optic Neuropathy Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 108010022337 Leucine Enkephalin Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000034038 Pathologic Neovascularization Diseases 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 102000001393 Platelet-Derived Growth Factor alpha Receptor Human genes 0.000 description 1
- 108010068588 Platelet-Derived Growth Factor alpha Receptor Proteins 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004146 Propane-1,2-diol Substances 0.000 description 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 101710150974 Regulator of chromosome condensation Proteins 0.000 description 1
- 102100039977 Regulator of chromosome condensation Human genes 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 101150073911 STK gene Proteins 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 229940048299 acetylated lanolin alcohols Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960001456 adenosine triphosphate Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000005466 alkylenyl group Chemical group 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 201000007058 anterior ischemic optic neuropathy Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- GHRQXJHBXKYCLZ-UHFFFAOYSA-L beta-glycerolphosphate Chemical compound [Na+].[Na+].CC(CO)OOP([O-])([O-])=O GHRQXJHBXKYCLZ-UHFFFAOYSA-L 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 125000006580 bicyclic heterocycloalkyl group Chemical group 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- DHAZIUXMHRHVMP-UHFFFAOYSA-N butyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCCCC DHAZIUXMHRHVMP-UHFFFAOYSA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 125000005518 carboxamido group Chemical group 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 210000003793 centrosome Anatomy 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000002153 concerted effect Effects 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- 108010024505 crosstide peptide Proteins 0.000 description 1
- 239000013078 crystal Chemical group 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 210000000448 cultured tumor cell Anatomy 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 description 1
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical class O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229940028356 diethylene glycol monobutyl ether Drugs 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- QQQMUBLXDAFBRH-UHFFFAOYSA-N dodecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCOC(=O)C(C)O QQQMUBLXDAFBRH-UHFFFAOYSA-N 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 108060002566 ephrin Proteins 0.000 description 1
- 102000012803 ephrin Human genes 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229960004667 ethyl cellulose Drugs 0.000 description 1
- 235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
- 239000001761 ethyl methyl cellulose Substances 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000008369 fruit flavor Substances 0.000 description 1
- 229910000286 fullers earth Inorganic materials 0.000 description 1
- 229910021485 fumed silica Inorganic materials 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000006650 fundamental cellular process Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- ZYCMDWDFIQDPLP-UHFFFAOYSA-N hbr bromine Chemical compound Br.Br ZYCMDWDFIQDPLP-UHFFFAOYSA-N 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- 229940100463 hexyl laurate Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 150000004677 hydrates Chemical group 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000001282 iso-butane Substances 0.000 description 1
- 235000013847 iso-butane Nutrition 0.000 description 1
- 229940078545 isocetyl stearate Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940093629 isopropyl isostearate Drugs 0.000 description 1
- 229940033357 isopropyl laurate Drugs 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229940075495 isopropyl palmitate Drugs 0.000 description 1
- 229940089456 isopropyl stearate Drugs 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- URLZCHNOLZSCCA-UHFFFAOYSA-N leu-enkephalin Chemical compound C=1C=C(O)C=CC=1CC(N)C(=O)NCC(=O)NCC(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=CC=C1 URLZCHNOLZSCCA-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 229940078812 myristyl myristate Drugs 0.000 description 1
- 229940078555 myristyl propionate Drugs 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 150000002829 nitrogen Chemical class 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 210000004882 non-tumor cell Anatomy 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical group C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- OXGBCSQEKCRCHN-UHFFFAOYSA-N octadecan-2-ol Chemical compound CCCCCCCCCCCCCCCCC(C)O OXGBCSQEKCRCHN-UHFFFAOYSA-N 0.000 description 1
- 229940060184 oil ingredients Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- 230000005959 oncogenic signaling Effects 0.000 description 1
- 230000006712 oncogenic signaling pathway Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- JCGNDDUYTRNOFT-UHFFFAOYSA-N oxolane-2,4-dione Chemical compound O=C1COC(=O)C1 JCGNDDUYTRNOFT-UHFFFAOYSA-N 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 239000007967 peppermint flavor Substances 0.000 description 1
- 210000003668 pericyte Anatomy 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 230000006555 post-translational control Effects 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- XEIOPEQGDSYOIH-MURFETPASA-N propan-2-yl (9z,12z)-octadeca-9,12-dienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC(C)C XEIOPEQGDSYOIH-MURFETPASA-N 0.000 description 1
- NEOZOXKVMDBOSG-UHFFFAOYSA-N propan-2-yl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OC(C)C NEOZOXKVMDBOSG-UHFFFAOYSA-N 0.000 description 1
- ZPWFUIUNWDIYCJ-UHFFFAOYSA-N propan-2-yl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(C)C ZPWFUIUNWDIYCJ-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000004063 proteosomal degradation Effects 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 150000003216 pyrazines Chemical class 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 230000003439 radiotherapeutic effect Effects 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 239000010979 ruby Substances 0.000 description 1
- 229910001750 ruby Inorganic materials 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000007727 signaling mechanism Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- CRPCXAMJWCDHFM-UHFFFAOYSA-M sodium;5-oxopyrrolidine-2-carboxylate Chemical compound [Na+].[O-]C(=O)C1CCC(=O)N1 CRPCXAMJWCDHFM-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 108020003113 steroid hormone receptors Proteins 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 description 1
- 229950007866 tanespimycin Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- BORJONZPSTVSFP-UHFFFAOYSA-N tetradecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCCCOC(=O)C(C)O BORJONZPSTVSFP-UHFFFAOYSA-N 0.000 description 1
- YRZGMTHQPGNLEK-UHFFFAOYSA-N tetradecyl propionate Chemical compound CCCCCCCCCCCCCCOC(=O)CC YRZGMTHQPGNLEK-UHFFFAOYSA-N 0.000 description 1
- DZKXJUASMGQEMA-UHFFFAOYSA-N tetradecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC DZKXJUASMGQEMA-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000012384 transportation and delivery Methods 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 229910000166 zirconium phosphate Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Definitions
- This invention relates to certain imidazo[l,2-a]pyrazin-8-ylamines and related compounds, which when appropriately substituted are modulators of Hsp90 complex activity.
- Certain compounds provided herein are highly active inhibitors of Hsp90 complex activity.
- This invention also provides pharmaceutical compositions comprising such compounds, as well as methods for treating a variety of diseases and disorders responsive to Hsp90 complex modulation. Additionally, this invention provides labeled imidazo[l,2-a]pyrazin-8-ylamines as probes for the detection and localization of Hsp90 complex in biological samples.
- One of the central post-translational control elements in eukaryotic signal transduction is the phosphorylation of the hydroxyl moiety of a ldnase serine, threonine, or tyrosine.
- the phosphorylation state of a given protein can govern its enzyme activity, stability, protein-protein binding interactions, and cellular distribution. Phosphorylation and dephosphorylation is thus a "chemical switch" that allows the cell to transmit signals from the plasma membrane to the nucleus, and to ultimately control gene expression.
- Kinases are involved in the control of cell metabolism, growth, differentiation, and apoptosis.
- kinases have been implicated in the onset of cancer, metabolic disorders (for example diabetes), inflammation, immune system disorders, and neurodegeneration. Certain kinases have been implicated in cell proliferation and carcinogenesis. For example, many human cancers are caused by disregulation of a normal protein (e.g., when a kinase proto-oncogene is converted to a kinase oncogene through a gene translocation). [0004] Because kinases are key regulators they are ideal drug design targets. Inhibitors of kinases are among the most important classes of pharmaceutical compounds known. Highly selective, cell-permeable modulators of one or more individual kinases are useful for the treatment of various kinase-implicated disorders. Kinase modulating compounds are additionally useful for the systematic investigation of the cellular function of one or more kinases, and thus, provide valuable tools for the identification of various ldnases of therapeutic interest.
- Some kinase inhibitors include tyrosine kinase inhibitors, inhibit T-cell proliferation, and are thus useful as immunosuppressive agents for the prevention or treatment of graft rejection following transplant surgery and for the prevention or treatment of autoimmune diseases such as rheumatoid arthritis and psoriasis.
- Kinases also play a critical role in angiogenesis.
- Angiogenesis the formation of new blood vessels from preexisting ones, plays a critical role in many pathological settings, including cancer, chronic inflammation, diabetic retinopathy and macular degeneration.
- Angiogenesis is regulated by multiple cell-signaling pathways, including pathways controlled by cellular kinases. Blocking angiogenesis, through the modulation of cell kinases, therefore, represents an effective approach to the treatment of diseases such as cancer.
- angiogenesis mediators including vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and angiopoietin 1 and 2 (Angl and Ang2) that bind to their cognate receptors (VEGFRs, FGFRs and Tiel and Tie2, respectively) expressed on endothelial cells, as well as platelet-derived growth factor (PDGF) that binds to its receptor (PDGFRs) expressed on pericytes and smooth muscle cells, have been identified.
- VEGF vascular endothelial growth factor
- FGF fibroblast growth factor
- Angl and Ang2 angiopoietin 1 and 2
- PDGF platelet-derived growth factor
- Hsp90 is a molecular chaperone, a class of proteins that regulates protein folding in cells.
- Hsp90 is a 90kD protein that functions as a homodimer.
- Hsp90 regulates its own expression by sequestering the transcription factor, HSFl, under non- stress conditions. Upon heat shock, HSFl is released from Hsp90 leading to transcription and increased synthesis of Hsp90, thereby controlling the cellular stress response.
- Hsp90 is an ATP binding site, where ATP is bound and subsequently hydrolyzed.
- Hsp90 is an ATPase, and has been classified as a member of the GHKL ATPase superfamily. It is believed that unfolded, or partially folded substrate proteins, also called Hsp90 client proteins, are stably bound to Hsp90 in its ATP bound state, and released upon ATP hydrolysis.
- Hsp90 is an important cell cycle regulatory protein, implicated in the correct folding of multiple proteins in the mitogenic signal cascade. Hsp90 also plays a role in cyclin dependent progression through Gl and G2 and in centrosome function in mitosis. Hsp90 substrates include a number of steroid hormone receptors including the androgen receptor (AR), estrogen receptor, and glucocorticoid receptor.
- AR androgen receptor
- glucocorticoid receptor include a number of steroid hormone receptors including the androgen receptor (AR), estrogen receptor, and glucocorticoid receptor.
- Hsp90 has been specifically implicated in the proper folding of a number of tyrosine and threonine kinases. It also insures the correct folding and activity of numerous ldnases involved in cell proliferation and differentiation, many of which also play roles in oncogenesis. [0014] Hsp90 can also function as part of a multi-component complex interacting with many other co-chaperone proteins. While Hsp90 forms a multi-component complex to some extent in normal cells, nearly all Hsp90 present in cultured tumor cells has been shown to be part of a multi-component complex. A number of known oncogenic proteins that are Hsp90 substrate proteins, depend on the chaperone activity of the Hsp90 complex for correct folding. Thus Hsp90 functions as a supplier of oncogenic proteins in tumor cells. Hsp90 complex in tumor cells also exhibits higher ATPase activity than Hsp90 from non-cancerous cell lines.
- Geldanamycin a natural product, is an Hsp 90 inhibitor that binds to the ATP binding site of Hsp90 inhibiting ATP hydrolysis but not substrate protein binding. Substrate proteins that reside longer on Hsp90 when ATP hydrolysis is inhibited are ubiquinated, and subsequently degraded. Disrupting the function of the Hsp90 complex has been shown to deplete oncogenic kinases (via ubiquitin-mediated proteasomal degradation) and decrease tumor growth. The Hsp90 complex present in tumor cells exhibits much higher affinity for geldanamycin and for 17-AAG, a geldanamycin derivative, than Hsp90 in non-tumor cells. Thus inhibitors of the Hsp90 complex have the ability to convert this protein from a chaperone that insures correct protein folding of oncogenic proteins to a selective protein degradation tool.
- Hsp90 complex Because of its roles in cell cycle control, cell growth, and oncogenesis the Hsp90 complex is an important target for anti-cancer therapeutics. The ability of certain Hsp90 complex inhibitors to cause this protein complex to selectively target its substrate proteins for degradation makes the Hsp90 complex an especially desirable anti-cancer target. Hsp90 is also a potential drug target for autoimmune and degenerative disease because of its role in modulating the cellular stress response.
- Hsp90 complex Agents capable of modulating the Hsp90 complex, are highly desirable for the treatment of a variety of diseases and disorders, including cancer. Small molecule, non-peptide antagonists of the Hsp90 complex are of particular value for such therapies.
- the present invention fulfills this need, and provides further related advantages.
- the invention provides modulators of kinase activity and Hsp90 complex activity which may generally be described as substituted imidazo[l,2-a]pyrazin-8- ylamines and related compounds. Certain compounds provided herein are highly active inhibitors of Hsp90 complex activity.
- the invention includes compounds of Formula I:
- R 1 is hydrogen, halogen, C 1 -C alkyl, C ⁇ -C 6 alkoxy, (C 3 -C cycloalkyl)C 0 -C 2 alkyl, (heterocycloalkyl)Co-C 2 alkyl, sulfonamide, (C ⁇ -C 6 alkoxy)C ⁇ -C 6 alkyl, (C ⁇ -C 6 alkoxy)C ⁇ - C 6 alkoxy, mono- or di-(C 1 -C6alkyl)amino, or mono- or di-(C ⁇ -C 6 alkyl)amino(C ⁇ - C 6 alkyl); or
- Ri is phenyl, phenyl fused to a 5 to 7-membered heterocycloalkyl ring containing 1 or 2 heteroatoms chosen from N, O, and S, or heteroaryl, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, -CHO, halogen, -C ⁇ alkyl, C2-C 6 alkenyl, C2-C 6 alkynyl, C 3 -C 7 cycloalkyl, Ci-C 6 alkoxy, C ⁇ -C 6 haloalkyl, Ci-C ⁇ haloalkoxy, -Cealkylthio, (C ⁇ -C 6 alkoxy)C ⁇ - C 6 alkyl, (C 1 -C 6 alkoxy)C 1 -C 6 alkoxy, mono- and di-(C 1 -C 6 alkyl)amino, amino(C 1 - C 6 alkyl), mono- and di-
- R4 and R 5 are independently hydrogen, C ⁇ -C 6 alkyl, sulfonamide, or halogen; and m is 0, 1, or 2;
- R 6 and R are independently (i) hydrogen or Ci-C 6 alkyl or ii) phenyl or heteroaryl, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, -CHO, halogen, d-C ⁇ alkyl, C 2 - C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl, Ci-C 6 alkoxy, C ⁇ -C 6 haloalkyl, Ci- C 6 haloalkoxy, (C ⁇ -C 6 alkoxy)Ci-C 6 alkyl, (C 1 -C 6 alkoxy)C 1 -C 6 alkoxy, Ci-C 6 alkylthio, mono- and di-(C 1 -
- W is phenyl or a 5- or 6-membered heteroaryl containing from 1 to 4 heteroatoms independently chosen from nitrogen, oxygen, and sulfur; wherein W is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, - CHO, halogen, oxo, C ⁇ -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl, Ci- C 6 alkoxy, Ci-C ⁇ haloalkyl, C ⁇ -C 6 haloalkoxy, (C 1 -C 6 alkoxy)C 1 -C6alkyl, (C ⁇ -C 6 alkoxy)Cr C 6 alkoxy, C ⁇ -C 6 alkylthio, mono- and di-(C ⁇ -C 6 alkyl)amino, amino(C ⁇ -C 6 alkyl), mono- and di-(C ⁇ -C 6 al
- X is N or CH.
- R 2 is C 1 -C 7 alkyl, C 3 -C 7 cycloalkyl(Co-C 2 allcyl), heterocycloalkyl(Co-C2alkyl), Q- C 6 alkoxy, (C 1 -C 6 alkoxy)C ⁇ -C 6 alkyl, or (C ⁇ -C 6 alkoxy)C ⁇ -C 6 alkoxy; or
- R 2 is phenyl(C 0 -C 2 alkyl) or heteroaryl(C 0 -C 2 alkyl), each of which is substituted with 0 to 3 substituents independently chosen from (i) hydroxy, halogen, nitro, cyano, amino, sulfonamide, -CHO, Ci-C 6 haloalkyl, and Ci-C 6 haloalkoxy,and (ii) Ci-C 6 alkyl, C 2 - C 6 alkenyl, C2-C 6 alkynyl, C3-C cycloalkyl, C ⁇ -C 6 alkoxy, (Ci-C 6 alkoxy)Ci-C 6 alkyl, (d ⁇ C 6 alkoxy)C ⁇ -C 6 alkoxy, C ⁇ -C 6 alkylthio, mono- and di-(C 1 -C 6 alkyl)amino, amino(C ⁇ - C 6 alkyl), mono- and di-(C 1 -C 6 alkyl)
- R 8 and R 9 are independently hydrogen, Ci-C 6 alkyl, C ⁇ -C 6 alkoxy, or halogen; and n is 0, 1, or 2; and R 10 and Rn are independently (v) hydrogen or Ci-C ⁇ alkyl; or (vi) phenyl or heteroaryl, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, -CHO, halogen, Ci-C 6 alkyl, C2- C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl, Ci-C 6 alkoxy, CrC ⁇ haloalkyl, Ci- C 6 haloalkoxy, (Ci-C 6 alkoxy)C ⁇ -C 6 alkyl, (Ci-C 6 alkoxy)C ⁇ -C 6 alkoxy, Ci-C 6 alkylthio, mono- and di-(C ⁇ -C 6 alkyl)
- R 3 is hydrogen or C C ⁇ alkyl, or R 3 is C 3 -C 7 cycloalkyl(Co-C 2 alkyl), heterocycloalkyl(Co-C 2 allcyl), phenyl, or heteroaryl, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, - CHO, halogen, CrC ⁇ alkyl, C 2 -C 6 alkenyl, C2-C 6 alkynyl, C 3 -C 7 cycloalkyl, C ⁇ -C 6 alkoxy, Ci-C ⁇ haloalkyl, CrC ⁇ haloalkoxy, (C ⁇ -C 6 alkoxy)Ci-C 6 alkyl, (C 1 -C 6 alkoxy)C ⁇ -C6alkoxy, C ⁇ -C 6 alkylthio, mono- and di-(C ⁇ -C 6 alkyl)amino, amino(Ci-
- R 3 is phenoxyphenyl, each of which phenyl rings is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, - CHO, halogen, d-C ⁇ alkyl, C2-C6alkenyl, C2-C 6 alkynyl, C 3 -C cycloalkyl, C ⁇ -C 6 alkoxy, C ⁇ -C 6 haloalkyl, C ⁇ -C 6 haloalkoxy, (C 1 -C 6 alkoxy)C ⁇ -C 6 alkyl, (Ci-C 6 alkoxy)Ci-C 6 alkoxy, Ci-Cealkylthio, mono- and di-(C ⁇ -C 6 alkyl)amino, amino(C ⁇ -C 6 alkyl), mono- and di-(C ⁇ - Cealkyl)amino(Ci-Cealkyl), C2-C 6 alkanoyl, and-C(
- the invention includes compounds of Formula I, which exhibit an IC 50 of 5 micromolar or less, 1 micromolar or less, or 500 nanomolar or less in an in vitro assay of tumor cell proliferation, such as the cell proliferation assay described in Example 11.
- the invention includes a pharmaceutical composition, comprising one or more compounds Formula I or any pharmaceutically acceptable form thereof, together with at least one pharmaceutically acceptable carrier or excipient.
- the invention also pertains to packaged pharmaceutical compositions which comprise a pharmaceutical composition, comprising one or more compounds Formula I or any pharmaceutically acceptable form thereof, together with at least one pharmaceutically acceptable carrier or excipient in a container and with instructions for using the pharmaceutical composition to treat a patient suffering from a disease or disorder responsive to Hsp90 complex modulation.
- the invention further pertains to a method for modulating binding of ATP to the Hsp90 complex, the method comprising contacting a cell or cells expressing the Hsp90 complex with a compound according to Formula I or form thereof in an amount sufficient to detectably decrease the level of an Hsp90 substrate protein in vitro.
- the Hsp90 substrate protein is Raf, Akt, or ErbB2.
- the invention includes a method for treating a patient having a disease or disorder responsive to Hsp90 complex modulation, comprising administering to the patient and effective amount of a compound or form thereof according to Formula I.
- the invention includes methods of treatment in which the patient is a human patient, and in which the patient is a companion animal, such as a cat or dog, and in which the patient is a livestock animal, such as a horse, cow, or pig.
- the invention particularly includes methods in which the disease or disorder responsive to Hsp90 complex modulation is cancer, an autoimmune disease, inflammation, or a neurodegenerative disease.
- Methods of treatment include administering a compound of Formula I as a single active agent or administering a compound of Formula I in combination with one or more other active agent.
- the invention includes a method for determining the presence or absence of Hsp90 complex in a sample comprising contacting the sample with a compound or form thereof of Formula I under conditions that permit binding of the compound or form to the Hsp90 complex, detecting a level of the compound or form bound to the Hsp90 complex, and therefrom determining the presence or absence of Hsp90 complex.
- Formula I includes all subformulae thereof.
- Formula I includes compounds of Formulas 1 to 14.
- the compounds of Formula I may contain one or more asymmetric elements such as stereogenic centers, stereogenic axes and the like, e.g. asymmetric carbon atoms, so that the compounds can exist in different stereoisomeric forms.
- asymmetric elements such as stereogenic centers, stereogenic axes and the like, e.g. asymmetric carbon atoms, so that the compounds can exist in different stereoisomeric forms.
- These compounds can be, for example, racemates or optically active forms.
- these compounds with two or more asymmetric elements these compounds can additionally be mixtures of diastereomers.
- compounds having asymmetric centers it should be understood that all of the optical isomers and mixtures thereof are encompassed.
- compounds with carbon-carbon double bonds may occur in Z- and E-forms, with all isomeric forms of the compounds being included in the present invention.
- the single enantiomers i.e., optically active forms
- Resolution of the racemates can also be accomplished, for example, by conventional methods such as crystallization in the presence of a resolving agent, or chromatography, using, for example a chiral HPLC column.
- the present invention is intended to include all isotopes of atoms occurring in the present compounds.
- Isotopes include those atoms having the same atomic number but different mass numbers.
- isotopes of hydrogen include tritium and deuterium and isotopes of carbon include U C, 13 C, and 14 C.
- substituted means that any one or more hydrogens on the designated atom or group is replaced with a selection from the indicated group, provided that the designated atom's normal valence is not exceeded.
- 2 hydrogens on the atom are replaced.
- aromatic moieties are substituted by an oxo group
- the aromatic ring is replaced by the corresponding partially unsaturated ring.
- a pyridyl group substituted by oxo is a pyridone.
- Suitable groups that may be present on a "substituted" position include, but are not limited to, e.g., halogen; cyano; hydroxyl; nitro; azido; alkanoyl (such as a C 2 - C 6 alkanoyl group such as acyl or the like); carboxamido; alkyl groups (typically having 1 to about 8 carbon atoms, or 1 to about 6 carbon atoms); cycloalkyl groups, alkenyl and alkynyl groups (including groups having one or more unsaturated linkages and from 2 to about 8, or 2 to about 6 carbon atoms); alkoxy groups having one or more oxygen linkages and from 1 to about 8, or from 1 to about 6 carbon atoms; aryloxy such as phenoxy; alkylthio groups including those having one or more thio
- alkyl includes both branched and straight chain saturated aliphatic hydrocarbon groups, having the specified number of carbon atoms, generally from 1 to about 12 carbon atoms.
- Ci-C ⁇ alkyl indicates an alkyl group having from 1 to about 7 carbon atoms.
- heterocycloalkyl When C 0 -C n alkyl is used herein in conjunction with another group, for example, heterocycloalkyl(Co-C 2 alkyl), the indicated group, in this case heterocycloalkyl, is either directly bound by a single covalent bond (C 0 ), or attached by an alkyl chain having the specified number of carbon atoms, in this case from 1 to about 2 carbon atoms.
- alkyl include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, 3-methylbutyl, t-butyl, n- pentyl, and sec-pentyl.
- Alkyl groups described herein typically have from 1 to about 12 carbons atoms.
- Preferred alkyl groups are lower alkyl groups, those alkyl groups having from 1 to about 8 carbon atoms, from 1 to about 6 carbon atoms, or from 1 to about 4 carbons atoms e.g. Ci-Cs, Ci-Cg, and Ci-C 4 alkyl groups.
- Alkenyl indicates a straight or branched hydrocarbon chain comprising one or more unsaturated carbon-carbon bonds, which may occur in any stable point along the chain.
- Alkenyl groups described herein typically have from 2 to about 12 carbons atoms.
- Preferred alkenyl groups are lower alkenyl groups, those alkenyl groups having from 2 to about 8 carbon atoms, e.g. C 2 -Q, C 2 -C 6 , and C2-C 4 alkenyl groups.
- alkenyl groups include ethenyl, propenyl, and butenyl groups.
- Alkynyl indicates a straight or branched hydrocarbon chain comprising one or more triple carbon-carbon bonds that may occur in any stable point along the chain, such as ethynyl and propynyl.
- Alkynyl groups described herein typically have from 2 to about 12 carbons atoms.
- Preferred alkynyl groups are lower alkynyl groups, those alkynyl groups having from 2 to about 8 carbon atoms, e.g. C 2 -C 8 , C 2 -C 6 , and C2-C4 alkynyl groups.
- Alkoxy indicates an alkyl group as defined above with the indicated number of carbon atoms attached through an oxygen bridge (-O-).
- alkoxy include, but are not limited to, methoxy, ethoxy, n- propoxy, i- propoxy, n-butoxy, 2- butoxy, t-butoxy, n-pentoxy, 2-pentoxy, 3- pentoxy, isopentoxy, neopentoxy, n-hexoxy, 2-hexoxy, 3-hexoxy, and 3- methylpentoxy.
- (Alkoxy) alkyl alkoxy and alkyl are as defined above and the point of attachment is on the alkyl group.
- (C ⁇ -C 6 alkoxy)C ⁇ -C 6 alkyl indicates an alkoxy group have from 1 to about 6 carbon atom attached through its oxygen atom to an alkyl group have from 1 to about 6 carbon atoms and further attached to the core molecule through a carbon atom in the C ⁇ -C 6 alkyl portion.
- (Alkoxy)alkoxy alkoxy is as defined above and the point of attachment is on the oxygen of the second listed alkoxy group.
- (Ci- C 6 alkoxy)C ⁇ -C 4 alkoxy indicates an alkoxy group have from 1 to about 6 carbon atom attached through its oxygen atom to an second alkoxy group, this one having from 1 to about 4 carbon atoms and further attached to the core molecule through an oxygen bridge.
- alkylthio means alkyl-S-, where the alkyl group is an alkyl group as defined above having the defined number of carbon atoms.
- An exemplary alkylthio group is methylthio.
- the alkoxy moiety of the alkoxycarbonyl group has the indicated number of carbon atoms.
- the carbon of the keto bridge is not included in this number.
- amino(alkyl) is an alkyl group as defined herein, having the indicated number of carbon atoms, and substituted with at least one amino substituent (-NH2).
- aminoalkyl groups like other groups described herein, may be additionally substituted.
- the term "mono- and/ or di-(alkyl)amino” indicates secondary or tertiary alkyl amino groups, wherein the alkyl groups are as defined above and have the indicated number of carbon atoms. The point of attachment of the alkylamino group is on the nitrogen.
- the alkyl groups are independently chosen. Examples of mono- and or di-alkylamino groups include ethylamino, dimethylamino, and methyl-propyl-amino.
- “Mono- and/or dialkylaminoalkyl” groups are mono- and/ or di-alkylamino groups attached through an alkyl linker having the specified number of carbon atoms, for example a di-methylaminoethyl group.
- Tertiary amino substituents may by designated by nomenclature of the form N-R-N-R', indicating that the groups R and R' are both attached to a single nitrogen atom.
- the term "mono- and/ or di-(alkyl)amino(alkyl)” indicates a mono- and/ or di-(alkyl) group as defined attached through an alkyl linker having the specified number of carbon atoms.
- aryl indicates aromatic groups containing only carbon in the aromatic ring or rings. Such aromatic groups may be further substituted with carbon or non-carbon atoms or groups. Typical aryl groups contain 1 or 2 separate, fused, or pendant rings and from 6 to about 12 ring atoms, without heteroatoms as ring members. Where indicated aryl groups may be substituted. Such substitution may include fusion to a 5 to 7-membered saturated cyclic group that optionally contains 1 or 2 heteroatoms independently chosen from ⁇ , O, and S, to form, for example, a 3,4- methylenedioxy-phenyl group.
- Aryl groups include, for example, phenyl, naphthyl, including 1- naphthyl and 2-naphthyl, and bi-phenyl.
- Cycloalkyl indicates a monocyclic or multicyclic saturated hydrocarbon ring group, having the specified number of carbon atoms, usually from 3 to about 10 ring carbon atoms.
- Monocyclic cycloalkyl groups typically have from 3 to about 8 carbon ring atoms or from 3 to about 7 carbon ring atoms.
- Multicyclic cycloalkyl groups may have 2 or 3 fused cycloalkyl rings or contain bridged or caged cycloalkyl groups. Cycloalkyl substituents may be pendant to the substituted nitrogen or carbon atom, or where a substituted carbon atom may have two substituents a cycloalkyl group may be attached as a spiro group.
- cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl as well as bridged or caged saturated ring groups such as norbornane or adamantane.
- Cycloalkyl(C 0 -C2alkyl) indicates a cycloalkyl groups as defined above either directly attached via a single covalent bond or attached through an ethylene (-CH 2 CH 2 -) or methylene (-CH 2 -) linker.
- haloalkyl indicates both branched and straight-chain alkyl groups having the specified number of carbon atoms, substituted with 1 or more halogen atoms, generally up to the maximum allowable number of halogen atoms.
- haloalkyl include, but are not limited to, trifluoromethyl, difluoromethyl, 2- fluoroethyl, and penta-fluoroethyl.
- Haloalkoxy indicates a haloalkyl group as defined above attached through an oxygen bridge.
- Halo or "halogen” as used herein refers to fluoro, chloro, bromo, or iodo.
- heteroaryl indicates a stable 5- to 7-membered monocyclic aromatic ring which contains from 1 to 4, or preferably from 1 to 2, heteroatoms chosen from N, O, and S, with remaining ring atoms being carbon, or a stable bicyclic or tricyclic system containing at least one 5 to 7 membered aromatic ring which contains from 1 to 4, or preferably from 1 to 2, heteroatoms chosen from N, O, and S, with remaining ring atoms being carbon.
- the total number of S and O atoms in the heteroaryl group exceeds 1, these heteroatoms are not adjacent to one another. It is preferred that the total number of S and O atoms in the heteroaryl group is not more than 2.
- heteroaryl groups include, but are not limited to, oxazolyl, pyranyl, pyrazinyl, pyrazolopyrimidinyl, pyrazolyl, pyridizinyl, pyridyl, pyrimidinyl, pyrrolyl, quinolinyl, tetrazolyl, thiazolyl, thienylpyrazolyl, thiophenyl, triazolyl, benzo[d]oxazolyl, benzofuranyl, benzothiazolyl, benzothiophenyl, benzoxadiazolyl, dihydrobenzodioxynyl, furanyl, imidazolyl, indolyl, and isoxazolyl.
- heterocycloalkyl indicates a saturated monocyclic group containing from 1 to about 3 heteroatoms chosen from N, O, and S, with remaining ring atoms being carbon, or a saturated bicyclic ring system having at least one N, O, or S ring atom with remaining atoms being carbon.
- Monocyclic heterocycloalkyl groups have from 4 to about 8 ring atoms, and more typically have from 5 to 7 ring atoms.
- Bicyclic heterocycloalkyl groups typically have from about five to about 12 ring atoms. The number of ring atoms size of a heterocycloalkyl groups is given by the number of ring carbon atoms the group contains.
- a C 2 -C 7 heterocycloalkyl group contains from 2 to about 7 ring carbon atoms with the remaining ring atoms, up to about 3 per ring, being chosen from N, O, and S.
- Preferred heterocycloalkyl groups include Cs-Ce monocyclic heterocycloalkyl groups that contain from 5 to 7 ring atoms and 1 or 2 heteroatoms independently chosen from N, O, and S.
- Examples of heterocycloalkyl groups include morpholinyl, piperazinyl, piperidinyl, and pyrrolidinyl groups.
- heterocycloalkyl alkyl
- the groups heterocycloalkyl and alkyl are as defined above and the point of attachment to the core structure is on the alkyl group.
- sulfonamide is meant -S(O) 2 N- in either S-linked or N-linked orientation, where the nitrogen atom can be unsubstituted or mono- or di-substituted , for example with C 3 -C 6 cycloalkylmethyl, straight or branched chain C 1 -C alkyl.
- “Pharmaceutically acceptable forms” of the compounds recited herein include pharmaceutically acceptable salts, hydrates, solvates, crystal forms, polymorphs, chelates, non-covalent complexes, esters, clathrates, prodrugs, and mixtures of such compounds.
- “Pharmaceutically acceptable salts” include derivatives of the disclosed compounds wherein the parent compound is modified by making non-toxic acid or base salts thereof, and further refers to pharmaceutically acceptable solvates of such compounds and such salts.
- pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
- the pharmaceutically acceptable salts include the conventional non-toxic salts and the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
- conventional non-toxic acid salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, mesylic, esylic, besylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, HOOC-(CH 2 ) n -COOH where n is 0-4, and the like.
- inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phospho
- the pharmaceutically acceptable salts of the present invention can be synthesized from a parent compound, a basic or acidic moiety, by conventional chemical methods.
- such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of the appropriate base (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate, or the like), or by reacting free base forms of these compounds with a stoichiometric amount of the appropriate acid.
- Such reactions are typically carried out in water or in an organic solvent, or in a mixture of the two.
- non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred, where practicable. Lists of additional suitable salts may be found, e.g., in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., p. 1418 (1985).
- prodrugs includes any compounds that become compounds of Formula I when administered to a mammalian subject, e.g., upon metabolic processing of the prodrug.
- examples of prodrugs include, but are not limited to, acetate, formate and benzoate and like derivatives of functional groups (such as alcohol or amine groups) in the compounds of Fonnula I.
- active agent is used to indicate a compound, including any pharmaceutically form thereof, or natural product, which has biological activity.
- an “active agent” is a compound having pharmaceutical utility.
- an active agent may be an anti-cancer therapeutic.
- the term "effective amount" or an of a compound of this invention means an amount effective, when administered to a human or non- human patient, to provide a therapeutic benefit such as an amelioration of symptoms, e.g., an amount effective to decrease the symptoms of a disease or disorder responsive to kinase or Hsp90 complex modulation, and preferably an amount sufficient to reduce cancer symptoms, decrease the number of detectable cancerous cells in an organism, detectably slow or stop the growth of a cancerous tumor, or more preferably and amount sufficient to shrink a cancerous tumor. In certain circumstances a patient suffering from cancer may not present symptoms of being infected.
- a therapeutically effective amount of a compound is also an amount sufficient to prevent a significant increase or significantly reduce the detectable level of cancerous cells or cancer markers in the patient's blood, serum, or tissues.
- a significant increase or reduction in the detectable level of cancerous cells or cancer markers is any detectable change that is statistically significant in a standard parametric test of statistical significance such as Student's T-test, where p ⁇ 0.05.
- R 1 is hydrogen, halogen, C ⁇ -C 7 alkyl, Ci-C 6 alkoxy, C 3 -C 7 cycloalkyl(C 0 -C 2 alkyl), heterocycloalkyl(C 0 -C 2 alkyl), sulfonamide, (Ci-C 6 alkoxy)C ⁇ -C 6 alkyl, (C ⁇ -C 6 alkoxy)Ci- C 6 alkoxy, mono- or di-(C 1 -C 6 alkyl)amino, or mono- or di-(C 1 -C6alkyl)amino(C ⁇ - C 6 alkyl); or Ri is phenyl or phenyl fused to a 5 to 7-membered heterocycloalkyl ring containing 1 or 2 heteroatoms chosen from N, O, and S, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, -CHO, hal
- W is phenyl or a 5- or 6-membered heteroaryl containing from 1 to 4 heteroatoms independently chosen from nitrogen, oxygen, and sulfur; wherein W is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, - CHO, halogen, oxo, -Ceal yl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl, Q- Qalkoxy, C ⁇ -C 6 haloalkyl, C ⁇ -C 6 haloalkoxy, (C ⁇ -C 6 alkoxy)C ⁇ -C 6 alkyl, (C 1 -C 6 alkoxy)C 1 - C ⁇ alkoxy, Ci-C ⁇ alkylthio, mono- and di-(Ci-C 6 alkyl)amino, amino(C ⁇ -C6alkyl), mono- and di-(C ⁇ -
- X is N or CH.
- R 2 is C ⁇ -C 7 alkyl, C 3 -C 7 cycloalkyl(C 0 -C 2 alkyl), heterocycloalkyl(Co-C 2 alkyl), Q- C 6 alkoxy, (Ci-C 6 alkoxy)C ⁇ -C 6 alkyl, or (Ci-C 6 alkoxy)Ci-C 6 alkoxy; or R 2 is phenyl(Cn- C 2 alkyl) or heteiOaryl(Co-C 2 alkyl), each of which is substituted with 0 to 3 substituents independently chosen from (i) hydroxy, halogen, nitro, cyano, amino, sulfonamide, - CHO, Ci-C ⁇ haloalkyl, and C ⁇ -C 6 haloalkoxy,and (ii) C ⁇ -C 6 alkyl, C 2 -C 6 alkenyl, C 2 - C 6 alkynyl, C 3 -C cycloalkyl,
- R 8 and R 9 are independently hydrogen, C ⁇ -C 6 alkyl, C ⁇ -C 6 alkoxy, or halogen; and n is 0, 1, or 2; Rio and R ⁇ are independently (iii) hydrogen or C ⁇ -C 6 alkyl; or (iv) phenyl or heteroaryl, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, -CHO, halogen, Ci-C 6 alkyl, C 2 - C 6 alkenyl, C2-C 6 alkynyl, C 3 -C 7 cycloalkyl, C ⁇ -C 6 alkoxy, C ⁇ -C 6 haloalkyl, Ci- C 6 haloalkoxy, (C ⁇ -C 6 alkoxy)C ⁇ -C 6 alkyl, (C ⁇ -C 6 alkoxy)C ⁇ -C 6 alkoxy, C ⁇ -C 6 alkylthio, mono- and di-(C ⁇ --
- R 3 is hydrogen or C ⁇ -C 6 alkyl, or R 3 is C 3 -C 7 cycloalkyl(C 0 -C2alkyl), heterocycloalkyl(C 0 -C2alkyl), phenyl, or heteroaryl, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, - CHO, halogen, C ⁇ -C 6 alkyl, C2-C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl, Ci-C ⁇ alkoxy, C ⁇ -C 6 haloalkyl, Ci-C ⁇ haloalkoxy, (C ⁇ -C 6 alkoxy)C ⁇ -C 6 alkyl, (C ⁇ -C 6 alkoxy)C ⁇ -C 6 alkoxy, C ⁇ -C 6 alkylthio, mono- and di-(C ⁇ -C6alkyl)amin
- Ri is hydrogen, halogen, C ⁇ -C 7 alkyl, C ⁇ -C 6 alkoxy, C3-C cycloalkyl(C 0 -C 2 alkyl), heterocycloalkyl(Co-C 2 alkyl), sulfonamide, (C ⁇ -C 6 alkoxy)Ci-C 6 alkyl, (C ⁇ -C 6 alkoxy)C ⁇ - C 6 alkoxy, mono- or di-(C ⁇ -C 6 alkyl)amino, or mono- or di ⁇ (Ci ⁇ C 6 alkyl)amino(C ⁇ - C 6 alkyl); or
- Ri is phenyl or a 5- or 6-membered heteroaryl ring containing 1 or 2 heteroatoms, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, -CHO, halogen, C ⁇ -C 6 alkyl, C2-C 6 alkenyl, C2- C 6 alkynyl, C 3 -C 7 cycloalkyl, C ⁇ -C 6 alkoxy, Ci-C 6 haloalkyl, C ⁇ -C 6 haloalkoxy, ( - C 6 alkoxy)C ⁇ -C 6 alkyl, (C ⁇ -C 6 alkoxy)C ⁇ -C 6 alkoxy, C ⁇ -C 6 alkylthio, mono- and di-(C ⁇ - C 6 alkyl)amino, amino(C ⁇ -C 6 alkyl), mono- and di-(C ⁇ -C 6 alkyl)amino(C ⁇ -C 6 alkyl), and C
- W is phenyl or a 5- or 6-membered heteroaryl ring; substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, - CHO, halogen, oxo, C ⁇ -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl, Ci- C 6 alkoxy, d-C ⁇ haloalkyl, C ⁇ -C 6 haloalkoxy, (C ⁇ -C 6 alkoxy)C ⁇ -C 6 alkyl, (C ⁇ -C 6 alkoxy)C ⁇ - C 6 alkoxy, C ⁇ -C 6 alkylthio, mono- and di-(C ⁇ -C 6 all l)amino, amino(C ⁇ -C6alkyl), mono- and di-(C ⁇ -C 6 alkyl)amino(C ⁇ -C 6 alkyl), and C
- X is N or CH.
- R 2 is C ⁇ -C 7 alkyl, C 3 -C 7 cycloalkyl(Co-C 2 allcyl), heterocycloalkyl, (heterocycloalkyl)C ⁇ -C 2 alkyl, C ⁇ -C 6 alkoxy, (C ⁇ -C 6 alkoxy)C ⁇ -C 6 alkyl, or (Ci- C 6 alkoxy)C ⁇ -C 6 alkoxy; or
- R 2 is phenyl(Co-C2alkyl) or 5- or 6-membered heteroaryl(Co-C2alkyl), each of which is substituted with 0 to 3 substituents independently chosen from (i) hydroxy, halogen, nitro, cyano, amino, sulfonamide, -CHO, C ⁇ C 6 haloalkyl, and C ⁇ -C 6 haloalkoxy, and (ii) C ⁇ -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl, C ⁇ -C 6 alkoxy, (Q- C 6 alkoxy)C ⁇ -C 6 alkyl, (C ⁇ -C 6 alkoxy)C ⁇ -C 6 alkoxy, C ⁇ -C 6 alkylthio, mono- and di-(C ⁇ - C 6 alkyl)amino, amino(C ⁇ -C 6 alkyl), mono- and di-(C ⁇ -C 6
- R 8 and R 9 are independently hydrogen, C ⁇ -C 6 alkyl, C ⁇ -C 6 alkoxy, or halogen; Rio and R 11 are independently (iii) hydrogen or C ⁇ -C 6 alkyl; or (iv) phenyl or a 5- or 6 membered heteroaryl ring, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, -CHO, halogen, Ci-C ⁇ alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl, C ⁇ -C 6 alkoxy, C ⁇ -C 6 haloalkyl, C ⁇ -C 6 haloalkoxy, (C ⁇ -C 6 alkoxy)C ⁇ -C 6 alkyl, (C ⁇ -C 6 alkoxy)C ⁇ -C 6 alkoxy, C ⁇ -C 6 alkylthio, mono- and di
- R 3 is hydrogen or C ⁇ -C 6 alkyl, or R 3 is C 3 -C 7 cycloalkyl(Co-C 2 alkyl), heterocycloalkyl(Co-C 2 alkyl), phenyl, or a 5- or 6-membered heteroaryl, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, -CHO, halogen, Ci-C ⁇ alkyl, QrC ⁇ alkenyl, C 2 -C 6 alkynyl, C3- C cycloalkyl, C ⁇ -C 6 alkoxy, Ci-Cehaloalkyl, C ⁇ -C 6 haloalkoxy, (C ⁇ -C 6 alkoxy)C ⁇ -C6alkyl, (C ⁇ -C 6 alkoxy)C ⁇ -C 6 alkoxy, C ⁇ -C 6 alkylthio, mono- and di-(C ⁇ -C 6 alkyl)a
- the invention includes compounds and pharmaceutically acceptable forms of Formula 1 and 1-A in which:
- Ri is halogen, C ⁇ -C alkyl, C ⁇ -C 6 alkoxy, (C3-C 7 cycloalkyl)C 0 -C2alkyl, or (heterocycloalkyl)C 0 -C 2 alkyl; or Ri is phenyl substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, -CHO, halogen, C ⁇ -C 6 alkyl, C 2 -C 6 alkenyl, C -C 6 alkynyl, C 3 -C 7 cycloalkyl, C ⁇ -C 6 alkoxy, C ⁇ -C 6 haloalkyl, C ⁇ -C 6 haloalkoxy, (C ⁇ -C 6 alkoxy)C ⁇ -C 6 alkyl, (C ⁇ -C6alkoxy)C ⁇ -C 6 alkoxy, C ⁇ -C 6 alkylthio, mono- and di-(C ⁇ -C 6 al
- the invention includes compounds and pharmaceutically acceptable forms of Formula 1 and Formula 1-A in which:
- Ri is halogen or d-C ⁇ lkyl; or Ri is phenyl substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, halogen, C ⁇ -C 6 alkyl, C 3 - C cycloalkyl, C ⁇ C 6 alkoxy, C ⁇ -C 2 haloalkyl, C ⁇ -C 2 haloalkoxy, and mono- and di-(C ⁇ - C 4 alkyl)amino.
- Ri is phenyl substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, halogen, C ⁇ -C alkyl, C ⁇ -C 4 alkoxy, C ⁇ -C 2 haloalkyl, C ⁇ -C 2 haloalkoxy, and mono- and di-(C ⁇ -C 4 alkyl)amino.
- the invention also pertains to compounds and pharmaceutically acceptable forms of Formula 1 and Formula 1-A in which: Ri is bromo or C 1 -C alkyl; or Ri is phenyl substituted with 0 to 2 substituents independently chosen from fluoro, chloro, bromo, C ⁇ -C 2 alkyl, and C ⁇ -C 2 alkoxy.
- Ri is bromo or C 1 -C alkyl
- Ri is phenyl substituted with 0 to 2 substituents independently chosen from fluoro, chloro, bromo, C ⁇ -C 2 alkyl, and C ⁇ -C 2 alkoxy.
- the invention includes compounds and pharmaceutically acceptable forms of Formula 1 and Formula 1-A in which:
- W is phenyl, pyridyl, pyrimidinyl, imidazolyl, pyrrolyl, pyrazolyl, furanyl, thienyl, oxazolyl, or isoxazolyl, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, -CHO, halogen, oxo, C ⁇ -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl, C ⁇ -C 6 alkoxy, d- C 6 haloalkyl, C ⁇ -C 6 haloalkoxy, (C ⁇ -C 6 alkoxy)C ⁇ -C 6 alkyl, (C ⁇ -C 6 alkoxy)C ⁇ -C 6 alkoxy, d- C 6 alkylthio, mono- and di-(C ⁇ -C 6 alkyl
- the invention also includes compounds and pharmaceutically acceptable forms of Formula 1 and Formula 1-A in which:
- W is phenyl, pyridyl, pyrimidinyl, imidazolyl, pyrrolyl, pyrazolyl, furanyl, thienyl, oxazolyl, or isoxazolyl, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, halogen, oxo, - alkyl, Ci- C 4 alkoxy, d-C 2 haloalkyl, d-dhaloalkoxy, and mono- and di-(d-C alkyl)amino.
- W is imidazolyl, pyrrolyl, or pyrazolyl, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, cyano, halogen, oxo, d-C 4 alkyl, d- C 4 alkoxy, trifluoromethyl, and trifluoromethoxy.
- the invention includes compounds and pharmaceutically acceptable forms in which W is an imidazolyl group substituted with Ri at the 4-position or at the 2- position, i.e. compounds of Formula 2 and Formula 3:
- the invention includes compounds and pharmaceutically acceptable forms in which W is a pyrazolyl group substituted with Ri at the 3-position, i.e., compounds of Formula 4:
- the invention includes compounds and pharmaceutically acceptable forms of Formula 1 and Formula 1-A in which X is N. In other embodiments X is CH. Tli e Z? Variable
- the invention includes compounds and pharmaceutically acceptable fo ⁇ ns of Fo ⁇ nula 1 and Formula 1-A in which: Z 2 is
- R 8 and R 9 are independently hydrogen or C ⁇ -C 6 alkyl; n is 0, 1, or 2; and Rio and R 1 1 are independently hydrogen, C ⁇ -C 6 alkyl, or phenyl.
- the invention includes compounds and pharmaceutically acceptable forms of Formula 1 and Formula 1-A in which: Z 2 is
- Rio and R ⁇ are independently hydrogen, methyl or ethyl.
- Rio and R ⁇ are both hydrogen. Tlie Ri Variable
- the invention includes compounds and pharmaceutically acceptable forms of Formula 1 and Formula 1-A in which:
- R 2 is phenyl, pyridyl, pyrimidinyl, pyrazinyl, imidazolyl, pyrrolyl, furanyl, thienyl, oxazolyl, or isoxazolyl, each of which may be either directly attached or bound via a C ⁇ -C 2 alkyl linker, and each of which is substituted with 0 to 3 substituents independently chosen from: (i) hydroxy, halogen, nitro, cyano, amino, sulfonamide, - CHO, d-C ⁇ haloalkyl, and Ci-Cehaloalkoxy, and (ii) C ⁇ -C 6 alkyl, C2-C 6 alkenyl, C2- Qalkynyl, C 3 -C cycloalkyl, C ⁇ -C 6 alkoxy, (C ⁇ -C 6 alkoxy)C ⁇ -C 6 alkyl, (C ⁇ -C 6 alkoxy)C ⁇ - C 6 alkoxy, C
- the invention includes compounds and pharmaceutically acceptable forms of Formula 1 and Formula 1-A in which:
- R 2 is phenyl(Co-C 2 alkyl), pyridyl(Co-C 2 alkyl), or pyrimidinyl(C 0 -C 2 alkyl), each of which is substituted with 0 to 3 substituents independently chosen from: (i) hydroxy, halogen, nitro, cyano, amino, Ci-dhaloalkyl, and Ci-dhaloalkoxy, and (ii) C ⁇ -C 6 alkyl, d-dcycloalkyl, C ⁇ -C 6 alkoxy, (C ⁇ -C 6 alkoxy)C ⁇ -C 6 alkyl, mono- and di-(C ⁇ - C 4 alkyl)amino, mono- and di-(C ⁇ -C4alkyl)amino(C ⁇ -C 4 alkyl), and heterocycloalkyl(Co- C 2 alkyl); each of which (ii) is substituted with 0 to 3 substituents independently chosen from halogen, hydroxy, amino, nitro,
- the invention further includes compounds and pharmaceutically acceptable forms of Formula 1 and Formula 1-A in which:
- R 2 is phenyl, pyridyl, or pyrimidinyl, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, halogen, Ci- C 6 alkyl, d-dcycloalkyl, C ⁇ -C 6 alkoxy, Ci-dhaloalkyl, Ci-dhaloalkoxy, and mono- and di-(C 1 -C 4 alkyl)amino .
- the invention includes compounds and pharmaceutically acceptable forms of Formula I and Formula 1-A in which:
- R 3 is hydrogen or C ⁇ -C 6 alkyl, or R 3 is C 3 -C 7 cycloalkyl(C 0 -C 2 alkyl), heterocycloalkyl(Co-C 2 alkyl), phenyl, phenyl, pyridyl, pyrimidinyl, pyrazinyl, imidazolyl, pyrrolyl, furanyl, thienyl, oxazolyl, or isoxazolyl, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, halogen, C ⁇ -C 6 alkyl, d-dcycloalkyl, C ⁇ -C 6 alkoxy, Ci-dhaloalkyl, Ci-dhaloalkoxy, and mono- and di-(C ⁇ -C 4 alkyl)amino; or R 3 is phenoxy phenyl, each of which phenyl rings is substituted with 0 to 3 substituent
- R 3 is hydrogen, C ⁇ -C 6 alkyl, C 3 -C 7 cycloalkyl(Co-dalkyl), phenyl, or phenoxyphenyl. In some preferred embodiments R 3 is hydrogen or C ⁇ -C 4 alkyl. Formulas 6, 7, and 8
- the invention pertains to compounds and pharmaceutically acceptable forms of Formula 6
- the invention pertains to compounds and pharmaceutically acceptable forms of Formula 9 to 14:
- the invention includes compounds and pharmaceutically acceptable forms, in which:
- Ri is bromo or Ci-dalkyl
- Ri is phenyl substituted with 0 to 2 substituents independently chosen from fluoro, chloro, bromo, Ci-dalkyl, and C ⁇ -C 2 alkoxy;
- R 2 is phenyl or benzyl, each of which is substituted with 0 to 3 substituents independently chosen from: (i) hydroxy, halogen, amino, C ⁇ -C haloalkyl, and Ci- dhaloalkoxy; and (ii) Ci-C ⁇ al yl, C ⁇ -C 6 alkoxy, mono- and di-(Ci-C 4 alkyl)amino, mono- and di-(C ⁇ -C 4 alkyl)amino(C ⁇ -C 4 alkyl), piperazinyl(Co-C ⁇ alkyl), piperidinyl(Co-C ⁇ alkyl) and mo holinyl(Co-C ⁇ alkyl); each of which (ii) is substituted with 0 to 3 substituents independently chosen from halogen, hydroxy, amino, C ⁇ -C 2 alkoxy, and mono- and di- (C ⁇ -C 4 alkyl)amino.
- R 3 is hydrogen or C ⁇ -C 4 alkyl.
- Certain compounds of Formula I described herein modulate ldnase and/or Hsp90 complex activity. Certain preferred compounds of Formula I are highly active inhibitors of Hsp90 complex activity.
- Modulation of ldnase activity is determined by a biochemical assay such as the EphB4 biochemical assay of Example 8, or the c-Kit, TIE-2, and VEGF-R2 assays of Example 9.
- Hsp90 complex activity inhibition results in reduced cell proliferation.
- modulation of Hsp90 complex activity is determined by a cell proliferation assay such as the tumor cell proliferation assay of Example 11.
- Hsp90 complex activity inhibition may also be observed via Western blot, for example by the Western blot protocol of Example 10. In this protocol reduced level of Hsp90 substrate proteins, such as ErbB2, Raf, or Aid:, indicates inhibition of Hsp90 complex activity.
- the invention includes compounds of Formula I, which exhibit an IC50 of 25 micromolar or less, and more preferably 10 micromolar or less in an in vitro assay of tumor cell proliferation (such as the assay of Example 11).
- the invention includes a method of modulating binding of ATP to the Hsp90 complex, the method comprising contacting a cell or cells expressing Hsp90 complex with a compound of Formula I or any pharmaceutically acceptable form thereof according in an amount sufficient to detectably decrease the level of an Hsp90 complex substrate protein in vitro.
- Decreased level of Hsp90 complex substrate protein may be observed via Western blot, for example by the Western blot protocol of Example 10.
- the substrate may be ErbB2 or other Hsp90 complex substrate, such as Raf or Akt.
- Modulation of ATP binding to Hsp90 complex may be in vivo or in vitro.
- the cell(s) expressing Hsp90 complex are present in a mammal.
- the mammal may be a human, companion animal, such as a cat or dog, livestock animal, or other mammal.
- compositions comprising a compound or pharmaceutically acceptable form of Formula I, together with one or more pharmaceutically acceptable carriers, excipients, adjuvants, diluents, or other ingredients.
- Pharmaceutical carriers must be of sufficiently high purity and sufficiently low toxicity to render them suitable for administration to the animal being treated.
- the carrier can be inert or it can possess pharmaceutical benefits.
- the amount of carrier employed in conjunction with the compound is sufficient to provide a practical quantity of material for administration per unit dose of the compound.
- Exemplary pharmaceutically acceptable carriers or components thereof are sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose, and methyl cellulose; powdered tragacanth; malt; gelatin; talc; solid lubricants, such as stearic acid and magnesium stearate; calcium sulfate; synthetic oils; vegetable oils, such as peanut oil, cottonseed oil, sesame oil, olive oil, and corn oil; polyols such as propylene glycol, glycerine, sorbitol, mannitol, and polyethylene glycol; alginic acid; phosphate buffer solutions; emulsifiers, such as the TWEENS; wetting agents, such sodium lauryl sulfate; coloring agents; flavoring agents; tableting agents; stabilizers; antioxidants; preservatives; pyrogen-free water; iso
- Optional active agents may be included in a pharmaceutical composition, which do not substantially interfere with the activity of the compound of the present invention.
- Effective concentrations of one or more of the compounds of the invention including pharmaceutically acceptable salts, esters or other derivatives thereof are mixed with a suitable pharmaceutical earner, excipients, adjuvant, or vehicle.
- methods for solubilizing compounds may be used. Such methods are known to those of skill in this art, and include, but are not limited to, using cosolvents, such as dimethylsulfoxide (DMSO), using surfactants, such as TWEEN, or dissolution in aqueous sodium bicarbonate.
- cosolvents such as dimethylsulfoxide (DMSO)
- surfactants such as TWEEN
- dissolution in aqueous sodium bicarbonate such as sodium bicarbonate
- Derivatives of the compounds, such as salts of the compounds or prodrugs of the compounds may also be used in formulating effective pharmaceutical compositions.
- the resulting mixture may be a solution, suspension, emulsion or the like.
- the form of the resulting mixture depends upon a number of factors, including the intended mode of administration and the solubility of the compound in the chosen carrier or vehicle.
- the effective concentration sufficient for ameliorating the symptoms of the disease, disorder, or condition treated may be empirically determined.
- Compounds of general the invention may be administered orally, topically, parenterally, intravenously, by intramuscular injection, by inhalation or spray, sublingually, transdermally, via buccal administration, rectally, as an ophthalmic solution, or by other means, in dosage unit formulations.
- Dosage formulations suitable for oral use include, for example, tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs.
- Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents, such as sweetening agents, flavoring agents, coloring agents and preserving agents, in order to provide pharmaceutically elegant and palatable preparations.
- Oral formulations contain between 0.1 and 99% of a compound of the invention and usually at least about 5% (weight %) of a compound of the present invention. Some embodiments contain from about 25% to about 50% or from 5% to 75 % of a compound of invention.
- Orally administered compositions also include liquid solutions, emulsions, suspensions, powders, granules, elixirs, tinctures, syrups, and the like.
- the pharmaceutically acceptable carriers suitable for preparation of such compositions are well known in the art.
- Oral formulations may contain preservatives, flavoring agents, sweetening agents, such as sucrose or saccharin, taste-masldng agents, and coloring agents.
- Typical components of carriers for syrups, elixirs, emulsions and suspensions include ethanol, glycerol, propylene glycol, polyethylene glycol, liquid sucrose, sorbitol and water. Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent. Orally Administered Liquids formulations [00109] Compounds of the invention can be incorporated into oral liquid preparations such as aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, for example.
- formulations containing these compounds can be presented as a dry product for constitution with water or other suitable vehicle before use.
- liquid preparations can contain conventional additives, such as suspending agents (e.g., sorbitol syrup, methyl cellulose, glucose/sugar, syrup, gelatin, hydroxyethyl cellulose, carboxymethyl cellulose, aluminum stearate gel, and hydrogenated edible fats), emulsifying agents (e.g., lecithin, sorbitan monsoleate, or acacia), non-aqueous vehicles, which can include edible oils (e.g., almond oil, fractionated coconut oil, silyl esters, propylene glycol and ethyl alcohol), and preservatives (e.g., methyl or propyl p- hydroxybenzoate and sorbic acid).
- suspending agents e.g., sorbitol syrup, methyl cellulose, glucose/sugar, syrup, gelatin, hydroxyethyl cellulose, carboxymethyl cellulose
- typical suspending agents include methylcellulose, sodium carboxymethyl cellulose, AVICEL RC-591, tragacanth and sodium alginate; typical wetting agents include lecithin and polysorbate 80; and typical preservatives include methyl paraben and sodium benzoate.
- Aqueous suspensions contain the active material(s) in admixture with excipients suitable for the manufacture of aqueous suspensions.
- excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydropropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents; may be a naturally-occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol substitute, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan substitute
- the aqueous suspensions may also contain one or more preservatives, for example ethyl, or n- propyl p-hydroxybenzoate.
- Oily suspensions may be formulated by suspending the active ingredients in a vegetable oil, for example peanut oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin.
- the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide palatable oral preparations. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid. Emulsions
- compositions of the invention may also be in the form of oil-in-water emulsions.
- the oily phase may be a vegetable oil, for example olive oil or peanut oil, or a mineral oil, for example liquid paraffin or mixtures of these.
- Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol, anhydrides, for example sorbitan monoleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monoleate.
- Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Tablets and Capsules
- Tablets typically comprise conventional pharmaceutically compatible adjuvants as inert diluents, such as calcium carbonate, sodium carbonate, mannitol, lactose and cellulose; binders such as starch, gelatin and sucrose; disintegrants such as starch, alginic acid and croscarmelose; lubricants such as magnesium stearate, stearic acid and talc. Glidants such as silicon dioxide can be used to improve flow characteristics of the powder mixture. Coloring agents, such as the FD&C dyes, can be added for appearance. Sweeteners and flavoring agents, such as aspartame, saccharin, menthol, peppermint, and fruit flavors, are useful adjuvants for chewable tablets. Capsules (including time release and sustained release formulations) typically comprise one or more solid diluents disclosed above. The selection of carrier components often depends on secondary considerations like taste, cost, and shelf stability.
- compositions may also be coated by conventional methods, typically with pH or time-dependent coatings, such that the subject compound is released in the gastrointestinal tract in the vicinity of the desired topical application, or at various times to extend the desired action.
- dosage forms typically include, but are not limited to, one or more of cellulose acetate phthalate, polyvinylacetate phthalate, hydroxypropyl methylcellulose phthalate, ethyl cellulose, Eudragit coatings, waxes and shellac.
- Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.
- an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
- soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.
- compositions may be in the form of a sterile injectable aqueous or oleaginous suspension.
- This suspension may be fo ⁇ nulated according to the known art using those suitable dispersing or wetting agents and suspending agents that have been mentioned above.
- the sterile injectable preparation may also be sterile injectable solution or suspension in a non-toxic parentally acceptable diluent or solvent, for example as a solution in 1,3-butanediol.
- acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution.
- sterile, fixed oils are conventionally employed as a solvent or suspending medium.
- any bland fixed oil may be employed including synthetic mono- or diglycerides.
- compositions for parenteral administration include subcutaneous injections, intravenous, intramuscular, intrathecal injection or infusion techniques.
- the compound or compounds of the invention depending on the vehicle and concentration used, can either be suspended or dissolved in the vehicle.
- adjuvants such as local anesthetics, preservatives and buffering agents can be dissolved in the vehicle.
- the carrier comprises at least about 90% by weight of the total composition.
- Preferred carriers for parenteral administration include propylene glycol, ethyl oleate, pyrrolidone, ethanol, and sesame oil. Suppositories
- compositions of the invention may also be administered in the form of suppositories for rectal administration of the drug.
- suppositories for rectal administration of the drug.
- These compositions can be prepared by mixing the drug with a suitable non-irritating excipient that is solid at ordinary temperatures but liquid at rectal temperature and will therefore melt in the rectum to release the drug.
- suitable non-irritating excipient include cocoa butter and polyethylene glycols.
- Compounds of the invention may be formulated for local or topical application, such as for topical application to the skin and mucous membranes, such as in the eye, in the form of gels, creams, and lotions and for application to the eye.
- Topical compositions of the present invention may be in any form including, for example, solutions, creams, ointments, gels, lotions, milks, cleansers, moisturizers, sprays, skin patches, and the like.
- Such solutions maybe fo ⁇ nulated as 0.01% -10% isotonic solutions, pH about 5-7, with appropriate salts.
- Compounds of the invention may also be formulated for transdermal administration as a transdermal patch.
- Topical compositions containing the active compound can be admixed with a variety of carrier materials well known in the art, such as, for example, water, alcohols, aloe vera gel, allantoin, glycerine, vitamin A and E oils, mineral oil, propylene glycol, PPG-2 myristyl propionate, and the like.
- carrier materials such as, for example, water, alcohols, aloe vera gel, allantoin, glycerine, vitamin A and E oils, mineral oil, propylene glycol, PPG-2 myristyl propionate, and the like.
- Other materials suitable for use in topical carriers include, for example, emollients, solvents, humectants, thickeners and powders.
- Emollients such as stearyl alcohol, glyceryl monoricinoleate, glyceryl monostearate, propane- 1,2-diol, butane- 1, 3 -diol, mink oil, cetyl alcohol, iso-propyl isostearate, stearic acid, iso-butyl palmitate, isocetyl stearate, oleyl alcohol, isopropyl laurate, hexyl laurate, decyl oleate, octadecan-2-ol, isocetyl alcohol, cetyl palmitate, dimethylpolysiloxane, di-n-butyl sebacate, iso-propyl myristate, iso-propyl palmitate, isopropyl stearate, butyl stearate, polyethylene glycol, triethylene glycol
- Compounds of the invention may also be topically administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles.
- Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines. Other formulations
- compositions useful for attaining systemic delivery of the subject compounds include sublingual, buccal and nasal dosage forms.
- Such compositions typically comprise one or more of soluble filler substances such as sucrose, sorbitol and mannitol, and binders such as acacia, microcrystalline cellulose, carboxymethyl cellulose, and hydroxypropyl methylcellulose. Glidants, lubricants, sweeteners, colorants, antioxidants and flavoring agents disclosed above may also be included.
- compositions for inhalation typically can be provided in the form of a solution, suspension or emulsion that can be administered as a dry powder or in the form of an aerosol using a conventional propellant (e.g., dichlorodifluoromethane or trichloiOfluoromethane) .
- a conventional propellant e.g., dichlorodifluoromethane or trichloiOfluoromethane
- compositions of the present invention may also optionally comprise an activity enhancer.
- the activity enhancer can be chosen from a wide variety of molecules that function in different ways to enhance antimicrobial effects of compounds of the present invention.
- Particular classes of activity enhancers include skin penetration enhancers and absorption enhancers.
- compositions of the invention may also contain additional active agents can be chosen from a wide variety of molecules, which can function in different ways to enhance the therapeutic effects of a compound of the present invention. These optional other active agents, when present, are typically employed in the compositions of the invention at a level ranging from about 0.01% to about 15%. Some embodiments contain from about 0.1% to about 10% by weight of the composition. Other embodiments contain from about 0.5% to about 5% by weight of the composition.
- Active agents can be chosen from a wide variety of molecules, which can function in different ways to enhance the therapeutic effects of a compound of the present invention. These optional other active agents, when present, are typically employed in the compositions of the invention at a level ranging from about 0.01% to about 15%. Some embodiments contain from about 0.1% to about 10% by weight of the composition. Other embodiments contain from about 0.5% to about 5% by weight of the composition.
- the invention includes packaged pharmaceutical formulations.
- packaged formulations include a pharmaceutical composition containing one or more compounds, salts, or other pharmaceutically acceptable forms thereof, of the invention in a container and instructions for using the composition to treat an animal (typically a human patient) suffering from a disease or disorder responsive to ldnase modulation or Hsp90 complex modulation, or prevent in a patient.
- the packaged pharmaceutical formulation contains instructions for using the composition to treat a patient suffering from a disease or disorder responsive to Hsp90 complex modulation.
- the invention includes providing prescribing information; for example, to a patient or health care provider, or as a label in a packaged pharmaceutical formulation.
- Prescribing information may include for example efficacy, dosage and administration, contraindication and adverse reaction information pertaining to the pharmaceutical formulation.
- the invention includes new imidazo[l,2-a]pyrazines.
- Certain compounds described herein are modulators of protein kinases, for example EphB4, Tie-2, c-Kit, and VEGF-R2 kinases, and/ or the Hsp90 complex.
- Certain preferred compounds described herein are highly active inhibitors of the Hsp90 complex.
- the compounds of the present invention are useful for the treatment of diseases and disorders responsive to ldnase modulation and/ or Hsp90 complex modulation.
- Prefe ⁇ ed compounds described herein are useful for the treatment of diseases and disorders responsive to Hsp90 complex modulation.
- the invention includes a method of treating a mammal, preferably a human, having a disease or disorder responsive to ldnase or Hsp90 complex modulation, comprising administrating to the mammal of an effective amount of a compound of Formula I.
- Methods of treatment also include modulating kinase and/or Hsp90 complex activity, by inhibiting ATP binding or hydrolysis by a kinase or the Hsp90 complex or by some other mechanism, in vivo, in a patient suffering from a disease or disorder responsive to kinase or Hsp90 complex modulation, by administering a sufficient concentration of a compound of Formula I to inhibit kinase and/ or Hsp90 complex activity in vitro.
- sufficient concentration of a compound administered to the patient is meant the concentration of the compound available in the patient's system to combat the disease or disorder. Such a concentration be ascertained experimentally, for example by assaying blood concentration of the compound, or theoretically, by calculating bioavailability.
- the invention includes a method of treating a patient suffering from a disease or disorder responsive to Hsp90 complex modulation, wherein the disease or disorder is cancer, a neurodegenerative disorder, an autoimmune disease, or inflammation.
- the invention provides methods of treatment in which a compound of the invention is the only active agent given to a patient and also includes methods of treatment in which a compound of Formula I is given to a patient with one or more active agents.
- Certain compounds described herein are useful for treating a patient suffering from a disease or disorder responsive to ldnase modulation.
- Protein Idnases the largest family of human enzymes, are now considered to be the largest druggable target class. Encompassing well over 500 proteins (2% of the human genome), kinases play critical roles in signaling pathways controlling fundamental cellular processes such as proliferation, differentiation, and death (apoptosis). Abnormal ldnase activity has been implicated in a wide range of diseases, including multiple cancers and autoimmune and inflammatory diseases. The multifaceted role of kinases in key cell signaling pathways provides a significant opportunity to identify novel drugs targeting kinases and signaling pathways. Accordingly, there is intense industry-wide interest in this target family, with kinase related research accounting for nearly 25% of the discovery programs at many pharmaceutical and biotechnology companies.
- Kinases are implicated in a large variety of diseases, as certain mutations in protein kinases can lead to activation of pathways causing, for example, the production of tumors, while other mutations in protein kinases block pathways and prevent a response.
- Altered PKA cyclic AMP-dependent protein ldnase
- Altered MAP mitogen-activated protein
- ldnase expression is implicated in a variety of disease conditions including cancer, inflammation, immune disorders, and disorders affecting growth and development.
- RTKs receptor tyrosine Idnases
- CDKs CDKs
- STKs serine/threonine Idnases
- PTKs pathogenic conditions that have been associated with PTKs include, psoriasis, hepatic ci ⁇ hosis, diabetes, atherosclerosis, angiogenesis, restinosis, ocular diseases, rheumatoid arthritis and other inflammatory disorders, autoimmune disease, and a variety of renal disorders.
- the conditions, diseases and/or disorders that are affected using compounds of Formula I and compositions comprising such compounds include, but are not limited to, psoriasis, pathological angiogenesis, cancer (for example, chronic myelogenous leukemia, gastrointestinal stromal tumors, non-small cell lung cancer, breast cancer, ovarian cancer, recurrent ovarian cancer, prostate cancer such as hormonal refractory prostate cancer, kidney cancer, head and neck cancer, or colorectal cancer), immunoregulation (graft rejection), atherosclerosis, rheumatoid arthritis, Parkinson's disease, Alzheimer's disease, diabetes (for example insulin resistance or diabetic retinopathy), septic shock, and the like.
- cancer for example, chronic myelogenous leukemia, gastrointestinal stromal tumors, non-small cell lung cancer, breast cancer, ovarian cancer, recurrent ovarian cancer, prostate cancer such as hormonal refractory prostate cancer, kidney cancer, head and neck cancer, or colorectal cancer
- immunoregulation graft rejection
- Certain kinase inhibitory compounds play an active role in angiogenesis
- Certain compounds described herein are useful for modulating angiogenesis.
- Angiogenesis the formation of new blood vessels from preexisting ones, plays a critical role in many pathological settings, including cancer, chronic inflammation, diabetic retinopathy and macular degeneration.
- Angiogenesis is regulated by multiple cell- signaling pathways, including pathways controlled by cellular kinases. Blocking angiogenesis, through the modulation of cell kinases, therefore, represents an effective approach to the treatment of diseases such as cancer.
- methods of treatment include administering a sufficient amount of a compound or form thereof of the invention to decrease the symptoms or slow the progression of these diseases or disorders by inhibiting the rate of angiogenesis in a tissue.
- Certain compounds described herein are useful for treating a patient suffering from a disease or disorder responsive to Hsp90 complex modulation.
- Hsp90 complex inhibitors of the invention are particularly useful in the treatment of cancer, including, but not limited to, chronic myeloid leukemia, melanoma, breast, ovarian, brain, lung, thyroid, colorectal, prostate, and bladder cancer. Because of the role of Hsp90 in modulating the cellular stress response Hsp90 inhibitors of the invention are also useful in the treatment of heart disease, stroke, and neurodegenerative diseases including multiple sclerosis, Alzheimer's dementia, and ischemic optic neuropathy.
- methods of treatment include administering a sufficient amount of a compound or form thereof of the invention to decrease the symptoms or slow the progression of these diseases or disorders.
- Combination Therapy [00147]
- the invention further includes methods for combination drug therapy, in which a compound of the invention is given to a patient together with one or more other active agents.
- the invention provides a method of treating cancer, which comprises administering to a mammal in need thereof an effective amount of a compound of Formula I together with a second active agent, which is useful for treating cancer.
- the second agent may be an antitumor agent.
- Treatment with the second active agent may be prior to, concomitant with, or following treatment with a compound of Formula I.
- a compound of Formula I is combined with another active agent in a single dosage form.
- Suitable antitumor therapeutics that may be used in combination with a compound of Formula I include, but are not limited to chemotherapeutic agents, for example mitomycin C, carboplatin, taxol, cisplatin, paclitaxel, etoposide, doxorubicin, or a combination comprising at least one of the foregoing chemotherapeutic agents. Radiotherapeutic antitumor agents may also be used, alone or in combination with chemotherapeutic agents. Dosage Levels
- Dosage levels of the order of from about 0.1 mg to about 140 mg per kilogram of body weight per day are useful in the treatment of the conditions listed above (about 0.5 mg to about 7 g per patient per day).
- the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. Dosage unit forms will generally contain between from about 1 mg to about 500 mg of an active ingredient.
- Frequency of dosage may also vary depending on the compound used and the particular disease treated. However, for treatment of most infectious disorders, a dosage regimen of 4 times daily or less is prefe ⁇ ed and a dosage regimen of 1 or 2 times daily is particularly prefe ⁇ ed. [00150] It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, and rate of excretion, drug combination and the severity of the particular disease in the patient undergoing therapy.
- a mixture of bromoacetaldehyde diethyl acetal (1) (51 grams (g)), 48% hydrobromic acid (HBr) (11 milliliters (ml)), and water (11 ml) is heated at 120 °C for 1 hour (hr).
- the solution is cooled, poured into a mixture of sodium bicarbonate (NaHCO 3 ) (60 g), and isopropyl alcohol (IPA) (200 ml), and stirred for 0.5 hr.
- the mixture is filtered, and the filtrate treated with 3,5-dibromo-2-aminopyrazine (2) (33 g) and heated under reflux for 16 hr.
- Sodium hydride (NaH) (144 milligrams (mg) of a 60% dispersion in mineral oil) is added to a solution of 4-p-tolyl-lH-imidazole (571 mg) inN,N,- dimethylformamide (DMF) (10 ml) and the mixture is stirred at room temperature (rt) for 0.5 hr.
- a solution of 6,8-dibromoimidazo[l,2-a]pyrazine (3) (1.0 g) in DMF (10ml) is added. The mixture is sti ⁇ ed at room temperature (rt) for 16 hr.
- LC conditions RP-HPLC is performed on an AGILENT 1100 Binary HPLC system.
- the column is a Restek Ultra IBD 5 ⁇ m 1.0 x 30 mm (Cat. #: 9175331).
- the Mobile Phase contains component A, 0.2% Formic Acid/Water), and component B, Acetonitrile.
- MS conditions Electrospray MS is performed on a MICROMASS LCT equipped with a LockSpray source for accurate mass measurements. Spectra are acquired in positive ion mode from 100-1000 Da at an acquisition rate of 1 spectrum/0.9s with a 0. Is interscan delay. The instrument is tuned for a resolution of 5000 (FWHM). Every 5* scan is taken from the reference position of the Lockspray source. Leucine enkephalin (556.2771 [M+H]*) is used as the reference, or lock mass.
- the compounds of the invention are prepared as radiolabeled probes by carrying out their synthesis using precursors comprising at least one atom that is a radioisotope.
- the radioisotope is preferably selected from of at least one of carbon (preferably 14 C), hydrogen (preferably 3 H), sulfur (preferably . 35 S), or iodine (preferably 125 I).
- Radiolabeled probe compounds of the invention for use in positron emission tomography (PET) contain a positron emitting isotope such as C, N, O, or F.
- PET positron emission tomography
- Such radiolabeled probes are conveniently synthesized by a radioisotope supplier specializing in custom synthesis of radiolabeled probe compounds.
- Such suppliers include Amersham Corporation, Arlington Heights, 111.; Cambridge Isotope Laboratories, Inc. Andover, Mass.; SRI International, Menlo Park, Calif.; Wizard Laboratories, West Sacramento, Calif.; ChemSyn Laboratories, Lexena, Kans.; American Radiolabeled Chemicals, Inc., St. Louis, Mo.; and Morave Biochemicals Inc., Brea, Calif.
- Tritium labeled probe compounds are also conveniently prepared catalytically via platinum-catalyzed exchange in tritiated acetic acid, acid-catalyzed exchange in tritiated trifluoroacetic acid, or heterogeneous-catalyzed exchange with tritium gas. Tritium labeled probe compounds can also be prepared, when appropriate, by sodium borotritide reduction. Such preparations are also conveniently carried out as a custom radiolabeling by any of the suppliers listed in the preceding paragraph using the compound of the invention as substrate. EXAMPLE 5. RECEPTOR AUTO RADIOGRAPHY
- Receptor autoradiography (receptor mapping) is carried out in vitro as described by Kuhar in sections 8.1.1 to 8.1.9 of Current Protocols in Pharmacology (1998) John Wiley & Sons, New York, using radiolabeled compounds of the invention prepared as described in the preceding Example.
- EXAMPLE 6 AKT-1 KINASE ASSAY
- AKT-1 Kinase Assay used to test compounds disclosed in this application is performed as follows.
- Active recombinant N-terminus his-tagged AKT-1/PKB ⁇ kinase obtained from S/21 cells (UBI # 14-276; 50-100 ng; 19-38 nM; about 4.5-9 mU) is incubated in 25 millimolar (mM) Tris pH 7.6; 5 mM Beta-glycerophosphate; 2 mM dithiothreitol (DTT); 100 micromolar ( ⁇ M) sodium vanadate; and 10 mM magnesium chloride (MgCl 2 ).
- the final reaction volume is 40 microliters ( ⁇ l).
- reaction mixture is incubated in a 96- well Pierce REACTI-BIND streptavidin-coated high binding capacity coated white plate (Pierce # 15502) coated with saturating amounts of biotinylated Crosstide peptide (UBI #12-385; biotin-KGSGSGRPRTSSFAEG; 50 picomoles (pmoles); about 1.25 ⁇ M) and initiated with the addition of 2.5 microcurie ( ⁇ Ci) 32 P-gamma-ATP (specific activity 3000 Ci/mmole; 10 mCi/ml; about 21 nanomolar (nM)).
- Percent inhibition is calculated as [1-((AVE CPM compound - AVE CPM no peptide background )/(AVE CPM n o compound MAX — AVE CPM no peptide background))) * ' " 100] .
- Staurosporine a general ATP competitive kinase inhibitor is used as a reference compound. Staurosporine exhibits an IC50 of approximately 60-100 nM for AKT-1 in the current assay format. Approximate S/N ratios are 8-12 X with AVE CPM of Maximum about 15k and no peptide background about 1.5 K. Improved S/N ratios can be obtained using higher amounts of either AKT-1 kinase or P-gamma-ATP. Cold ATP is not added in current format but has been added at up to 200 ⁇ M in the presence of 5 ⁇ Ci 32 P- ⁇ ATP resulting in S/N ratios of approximately 5-1 OX. EXAMPLE 7. SECOND AKT-1 KINASE ASSAY
- AKT-1 Kinase Assay used to test compounds disclosed in this application may be performed as follows.
- Materials include: 96-well isoplates (Perkin-Elmer Corp., Cat.# 1450- 514) Biotinylated crosstide (Upstate Corp, Cat.#12-385), PKB ⁇ /AKT-1 (Panvera Corp., Cat# R3878), Adenosine 5'-triphosphate, [gamma- 32 P] (Perkin Elmer Corp., Cat.# NEG302H001MC). and Streptavidin Coated Beads (Amersham Corp., Cat # RPNQ0007).
- Kinase reaction buffer contains 3-[N-morpholino]propanesulfonic acid (MOPS) (4 mM), pH 7.2, beta-glycerol phosphate (5 mM), Ethylene glycol bis(2- aminoethylether)-N,N,N " ,N ' -tetraaceticacid (EGTA) (1 mM), 0.2 mM sodium orthovanadate, 0.2 mM dithiothreitol, magnesium chloride (15 mM), crosstide (1.2 ⁇ M) and 135 ng/well AKT.
- MOPS N-morpholino]propanesulfonic acid
- EGTA Ethylene glycol bis(2- aminoethylether)-N,N,N " ,N ' -tetraaceticacid
- EphB kinase amino acids 596-987, Homo sapiens EphB 4 , GENBANK Accession No. AY056047.1 with a C-terminal 6X his tag is purified from S 9 cells. Purity of >95% is assessed by Sypro-Ruby staining of SDS gels.
- PTK Biotinylated Peptide Substrate 2 is purchased from Promega, cat #V288A.
- LANCE Eu-W1024 labeled anti-phosphotyrosine antibody (PT66) is purchased from Perkin-Elmer, cat #AD0068.
- Kinase Buffer is purchased from Cell Signaling cat #9802. [00171] Dilutions of compounds are made in 100% DMSO at 20X the final desired concentration. Compounds in 100% DMSO are transferred (1.25 ⁇ L) to the 96 well assay plate. A 18.75 ⁇ L volume of master mix containing the final concentrations (in 25 ul) of 0.01% BSA, IX Cell Signaling Kinase Buffer, 0.5 ⁇ M PTK Biotinylated Peptide
- reaction plates are incubated at RT for at least 15 minutes after SA-APC Detection
- reaction plates are read on an Envision plate reader (Perkin- Elmer) with 605nm Excitation and 605nm and 640nm Emission wavelengths. Values are corrected for the fluorescence in the absence of enzyme and inhibition curves are fit to the data using a Logit curve-fitting algorithm. IC 50 values are determined from these inhibition curves.
- the following assay is a standard biochemical assay used to test activity of compounds as inhibitors of c-Kit, VEGF-R2, and Tie2 kinase activity.
- Test compounds are diluted 1:20 from an original 20 ⁇ M DMSO stock and incubated with recombinant c-Kit (10 ng), Tie-2 (6 ng), or VEGF-R2 (1 ng) enzyme (ProQinase GmbH, Germany), biotinylated peptide (PTK peptide 2, Promega) in Cell Signalling kinase buffer (c-Kit and Tie-2) or Upstate Kinase buffer (VEGF-R2) and 5 ul of ATP (final concentrations: 50 ⁇ M (50 ⁇ M for the VEGF-R2 assay, 60 ⁇ M for the Tie2 assay, and 150 ⁇ M for the c-Kit assay) for 60 minutes at room temperature.
- the final assay volume is 25 ⁇ l.
- Streptavidin-APC Detection Mix which includes 1 nM LANCE Eu-W1024 labeled anti-phosphotyrosine antibody PT66 (Perkin-Elmer, cat #AD0068) and 20 nM SA-APC (based on the SA moiety), is added.
- the reaction plates are incubated at room temperature for at least 15 minutes after SA-APC detection mix addition.
- the reaction plates are then read on an Envision plate reader (Perkin-Elmer) with 605nm excitation 615 nM and 640nm emission wavelengths.
- a negative control i.e. a readout in which the kinases are not inhibited
- the assay is run with without any test compound added.
- Staurosporine a general kinase inhibitor, is used as a positive control.
- IC 50 values are determined from an 11 -point saturation binding curve for test compounds that show significant inhibition of one of the tyrosine kinases. In these assays concentration of test compound ranges from 10 ⁇ M to 20nM. Equilibrium binding parameters are determined by fitting the allosteric Hill equation to the measured values with the aid of the computer program, such as FitP (BIOSOFT, Ferguson, MO). EXAMPLE 10. WESTERN BLOT
- Tumor cells such as MCF-7 or HCT-15 cells (both from ATCC, Manassas, VA), are grown to -50-70% confluency and are subsequently incubated for 4- 48 hr at 37 °C in DMEM media containing 20 ⁇ M test compound. Cells are washed in ice-cold PBS, lysed, and spun at 10,000 x g for 10 minutes to removes cellular debris. Protein concentration of the cleared lysates is determined using a commercially available protein assay, such as the Piece BCA assay. Equal protein amounts, approximately 30 ⁇ l/ lane are loaded onto an SDS-PAGE gel. Proteins are transferred via electrophoresis to nitrocellulose membrane for western blotting.
- MCF-7 or HCT-15 cells both from ATCC, Manassas, VA
- Hsp90 substrate protein such as ErbB2 (Anti-ErbB2: Santa Cruz Biotechnology, Inc., #SC-284), Raf, or Akt, and increased levels of Hsp70 (Anti-HSP70, Transduction Labs #610608).
- HRP horseradish peroxidase
- Test compounds are diluted to 1% DMSO, final concentration, and incubated with 3-5 x 10 3 tumor cells (for example MCF-7 or HCT-15 cells) in a final volume of 200 ⁇ l for 5 days.
- CELLTITER 96 AQUEOUS ONE Solution Cell Proliferation Assay Promega, Madison WI
- a colorimetric assay for determining the number of viable cells is used to quantitate cell growth.
- 10-20 ⁇ l MTS reagent is added to each well according to manufacturer's instructions, plates are incubated at 37°C and read at OD 490 nm.
- living cells covert the MTS reagent to a formazan product which absorbs at 490 nm.
- the 490 nm absorbance is directly proportional to the number of living cells in culture.
Abstract
This invention pertains to compounds of Formula (I) and the pharmaceutically-acceptable forms thereof. The variables R1, R2, R3, Z1, Z2, W, and X shown in Formula I are defined herein. The invention also provides pharmaceutical compositions containing one or more compound of Formula I, or pharmaceutically acceptable form of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain diseases and disorders responsive to Hsp90 complex modulation, which comprise administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease or disorder. These diseases include cancer, including chronic myeloid leukemia, melanoma, breast, ovarian, brain, thyroid, colorectal, prostate, and bladder cancer, heart disease, stroke, autoimmune/inflammatory diseases, and neurodegenerative diseases. Thus methods of treatment include administering a sufficient amount of a compound of Formula I or form thereof to decrease the symptoms or slow the progression of these diseases or disorders. The invention also encompasses methods of treating non-human patients, including livestock and domesticated companion animals, suffering from a disease or disorder responsive to Hsp90 complex modulation. Methods of treatment include administering a compound of Formula I as a single active agent or administering a compound of Formula I in combination with one or more other therapeutic agent. The invention also includes a method for determining the presence of certain kinases or Hsp90 complex in a sample, comprising contacting the sample with a compound of Formula I or form thereof, and detecting Hsp90 complex activity in the sample.
Description
CERTAIN 8-HETEROARYL-6-PHENYL-IMIDAZO[l,2-A]PYRAZINES AS MODULATORS OF HSP90 COMPLEX ACTIVITY
FIELD OF THE INVENTION
[0002] This invention relates to certain imidazo[l,2-a]pyrazin-8-ylamines and related compounds, which when appropriately substituted are modulators of Hsp90 complex activity. Certain compounds provided herein are highly active inhibitors of Hsp90 complex activity. This invention also provides pharmaceutical compositions comprising such compounds, as well as methods for treating a variety of diseases and disorders responsive to Hsp90 complex modulation. Additionally, this invention provides labeled imidazo[l,2-a]pyrazin-8-ylamines as probes for the detection and localization of Hsp90 complex in biological samples.
BACKGROUND
[0003] One of the central post-translational control elements in eukaryotic signal transduction is the phosphorylation of the hydroxyl moiety of a ldnase serine, threonine, or tyrosine. The phosphorylation state of a given protein can govern its enzyme activity, stability, protein-protein binding interactions, and cellular distribution. Phosphorylation and dephosphorylation is thus a "chemical switch" that allows the cell to transmit signals from the plasma membrane to the nucleus, and to ultimately control gene expression. Kinases are involved in the control of cell metabolism, growth, differentiation, and apoptosis. Kinase signaling mechanisms have been implicated in the onset of cancer, metabolic disorders (for example diabetes), inflammation, immune system disorders, and neurodegeneration. Certain kinases have been implicated in cell proliferation and carcinogenesis. For example, many human cancers are caused by disregulation of a normal protein (e.g., when a kinase proto-oncogene is converted to a kinase oncogene through a gene translocation).
[0004] Because kinases are key regulators they are ideal drug design targets. Inhibitors of kinases are among the most important classes of pharmaceutical compounds known. Highly selective, cell-permeable modulators of one or more individual kinases are useful for the treatment of various kinase-implicated disorders. Kinase modulating compounds are additionally useful for the systematic investigation of the cellular function of one or more kinases, and thus, provide valuable tools for the identification of various ldnases of therapeutic interest.
[0005] Some kinase inhibitors, including tyrosine kinase inhibitors, inhibit T-cell proliferation, and are thus useful as immunosuppressive agents for the prevention or treatment of graft rejection following transplant surgery and for the prevention or treatment of autoimmune diseases such as rheumatoid arthritis and psoriasis.
[0006] Kinases also play a critical role in angiogenesis. Angiogenesis, the formation of new blood vessels from preexisting ones, plays a critical role in many pathological settings, including cancer, chronic inflammation, diabetic retinopathy and macular degeneration. Angiogenesis is regulated by multiple cell-signaling pathways, including pathways controlled by cellular kinases. Blocking angiogenesis, through the modulation of cell kinases, therefore, represents an effective approach to the treatment of diseases such as cancer.
[0007] The process of angiogenesis is complex, requiring the concerted actions of multiple angiogenic mediators as well as the participation of different cell types. Key angiogenesis mediators, including vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and angiopoietin 1 and 2 (Angl and Ang2) that bind to their cognate receptors (VEGFRs, FGFRs and Tiel and Tie2, respectively) expressed on endothelial cells, as well as platelet-derived growth factor (PDGF) that binds to its receptor (PDGFRs) expressed on pericytes and smooth muscle cells, have been identified. Recent studies indicate that several members of the ephrin family and their receptor Eph family are novel regulators of vascular differentiation and development that have also been implicated in the angiogenesis in tumors. Thus, inhibitors of EphB4 tyrosine ldnase are desirable as anti-cancer agents and anti-angiogenesis agents.
[0008] Concurrent modulation of multiple cell-signaling pathways is also desirable for the treatment of cancer. Oncogenic signaling pathways have been shown to be mediated by kinase activity; therefore, modulating these oncogenic kinases is desirable for the treatment of cancer. Kinases that have been implicated in oncogenic signaling include, but are not limited to: EGFR, ErB2, c-Kit, PDGFRα, and Flt3.
[0009] Many of the cellular processes regulated by kinases are further regulated by Hsp90.
[0010] Hsp90 is a molecular chaperone, a class of proteins that regulates protein folding in cells. Hsp90 is a 90kD protein that functions as a homodimer. Hsp90 regulates its own expression by sequestering the transcription factor, HSFl, under non- stress conditions. Upon heat shock, HSFl is released from Hsp90 leading to transcription and increased synthesis of Hsp90, thereby controlling the cellular stress response.
[0011] Numerous contacts in the 190 C-teπninal amino acids of the protein are responsible for dimerization of this protein. The 25kD NH2-terminal of Hsp90 contains an ATP binding site, where ATP is bound and subsequently hydrolyzed. Thus Hsp90 is an ATPase, and has been classified as a member of the GHKL ATPase superfamily. It is believed that unfolded, or partially folded substrate proteins, also called Hsp90 client proteins, are stably bound to Hsp90 in its ATP bound state, and released upon ATP hydrolysis.
[0012] Hsp90 is an important cell cycle regulatory protein, implicated in the correct folding of multiple proteins in the mitogenic signal cascade. Hsp90 also plays a role in cyclin dependent progression through Gl and G2 and in centrosome function in mitosis. Hsp90 substrates include a number of steroid hormone receptors including the androgen receptor (AR), estrogen receptor, and glucocorticoid receptor.
[0013] Hsp90 has been specifically implicated in the proper folding of a number of tyrosine and threonine kinases. It also insures the correct folding and activity of numerous ldnases involved in cell proliferation and differentiation, many of which also play roles in oncogenesis.
[0014] Hsp90 can also function as part of a multi-component complex interacting with many other co-chaperone proteins. While Hsp90 forms a multi-component complex to some extent in normal cells, nearly all Hsp90 present in cultured tumor cells has been shown to be part of a multi-component complex. A number of known oncogenic proteins that are Hsp90 substrate proteins, depend on the chaperone activity of the Hsp90 complex for correct folding. Thus Hsp90 functions as a supplier of oncogenic proteins in tumor cells. Hsp90 complex in tumor cells also exhibits higher ATPase activity than Hsp90 from non-cancerous cell lines.
[0015] Geldanamycin, a natural product, is an Hsp 90 inhibitor that binds to the ATP binding site of Hsp90 inhibiting ATP hydrolysis but not substrate protein binding. Substrate proteins that reside longer on Hsp90 when ATP hydrolysis is inhibited are ubiquinated, and subsequently degraded. Disrupting the function of the Hsp90 complex has been shown to deplete oncogenic kinases (via ubiquitin-mediated proteasomal degradation) and decrease tumor growth. The Hsp90 complex present in tumor cells exhibits much higher affinity for geldanamycin and for 17-AAG, a geldanamycin derivative, than Hsp90 in non-tumor cells. Thus inhibitors of the Hsp90 complex have the ability to convert this protein from a chaperone that insures correct protein folding of oncogenic proteins to a selective protein degradation tool.
[0016] Because of its roles in cell cycle control, cell growth, and oncogenesis the Hsp90 complex is an important target for anti-cancer therapeutics. The ability of certain Hsp90 complex inhibitors to cause this protein complex to selectively target its substrate proteins for degradation makes the Hsp90 complex an especially desirable anti-cancer target. Hsp90 is also a potential drug target for autoimmune and degenerative disease because of its role in modulating the cellular stress response.
[0017] Agents capable of modulating the Hsp90 complex, are highly desirable for the treatment of a variety of diseases and disorders, including cancer. Small molecule, non-peptide antagonists of the Hsp90 complex are of particular value for such therapies. The present invention fulfills this need, and provides further related advantages.
SUMMARY OF THE INVENTION
[0018] The invention provides modulators of kinase activity and Hsp90 complex activity which may generally be described as substituted imidazo[l,2-a]pyrazin-8- ylamines and related compounds. Certain compounds provided herein are highly active inhibitors of Hsp90 complex activity.
[0019] Thus, the invention includes compounds of Formula I:
[0020] In Formula I the variables Rl5 R2, R3, Zi, Z2, W, and X are defined as follows:
R1 is hydrogen, halogen, C1-C alkyl, Cι-C6alkoxy, (C3-C cycloalkyl)C0-C2alkyl, (heterocycloalkyl)Co-C2alkyl, sulfonamide, (Cι-C6alkoxy)Cι-C6alkyl, (Cι-C6alkoxy)Cι- C6alkoxy, mono- or di-(C1-C6alkyl)amino, or mono- or di-(Cι-C6alkyl)amino(Cι- C6alkyl); or
Ri is phenyl, phenyl fused to a 5 to 7-membered heterocycloalkyl ring containing 1 or 2 heteroatoms chosen from N, O, and S, or heteroaryl, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, -CHO, halogen, -Cόalkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C7cycloalkyl, Ci-C6alkoxy, Cι-C6haloalkyl, Ci-Cόhaloalkoxy, -Cealkylthio, (Cι-C6alkoxy)Cι- C6alkyl, (C1-C6alkoxy)C1-C6alkoxy, mono- and di-(C1-C6alkyl)amino, amino(C1- C6alkyl), mono- and di-(C].-C6alkyl)amino(Cι-C6alkyl), C2-C6alkanoyl, and-C(O)R13 where R13 is -Cshaloalkyl, phenyl, heterocycloall yl, or heteroaryl.
wherein R4 and R5 are independently hydrogen, Cι-C6alkyl, sulfonamide, or halogen; and m is 0, 1, or 2; R6 and R are independently (i) hydrogen or Ci-C6alkyl or ii) phenyl or heteroaryl, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, -CHO, halogen, d-Cδalkyl, C2- C6alkenyl, C2-C6alkynyl, C3-C7cycloalkyl, Ci-C6alkoxy, Cι-C6haloalkyl, Ci- C6haloalkoxy, (Cι-C6alkoxy)Ci-C6alkyl, (C1-C6alkoxy)C1-C6alkoxy, Ci-C6alkylthio, mono- and di-(C1-C6alkyl)amino, amino(Cι-C6alkyl), mono- and di-(Cι- C6alkyl)amino(Cι-C6alkyl), C2-C6alkanoyl, and -C(O)Ri3.
W is phenyl or a 5- or 6-membered heteroaryl containing from 1 to 4 heteroatoms independently chosen from nitrogen, oxygen, and sulfur; wherein W is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, - CHO, halogen, oxo, Cι-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C7cycloalkyl, Ci- C6alkoxy, Ci-Cβhaloalkyl, Cι-C6haloalkoxy, (C1-C6alkoxy)C1-C6alkyl, (Cι-C6alkoxy)Cr C6alkoxy, Cι-C6alkylthio, mono- and di-(Cι-C6alkyl)amino, amino(Cι-C6alkyl), mono- and di-(Cι-C6alkyl)amino(Ci-C6alkyl), and C2-C6alkanoyl.
X is N or CH.
R2 is C1-C7alkyl, C3-C7cycloalkyl(Co-C2allcyl), heterocycloalkyl(Co-C2alkyl), Q- C6alkoxy, (C1-C6alkoxy)Cι-C6alkyl, or (Cι-C6alkoxy)Cι-C6alkoxy; or
R2 is phenyl(C0-C2alkyl) or heteroaryl(C0-C2alkyl), each of which is substituted with 0 to 3 substituents independently chosen from (i) hydroxy, halogen, nitro, cyano, amino, sulfonamide, -CHO, Ci-C6haloalkyl, and Ci-C6haloalkoxy,and (ii) Ci-C6alkyl, C2- C6alkenyl, C2-C6alkynyl, C3-C cycloalkyl, Cι-C6alkoxy, (Ci-C6alkoxy)Ci-C6alkyl, (d~ C6alkoxy)Cι-C6alkoxy, Cι-C6alkylthio, mono- and di-(C1-C6alkyl)amino, amino(Cι-
C6alkyl), mono- and di-(C1-C6alkyl)amino(C1-C6alkyl), C2-C6alkanoyl, heterocycloalkyl(C0-C2alkyl), and -C(O)Ri35 each of which (ii) is substituted with 0 to 3 substituents independently chosen from halogen, hydroxy, amino, nitro, cyano, - C4alkoxy, C3-C7cycloalkyl, and mono- and di-(Ci-C4alkyl)amino. Z2 is
wherein R8 and R9 are independently hydrogen, Ci-C6alkyl, Cι-C6alkoxy, or halogen; and n is 0, 1, or 2; and R10 and Rn are independently (v) hydrogen or Ci-Cδalkyl; or (vi) phenyl or heteroaryl, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, -CHO, halogen, Ci-C6alkyl, C2- C6alkenyl, C2-C6alkynyl, C3-C7cycloalkyl, Ci-C6alkoxy, CrCόhaloalkyl, Ci- C6haloalkoxy, (Ci-C6alkoxy)Cι-C6alkyl, (Ci-C6alkoxy)Cι-C6alkoxy, Ci-C6alkylthio, mono- and di-(Cι-C6alkyl)amino, amino(Ci-C6alkyl), mono- and di-(Cι- C6alkyl)amino(Cι-C6alkyl), C2-C6alkanoyl, and-C(O)Ri3.
R3 is hydrogen or C Cδalkyl, or R3 is C3-C7cycloalkyl(Co-C2alkyl), heterocycloalkyl(Co-C2allcyl), phenyl, or heteroaryl, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, - CHO, halogen, CrCβalkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C7cycloalkyl, Cι-C6alkoxy, Ci-Cβhaloalkyl, CrCδhaloalkoxy, (Cι-C6alkoxy)Ci-C6alkyl, (C1-C6alkoxy)Cι-C6alkoxy, Cι-C6alkylthio, mono- and di-(Cι-C6alkyl)amino, amino(Ci-C6alkyl), mono- and di-(Cι- C6alkyl)amino(C1-C6alkyl), C2-C6alkanoyl, and-C(O)Ri3; or
R3 is phenoxyphenyl, each of which phenyl rings is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, - CHO, halogen, d-Cδalkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C cycloalkyl, Cι-C6alkoxy, Cι-C6haloalkyl, Cι-C6haloalkoxy, (C1-C6alkoxy)Cι-C6alkyl, (Ci-C6alkoxy)Ci-C6alkoxy,
Ci-Cealkylthio, mono- and di-(Cι-C6alkyl)amino, amino(Cι-C6alkyl), mono- and di-(Cι- Cealkyl)amino(Ci-Cealkyl), C2-C6alkanoyl, and-C(O)Ri3.
[0021] In certain embodiments the invention includes compounds of Formula I, which exhibit an IC50 of 5 micromolar or less, 1 micromolar or less, or 500 nanomolar or less in an in vitro assay of tumor cell proliferation, such as the cell proliferation assay described in Example 11.
[0022] The invention includes a pharmaceutical composition, comprising one or more compounds Formula I or any pharmaceutically acceptable form thereof, together with at least one pharmaceutically acceptable carrier or excipient.
[0023] The invention also pertains to packaged pharmaceutical compositions which comprise a pharmaceutical composition, comprising one or more compounds Formula I or any pharmaceutically acceptable form thereof, together with at least one pharmaceutically acceptable carrier or excipient in a container and with instructions for using the pharmaceutical composition to treat a patient suffering from a disease or disorder responsive to Hsp90 complex modulation.
[0024] The invention further pertains to a method for modulating binding of ATP to the Hsp90 complex, the method comprising contacting a cell or cells expressing the Hsp90 complex with a compound according to Formula I or form thereof in an amount sufficient to detectably decrease the level of an Hsp90 substrate protein in vitro. In certain embodiments the Hsp90 substrate protein is Raf, Akt, or ErbB2.
[0025] Furthermore the invention includes a method for treating a patient having a disease or disorder responsive to Hsp90 complex modulation, comprising administering to the patient and effective amount of a compound or form thereof according to Formula I. The invention includes methods of treatment in which the patient is a human patient, and in which the patient is a companion animal, such as a cat or dog, and in which the patient is a livestock animal, such as a horse, cow, or pig. The invention particularly includes methods in which the disease or disorder responsive to Hsp90 complex modulation is cancer, an autoimmune disease, inflammation, or a neurodegenerative disease.
[0026] Methods of treatment include administering a compound of Formula I as a single active agent or administering a compound of Formula I in combination with one or more other active agent.
[0027] The invention includes a method for determining the presence or absence of Hsp90 complex in a sample comprising contacting the sample with a compound or form thereof of Formula I under conditions that permit binding of the compound or form to the Hsp90 complex, detecting a level of the compound or form bound to the Hsp90 complex, and therefrom determining the presence or absence of Hsp90 complex.
DETAILED DESCRIPTION OF THE INVENTION
[0028] Certain terms to be used herein are provided prior to setting forth the invention in detail. Compounds of the present invention are described using standard nomenclature. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this invention belongs. CHEMICAL DESCRIPTION AND TERMINOLOGY
[0029] Formula I includes all subformulae thereof. For example Formula I includes compounds of Formulas 1 to 14.
[0030] Certain compounds are described herein using a general formula that includes variables, e.g. Ri, R2, R3, W, X, Z\, and Z2. Unless otherwise specified, each variable within such a formula is defined independently of other variables.
[0031] In accordance with the usual meaning of "a" and "the" in patents, reference to "a" ldnase or "the" kinase is inclusive of one or more kinases. Unless otherwise specified the term "compounds" includes all pharmaceutically acceptable forms of the disclosed structures.
[0032] In certain situations, the compounds of Formula I may contain one or more asymmetric elements such as stereogenic centers, stereogenic axes and the like, e.g. asymmetric carbon atoms, so that the compounds can exist in different stereoisomeric forms. These compounds can be, for example, racemates or optically active forms. For
compounds with two or more asymmetric elements, these compounds can additionally be mixtures of diastereomers. For compounds having asymmetric centers, it should be understood that all of the optical isomers and mixtures thereof are encompassed. In addition, compounds with carbon-carbon double bonds may occur in Z- and E-forms, with all isomeric forms of the compounds being included in the present invention. In these situations, the single enantiomers, i.e., optically active forms, can be obtained by asymmetric synthesis, synthesis from optically pure precursors, or by resolution of the racemates. Resolution of the racemates can also be accomplished, for example, by conventional methods such as crystallization in the presence of a resolving agent, or chromatography, using, for example a chiral HPLC column.
[0033] Where a compound exists in various tautomeric forms, the invention is not limited to any one of the specific tautomers, but rather includes all tautomeric forms.
[0034] The present invention is intended to include all isotopes of atoms occurring in the present compounds. Isotopes include those atoms having the same atomic number but different mass numbers. By way of general example, and without limitation, isotopes of hydrogen include tritium and deuterium and isotopes of carbon include UC, 13C, and 14C.
[0035] The term "substituted", as used herein, means that any one or more hydrogens on the designated atom or group is replaced with a selection from the indicated group, provided that the designated atom's normal valence is not exceeded. When the substituent is oxo (i.e., =0), then 2 hydrogens on the atom are replaced. When aromatic moieties are substituted by an oxo group, the aromatic ring is replaced by the corresponding partially unsaturated ring. For example a pyridyl group substituted by oxo is a pyridone. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds or useful synthetic intermediates. A stable compound or stable structure is meant to imply a compound that is sufficiently robust to survive isolation from a reaction mixture, and subsequent formulation into an effective therapeutic agent.
[0036] Suitable groups that may be present on a "substituted" position include, but are not limited to, e.g., halogen; cyano; hydroxyl; nitro; azido; alkanoyl (such as a C2- C6 alkanoyl group such as acyl or the like); carboxamido; alkyl groups (typically having 1 to about 8 carbon atoms, or 1 to about 6 carbon atoms); cycloalkyl groups, alkenyl and alkynyl groups (including groups having one or more unsaturated linkages and from 2 to about 8, or 2 to about 6 carbon atoms); alkoxy groups having one or more oxygen linkages and from 1 to about 8, or from 1 to about 6 carbon atoms; aryloxy such as phenoxy; alkylthio groups including those having one or more thioether linkages and from 1 to about 8 carbon atoms, or from 1 to about 6 carbon atoms; alkylsulfinyl groups including those having one or more sulfinyl linkages and from 1 to about 8 carbon atoms, or from 1 to about 6 carbon atoms; alkylsulfonyl groups including those having one or more sulfonyl linkages and from 1 to about 8 carbon atoms, or from 1 to about 6 carbon atoms; aminoalkyl groups including groups having one or more N atoms and from 1 to about 8, or from 1 to about 6 carbon atoms; aryl having 6 or more carbons and one or more rings, (e.g., phenyl, biphenyl, naphthyl, or the like, each ring either substituted or unsubstituted aromatic); arylalkyl having 1 to 3 separate or fused rings and from 6 to about 18 ring carbon atoms, with benzyl being an exemplary arylalkyl group; arylalkoxy having 1 to 3 separate or fused rings and from 6 to about 18 ring carbon atoms, with benzyloxy being an exemplary arylalkoxy group; or a saturated, unsaturated, or aromatic heterocyclic group having 1 to 3 separate or fused rings with 3 to about 8 members per ring and one or more N, O, or S atoms, e.g. coumarinyl, quinolinyl, isoquinolinyl, quinazolinyl, pyridyl, pyrazinyl, pyrimidinyl, furanyl, pyrrolyl, thienyl, thiazolyl, triazinyl, oxazolyl, isoxazolyl, imidazolyl, indolyl, benzofuranyl, benzothiazolyl, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, morpholinyl, piperazinyl, and pyrrolidinyl. Such heterocyclic groups may be further substituted, e.g. with hydroxy, alkyl, alkoxy, halogen or amino.
[0037] A dash ("-") that is not between two letters or symbols is used to indicate a point of attachment for a substituent. For example, -CHO is attached through carbon of the carbonyl (C=O) group.
[0038] As used herein, "alkyl" includes both branched and straight chain saturated aliphatic hydrocarbon groups, having the specified number of carbon atoms, generally from 1 to about 12 carbon atoms. The term Ci-Cγalkyl as used herein indicates an alkyl group having from 1 to about 7 carbon atoms. When C0-Cnalkyl is used herein in conjunction with another group, for example, heterocycloalkyl(Co-C2alkyl), the indicated group, in this case heterocycloalkyl, is either directly bound by a single covalent bond (C0), or attached by an alkyl chain having the specified number of carbon atoms, in this case from 1 to about 2 carbon atoms. Examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, 3-methylbutyl, t-butyl, n- pentyl, and sec-pentyl. Alkyl groups described herein typically have from 1 to about 12 carbons atoms. Preferred alkyl groups are lower alkyl groups, those alkyl groups having from 1 to about 8 carbon atoms, from 1 to about 6 carbon atoms, or from 1 to about 4 carbons atoms e.g. Ci-Cs, Ci-Cg, and Ci-C4alkyl groups.
[0039] "Alkenyl" as used herein, indicates a straight or branched hydrocarbon chain comprising one or more unsaturated carbon-carbon bonds, which may occur in any stable point along the chain. Alkenyl groups described herein typically have from 2 to about 12 carbons atoms. Preferred alkenyl groups are lower alkenyl groups, those alkenyl groups having from 2 to about 8 carbon atoms, e.g. C2-Q, C2-C6, and C2-C4 alkenyl groups. Examples of alkenyl groups include ethenyl, propenyl, and butenyl groups.
[0040] "Alkynyl" as used herein, indicates a straight or branched hydrocarbon chain comprising one or more triple carbon-carbon bonds that may occur in any stable point along the chain, such as ethynyl and propynyl. Alkynyl groups described herein typically have from 2 to about 12 carbons atoms. Preferred alkynyl groups are lower alkynyl groups, those alkynyl groups having from 2 to about 8 carbon atoms, e.g. C2-C8, C2-C6, and C2-C4 alkynyl groups.
[0041] "Alkoxy" indicates an alkyl group as defined above with the indicated number of carbon atoms attached through an oxygen bridge (-O-). Examples of alkoxy include, but are not limited to, methoxy, ethoxy, n- propoxy, i- propoxy, n-butoxy, 2-
butoxy, t-butoxy, n-pentoxy, 2-pentoxy, 3- pentoxy, isopentoxy, neopentoxy, n-hexoxy, 2-hexoxy, 3-hexoxy, and 3- methylpentoxy.
[0042] In the term "(Alkoxy) alkyl" alkoxy and alkyl are as defined above and the point of attachment is on the alkyl group. For example (Cι-C6alkoxy)Cι-C6alkyl indicates an alkoxy group have from 1 to about 6 carbon atom attached through its oxygen atom to an alkyl group have from 1 to about 6 carbon atoms and further attached to the core molecule through a carbon atom in the Cι-C6alkyl portion.
[0043] In the term "(Alkoxy)alkoxy" alkoxy is as defined above and the point of attachment is on the oxygen of the second listed alkoxy group. For example (Ci- C6alkoxy)Cι-C4alkoxy indicates an alkoxy group have from 1 to about 6 carbon atom attached through its oxygen atom to an second alkoxy group, this one having from 1 to about 4 carbon atoms and further attached to the core molecule through an oxygen bridge.
[0044] "Alkanoyl" indicates an alkyl group as defined above, attached through a keto (-(C=O)-) bridge. Alkanoyl groups have the indicated number of carbon atoms, with the carbon of the keto group being included in the numbered carbon atoms. For example a C2alkanoyl group is an acetyl group having the formula CH3(C=O)-.
[0045] As used herein, "alkylthio" means alkyl-S-, where the alkyl group is an alkyl group as defined above having the defined number of carbon atoms. An exemplary alkylthio group is methylthio.
[0046] As used herein the term "alkoxycarbonyl" indicates an alkoxy group, as defined above, having the indicated number of carbon atoms, attached through a keto (- (C=O)-) bridge. The alkoxy moiety of the alkoxycarbonyl group has the indicated number of carbon atoms. The carbon of the keto bridge is not included in this number. C3alkoxycarbonyl indicates for example, groups of the formula CH3(CH2)2-O-(C=O)- or (CH3)2(CH)-O-(C=O)-.
[0047] As used herein "amino(alkyl)" is an alkyl group as defined herein, having the indicated number of carbon atoms, and substituted with at least one amino substituent
(-NH2). When indicated aminoalkyl groups, like other groups described herein, may be additionally substituted.
[0048] As used herein, the term "mono- and/ or di-(alkyl)amino" indicates secondary or tertiary alkyl amino groups, wherein the alkyl groups are as defined above and have the indicated number of carbon atoms. The point of attachment of the alkylamino group is on the nitrogen. The alkyl groups are independently chosen. Examples of mono- and or di-alkylamino groups include ethylamino, dimethylamino, and methyl-propyl-amino. "Mono- and/or dialkylaminoalkyl" groups are mono- and/ or di-alkylamino groups attached through an alkyl linker having the specified number of carbon atoms, for example a di-methylaminoethyl group. Tertiary amino substituents may by designated by nomenclature of the form N-R-N-R', indicating that the groups R and R' are both attached to a single nitrogen atom.
[0049] As used herein, the term "mono- and/ or di-(alkyl)amino(alkyl)" indicates a mono- and/ or di-(alkyl) group as defined attached through an alkyl linker having the specified number of carbon atoms.
[0050] As used herein, the term "aryl" indicates aromatic groups containing only carbon in the aromatic ring or rings. Such aromatic groups may be further substituted with carbon or non-carbon atoms or groups. Typical aryl groups contain 1 or 2 separate, fused, or pendant rings and from 6 to about 12 ring atoms, without heteroatoms as ring members. Where indicated aryl groups may be substituted. Such substitution may include fusion to a 5 to 7-membered saturated cyclic group that optionally contains 1 or 2 heteroatoms independently chosen from Ν, O, and S, to form, for example, a 3,4- methylenedioxy-phenyl group. Aryl groups include, for example, phenyl, naphthyl, including 1- naphthyl and 2-naphthyl, and bi-phenyl.
[0051] "Cycloalkyl" as used herein, indicates a monocyclic or multicyclic saturated hydrocarbon ring group, having the specified number of carbon atoms, usually from 3 to about 10 ring carbon atoms. Monocyclic cycloalkyl groups typically have from 3 to about 8 carbon ring atoms or from 3 to about 7 carbon ring atoms. Multicyclic cycloalkyl groups may have 2 or 3 fused cycloalkyl rings or contain bridged or caged
cycloalkyl groups. Cycloalkyl substituents may be pendant to the substituted nitrogen or carbon atom, or where a substituted carbon atom may have two substituents a cycloalkyl group may be attached as a spiro group. Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl as well as bridged or caged saturated ring groups such as norbornane or adamantane.
[0052] As used herein "Cycloalkyl(C0-C2alkyl) indicates a cycloalkyl groups as defined above either directly attached via a single covalent bond or attached through an ethylene (-CH2CH2-) or methylene (-CH2-) linker.
[0053] As used herein "haloalkyl" indicates both branched and straight-chain alkyl groups having the specified number of carbon atoms, substituted with 1 or more halogen atoms, generally up to the maximum allowable number of halogen atoms. Examples of haloalkyl include, but are not limited to, trifluoromethyl, difluoromethyl, 2- fluoroethyl, and penta-fluoroethyl.
[0054] "Haloalkoxy" indicates a haloalkyl group as defined above attached through an oxygen bridge.
[0055] "Halo" or "halogen" as used herein refers to fluoro, chloro, bromo, or iodo.
[0056] As used herein, "heteiOaryl" indicates a stable 5- to 7-membered monocyclic aromatic ring which contains from 1 to 4, or preferably from 1 to 2, heteroatoms chosen from N, O, and S, with remaining ring atoms being carbon, or a stable bicyclic or tricyclic system containing at least one 5 to 7 membered aromatic ring which contains from 1 to 4, or preferably from 1 to 2, heteroatoms chosen from N, O, and S, with remaining ring atoms being carbon. When the total number of S and O atoms in the heteroaryl group exceeds 1, these heteroatoms are not adjacent to one another. It is preferred that the total number of S and O atoms in the heteroaryl group is not more than 2. It is particularly preferred that the total number of S and O atoms in the aromatic heterocycle is not more than 1. Examples of heteroaryl groups include, but are not limited to, oxazolyl, pyranyl, pyrazinyl, pyrazolopyrimidinyl, pyrazolyl, pyridizinyl,
pyridyl, pyrimidinyl, pyrrolyl, quinolinyl, tetrazolyl, thiazolyl, thienylpyrazolyl, thiophenyl, triazolyl, benzo[d]oxazolyl, benzofuranyl, benzothiazolyl, benzothiophenyl, benzoxadiazolyl, dihydrobenzodioxynyl, furanyl, imidazolyl, indolyl, and isoxazolyl.
[0057] The term "heterocycloalkyl" indicates a saturated monocyclic group containing from 1 to about 3 heteroatoms chosen from N, O, and S, with remaining ring atoms being carbon, or a saturated bicyclic ring system having at least one N, O, or S ring atom with remaining atoms being carbon. Monocyclic heterocycloalkyl groups have from 4 to about 8 ring atoms, and more typically have from 5 to 7 ring atoms. Bicyclic heterocycloalkyl groups typically have from about five to about 12 ring atoms. The number of ring atoms size of a heterocycloalkyl groups is given by the number of ring carbon atoms the group contains. For example, a C2-C7heterocycloalkyl group contains from 2 to about 7 ring carbon atoms with the remaining ring atoms, up to about 3 per ring, being chosen from N, O, and S. Preferred heterocycloalkyl groups include Cs-Ce monocyclic heterocycloalkyl groups that contain from 5 to 7 ring atoms and 1 or 2 heteroatoms independently chosen from N, O, and S. Examples of heterocycloalkyl groups include morpholinyl, piperazinyl, piperidinyl, and pyrrolidinyl groups.
[0058] In the term "heterocycloalkyl (alkyl)" the groups heterocycloalkyl and alkyl are as defined above and the point of attachment to the core structure is on the alkyl group.
[0059] By "sulfonamide" is meant -S(O)2N- in either S-linked or N-linked orientation, where the nitrogen atom can be unsubstituted or mono- or di-substituted , for example with C3-C6cycloalkylmethyl, straight or branched chain C1-C alkyl.
[0060] "Pharmaceutically acceptable forms" of the compounds recited herein include pharmaceutically acceptable salts, hydrates, solvates, crystal forms, polymorphs, chelates, non-covalent complexes, esters, clathrates, prodrugs, and mixtures of such compounds.
[0061] "Pharmaceutically acceptable salts" include derivatives of the disclosed compounds wherein the parent compound is modified by making non-toxic acid or base salts thereof, and further refers to pharmaceutically acceptable solvates of such
compounds and such salts. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts include the conventional non-toxic salts and the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, conventional non-toxic acid salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, mesylic, esylic, besylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, HOOC-(CH2)n-COOH where n is 0-4, and the like. The pharmaceutically acceptable salts of the present invention can be synthesized from a parent compound, a basic or acidic moiety, by conventional chemical methods. Generally, such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of the appropriate base (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate, or the like), or by reacting free base forms of these compounds with a stoichiometric amount of the appropriate acid. Such reactions are typically carried out in water or in an organic solvent, or in a mixture of the two. Generally, non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred, where practicable. Lists of additional suitable salts may be found, e.g., in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., p. 1418 (1985).
[0062] The term "prodrugs" includes any compounds that become compounds of Formula I when administered to a mammalian subject, e.g., upon metabolic processing of the prodrug. Examples of prodrugs include, but are not limited to, acetate, formate and benzoate and like derivatives of functional groups (such as alcohol or amine groups) in the compounds of Fonnula I.
[0063] The term "active agent" is used to indicate a compound, including any pharmaceutically form thereof, or natural product, which has biological activity. Preferably an "active agent" is a compound having pharmaceutical utility. For example an active agent may be an anti-cancer therapeutic.
[0064] The term "effective amount" or an of a compound of this invention means an amount effective, when administered to a human or non- human patient, to provide a therapeutic benefit such as an amelioration of symptoms, e.g., an amount effective to decrease the symptoms of a disease or disorder responsive to kinase or Hsp90 complex modulation, and preferably an amount sufficient to reduce cancer symptoms, decrease the number of detectable cancerous cells in an organism, detectably slow or stop the growth of a cancerous tumor, or more preferably and amount sufficient to shrink a cancerous tumor. In certain circumstances a patient suffering from cancer may not present symptoms of being infected. Thus a therapeutically effective amount of a compound is also an amount sufficient to prevent a significant increase or significantly reduce the detectable level of cancerous cells or cancer markers in the patient's blood, serum, or tissues. A significant increase or reduction in the detectable level of cancerous cells or cancer markers is any detectable change that is statistically significant in a standard parametric test of statistical significance such as Student's T-test, where p < 0.05.
lMIDAZ0[l,2-α]PYRAZINE COMPOUNDS
[0065] In addition to compounds of Formula I described above, the invention also includes compounds of Formula 1
R1 is hydrogen, halogen, Cι-C7alkyl, Ci-C6alkoxy, C3-C7cycloalkyl(C0-C2alkyl), heterocycloalkyl(C0-C2alkyl), sulfonamide, (Ci-C6alkoxy)Cι-C6alkyl, (Cι-C6alkoxy)Ci- C6alkoxy, mono- or di-(C1-C6alkyl)amino, or mono- or di-(C1-C6alkyl)amino(Cι- C6alkyl); or Ri is phenyl or phenyl fused to a 5 to 7-membered heterocycloalkyl ring containing 1 or 2 heteroatoms chosen from N, O, and S, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, -CHO, halogen, Cι-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C7cycloalkyl, CrQalkoxy, Ci-C6haloalkyl, Cι-C6haloalkoxy, Ci-C6alkylthio, (Cι-C6alkoxy)Ci-C6alkyl, (Q- C6alkoxy)Ci-C6alkoxy, mono- and di-(Ci-C6alkyl)amino, amino(C1-C6alkyl), mono- and di-(Cι-C6all yl)amino(Cι-C6alkyl), C2-C6alkanoyl, and-C(O)Rπ where R13 is Q- Cshaloalkyl, phenyl, heterocycloalkyl, or heteroaryl.
W is phenyl or a 5- or 6-membered heteroaryl containing from 1 to 4 heteroatoms independently chosen from nitrogen, oxygen, and sulfur; wherein W is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, - CHO, halogen, oxo, -Ceal yl, C2-C6alkenyl, C2-C6alkynyl, C3-C7cycloalkyl, Q- Qalkoxy, Cι-C6haloalkyl, Cι-C6haloalkoxy, (Cι-C6alkoxy)Cι-C6alkyl, (C1-C6alkoxy)C1- Cδalkoxy, Ci-Cόalkylthio, mono- and di-(Ci-C6alkyl)amino, amino(Cι-C6alkyl), mono- and di-(Cι-C6alkyl)amino(Ci-C6alkyl), and C2-C6alkanoyl.
X is N or CH.
R2 is Cι-C7alkyl, C3-C7cycloalkyl(C0-C2alkyl), heterocycloalkyl(Co-C2alkyl), Q- C6alkoxy, (Ci-C6alkoxy)Cι-C6alkyl, or (Ci-C6alkoxy)Ci-C6alkoxy; or R2 is phenyl(Cn- C2alkyl) or heteiOaryl(Co-C2alkyl), each of which is substituted with 0 to 3 substituents independently chosen from (i) hydroxy, halogen, nitro, cyano, amino, sulfonamide, - CHO, Ci-Cβhaloalkyl, and Cι-C6haloalkoxy,and (ii) Cι-C6alkyl, C2-C6alkenyl, C2- C6alkynyl, C3-C cycloalkyl, Q-Cealkoxy, (Cι-C6alkoxy)C1-C6alkyl, (C1-C6alkoxy)Cι- C6alkoxy, Q-Cealkylthio, mono- and di-(Ci-C6alkyl)amino, amino(C1-C6alkyl), mono- and di-(Ci-C6alkyl)amino(Ci-C6alkyl), C2-C6alkanoyl, heterocycloalkyl(Co-C2alkyl), and
-C(O)R13; each of which (ii) is substituted with 0 to 3 substituents independently chosen from halogen, hydroxy, amino, nitro, cyano, C1-C4alkoxy, C3-C7cycloalkyl, and mono- and di-(Ci-C4alkyl)amino;
wherein R8 and R9 are independently hydrogen, Cι-C6alkyl, Cι-C6alkoxy, or halogen; and n is 0, 1, or 2; Rio and Rπ are independently (iii) hydrogen or Cι-C6alkyl; or (iv) phenyl or heteroaryl, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, -CHO, halogen, Ci-C6alkyl, C2- C6alkenyl, C2-C6alkynyl, C3-C7cycloalkyl, Cι-C6alkoxy, Cι-C6haloalkyl, Ci- C6haloalkoxy, (Cι-C6alkoxy)Cι-C6alkyl, (Cι-C6alkoxy)Cι-C6alkoxy, Cι-C6alkylthio, mono- and di-(Cι-C6alkyl)amino, amino(Cι-C6alkyl), mono- and di-(Cι- C6alkyl)amino(Cι-C6alkyl), C2-C6alkanoyl, and-C(O)Ri3.
R3 is hydrogen or Cι-C6alkyl, or R3 is C3-C7cycloalkyl(C0-C2alkyl), heterocycloalkyl(C0-C2alkyl), phenyl, or heteroaryl, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, - CHO, halogen, Cι-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C7cycloalkyl, Ci-Cόalkoxy, Cι-C6haloalkyl, Ci-Cβhaloalkoxy, (Cι-C6alkoxy)Cι-C6alkyl, (Cι-C6alkoxy)Cι-C6alkoxy, Cι-C6alkylthio, mono- and di-(Cι-C6alkyl)amino, amino(Cι-C6 alkyl), mono- and di-(C1- C6alkyl)amino(Cι-C6alkyl), C2-C6alkanoyl, and-C(O)Ro; or R3 is phenoxy phenyl, each of which phenyl rings is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, -CHO, halogen, Ci-Cδalkyl, C2-C6alkenyl, C2-Cόalkynyl, C3-C7cycloalkyl, Ci-Cβalkoxy, Cι-C6haloalkyl, Cι-C6haloalkoxy, (Ci- C6alkoxy)Cι-C6alkyl, (Cι-C6alkoxy)Cι-C6alkoxy, Cι-C6alkylthio, mono- and di-(C1- C6alkyl)amino, amino(Cι-C6alkyl), mono- and di-(Cι-C6alkyl)amino(Cι-C6alkyl), C2- C6alkanoyl, and -C(O)Rι3.
[0066] The invention further includes compounds of the same Formula 1 in which the variables Ri, R2, R3, Z2, W, and X are defined as follows:
Ri is hydrogen, halogen, Cι-C7alkyl, Cι-C6alkoxy, C3-C cycloalkyl(C0-C2alkyl), heterocycloalkyl(Co-C2alkyl), sulfonamide, (Cι-C6alkoxy)Ci-C6alkyl, (Cι-C6alkoxy)Cι- C6alkoxy, mono- or di-(Cι-C6alkyl)amino, or mono- or di~(Ci~C6alkyl)amino(Cι- C6alkyl); or
Ri is phenyl or a 5- or 6-membered heteroaryl ring containing 1 or 2 heteroatoms, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, -CHO, halogen, Cι-C6alkyl, C2-C6alkenyl, C2- C6alkynyl, C3-C7cycloalkyl, Cι-C6alkoxy, Ci-C6haloalkyl, Cι-C6haloalkoxy, ( - C6alkoxy)Cι-C6alkyl, (Cι-C6alkoxy)Cι-C6alkoxy, Cι-C6alkylthio, mono- and di-(Cι- C6alkyl)amino, amino(Cι-C6alkyl), mono- and di-(Cι-C6alkyl)amino(Cι-C6alkyl), and C2-C6alkanoyl.
W is phenyl or a 5- or 6-membered heteroaryl ring; substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, - CHO, halogen, oxo, Cι-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C7cycloalkyl, Ci- C6alkoxy, d-Cδhaloalkyl, Cι-C6haloalkoxy, (Cι-C6alkoxy)Cι-C6alkyl, (Cι-C6alkoxy)Cι- C6alkoxy, Cι-C6alkylthio, mono- and di-(Cι-C6all l)amino, amino(Cι-C6alkyl), mono- and di-(Cι-C6alkyl)amino(Cι-C6alkyl), and C2-C6alkanoyl.
X is N or CH.
R2 is Cι-C7alkyl, C3-C7cycloalkyl(Co-C2allcyl), heterocycloalkyl, (heterocycloalkyl)Cι-C2alkyl, Cι-C6alkoxy, (Cι-C6alkoxy)Cι-C6alkyl, or (Ci- C6alkoxy)Cι-C6alkoxy; or
R2 is phenyl(Co-C2alkyl) or 5- or 6-membered heteroaryl(Co-C2alkyl), each of which is substituted with 0 to 3 substituents independently chosen from (i) hydroxy, halogen, nitro, cyano, amino, sulfonamide, -CHO, Cι~C6haloalkyl, and Cι-C6haloalkoxy, and (ii) Cι-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C7cycloalkyl, Cι-C6alkoxy, (Q-
C6alkoxy)Cι-C6alkyl, (Cι-C6alkoxy)Cι-C6alkoxy, Cι-C6alkylthio, mono- and di-(Cι- C6alkyl)amino, amino(Cι-C6alkyl), mono- and di-(Cι-C6alkyl)amino(Cι-C6alkyl), C2- C6alkanoyl, and heterocycloalkyl(Co-C2alkyl); each of which (ii) is substituted with 0 to 3 substituents independently chosen from halogen, hydroxy, amino, nitro, cyano, Ci- C4alkoxy, C3-C7cycloalkyl, and mono- and di-(Ci-C4alkyl)amino. Z2 is
wherein R8 and R9 are independently hydrogen, Cι-C6alkyl, Cι-C6alkoxy, or halogen; Rio and R11 are independently (iii) hydrogen or Cι-C6alkyl; or (iv) phenyl or a 5- or 6 membered heteroaryl ring, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, -CHO, halogen, Ci-Cδalkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C7cycloalkyl, Cι-C6alkoxy, Cι-C6haloalkyl, Cι-C6haloalkoxy, (Cι-C6alkoxy)Cι-C6alkyl, (Cι-C6alkoxy)Cι-C6alkoxy, Cι-C6alkylthio, mono- and di-(Cι-C6alkyl)amino, amino(Cι-C6alkyl), mono- and di-(Cι- C6alkyl)amino(Cι-C6alkyl), and Ci-Cealkanoyl.
R3 is hydrogen or Cι-C6alkyl, or R3 is C3-C7cycloalkyl(Co-C2alkyl), heterocycloalkyl(Co-C2alkyl), phenyl, or a 5- or 6-membered heteroaryl, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, -CHO, halogen, Ci-Cδalkyl, QrCδalkenyl, C2-C6alkynyl, C3- C cycloalkyl, Cι-C6alkoxy, Ci-Cehaloalkyl, Cι-C6haloalkoxy, (Cι-C6alkoxy)Cι-C6alkyl, (Cι-C6alkoxy)Cι-C6alkoxy, Cι-C6alkylthio, mono- and di-(Cι-C6alkyl)amino, amino(Cι- C6alkyl), mono- and di-(Cι-C6alkyl)amino(Cι-C6alkyl), and C2-C6alkanoyl; or R3 is phenoxyphenyl, each of which phenyl rings is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, -CHO, halogen, Cι-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C7cycloalkyl, Cι-C6alkoxy, Cι-C6haloalkyl, Cι-C6haloalkoxy, (Cι-C6alkoxy)C1-C6alkyl, (Cι-C6alkoxy)Cι-C6alkoxy, Cι-C6alkylthio,
mono- and di-(Cι-C6alkyl)amino, amino(Cι-C6alkyl), mono- and di-(Cι- C6alkyl)amino(Cι-C6alkyl), and C2-C6alkanoyl.
[0067] Such compounds will be referred to as compounds of Formula 1-A. The Ri Variable
[0068] The invention includes compounds and pharmaceutically acceptable forms of Formula 1 and 1-A in which:
Ri is halogen, Cι-C alkyl, Cι-C6alkoxy, (C3-C7cycloalkyl)C0-C2alkyl, or (heterocycloalkyl)C0-C2alkyl; or Ri is phenyl substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, -CHO, halogen, Cι-C6alkyl, C2-C6alkenyl, C -C6alkynyl, C3-C7cycloalkyl, Cι-C6alkoxy, Cι-C6haloalkyl, Cι-C6haloalkoxy, (Cι-C6alkoxy)Cι-C6alkyl, (Cι-C6alkoxy)Cι-C6alkoxy, Cι-C6alkylthio, mono- and di-(Cι-C6alkyl)amino, amino(Cι-C6alkyl), mono- and di-(Cι- C6alkyl)amino(Cι-C6alkyl), and C2-C6alkanoyl.
[0069] In other embodiments the invention includes compounds and pharmaceutically acceptable forms of Formula 1 and Formula 1-A in which:
Ri is halogen or d-C^lkyl; or Ri is phenyl substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, halogen, Cι-C6alkyl, C3- C cycloalkyl, Cι~C6alkoxy, Cι-C2haloalkyl, Cι-C2haloalkoxy, and mono- and di-(Cι- C4alkyl)amino.
[0070] Also included in the invention are compounds and pharmaceutically acceptable forms of Formula 1 and Formula 1-A in which:
Ri is phenyl substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, halogen, Cι-C alkyl, Cι-C4alkoxy, Cι-C2haloalkyl, Cι-C2haloalkoxy, and mono- and di-(Cι-C4alkyl)amino.
[0071] The invention also pertains to compounds and pharmaceutically acceptable forms of Formula 1 and Formula 1-A in which: Ri is bromo or C1-C alkyl; or Ri is phenyl substituted with 0 to 2 substituents independently chosen from fluoro, chloro, bromo, Cι-C2alkyl, and Cι-C2alkoxy.
The W Variable
[0072] The invention includes compounds and pharmaceutically acceptable forms of Formula 1 and Formula 1-A in which:
W is phenyl, pyridyl, pyrimidinyl, imidazolyl, pyrrolyl, pyrazolyl, furanyl, thienyl, oxazolyl, or isoxazolyl, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, -CHO, halogen, oxo, Cι-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C7cycloalkyl, Cι-C6alkoxy, d- C6haloalkyl, Cι-C6haloalkoxy, (Cι-C6alkoxy)Cι-C6alkyl, (Cι-C6alkoxy)Cι-C6alkoxy, d- C6alkylthio, mono- and di-(Cι-C6alkyl)amino, amino(C1-C6alkyl), mono- and di-(Cι- C6alkyl)amino(Cι-C6alkyl), and C2-C6alkanoyl.
[0073] The invention also includes compounds and pharmaceutically acceptable forms of Formula 1 and Formula 1-A in which:
W is phenyl, pyridyl, pyrimidinyl, imidazolyl, pyrrolyl, pyrazolyl, furanyl, thienyl, oxazolyl, or isoxazolyl, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, halogen, oxo, - alkyl, Ci- C4 alkoxy, d-C2haloalkyl, d-dhaloalkoxy, and mono- and di-(d-C alkyl)amino.
[0074] Other embodiments of the invention include compounds and pharmaceutically acceptable forms of Formula 1 and 1 -A in which:
W is imidazolyl, pyrrolyl, or pyrazolyl, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, cyano, halogen, oxo, d-C4 alkyl, d- C4alkoxy, trifluoromethyl, and trifluoromethoxy.
[0075] The invention includes compounds and pharmaceutically acceptable forms in which W is an imidazolyl group substituted with Ri at the 4-position or at the 2- position, i.e. compounds of Formula 2 and Formula 3:
(Formula 2) (Formula 3).
[0076] The invention includes compounds and pharmaceutically acceptable forms in which W is a pyrazolyl group substituted with Ri at the 3-position, i.e., compounds of Formula 4:
[0077] The invention includes compounds and pharmaceutically acceptable forms of Formula 1 and Formula 1-A in which X is N. In other embodiments X is CH. Tli e Z? Variable
[0078] The invention includes compounds and pharmaceutically acceptable foπns of Foπnula 1 and Formula 1-A in which: Z2 is
wherein R8 and R9 are independently hydrogen or Cι-C6alkyl; n is 0, 1, or 2; and Rio and R11 are independently hydrogen, Cι-C6alkyl, or phenyl.
[0079] The invention includes compounds and pharmaceutically acceptable forms of Formula 1 and Formula 1-A in which: Z2 is
[0080] In certain embodiments Rio and Rπ are both hydrogen. Tlie Ri Variable
[0081] The invention includes compounds and pharmaceutically acceptable forms of Formula 1 and Formula 1-A in which:
R2 is phenyl, pyridyl, pyrimidinyl, pyrazinyl, imidazolyl, pyrrolyl, furanyl, thienyl, oxazolyl, or isoxazolyl, each of which may be either directly attached or bound via a Cι-C2alkyl linker, and each of which is substituted with 0 to 3 substituents independently chosen from: (i) hydroxy, halogen, nitro, cyano, amino, sulfonamide, - CHO, d-Cδhaloalkyl, and Ci-Cehaloalkoxy, and (ii) Cι-C6alkyl, C2-C6alkenyl, C2- Qalkynyl, C3-C cycloalkyl, Cι-C6alkoxy, (Cι-C6alkoxy)Cι-C6alkyl, (Cι-C6alkoxy)Cι- C6alkoxy, Cι-C6alkylthio, mono- and di-(Cι-C6alkyl)amino, amino(Cι-C6alkyl), mono- and di-(Cι-C6alkyl)amino(Cι-C6alkyl), C2-C6alkanoyl, and heterocycloalkyl(C0-C2alkyl); each of which (ii) is substituted with 0 to 3 substituents independently chosen from halogen, hydroxy, amino, nitro, cyano, Cι-C4alkoxy, C3-C7cycloalkyl, and mono- and di- (C ι-C4all yl)amino .
[0082] In other embodiments the invention includes compounds and pharmaceutically acceptable forms of Formula 1 and Formula 1-A in which:
R2 is phenyl(Co-C2alkyl), pyridyl(Co-C2alkyl), or pyrimidinyl(C0-C2alkyl), each of which is substituted with 0 to 3 substituents independently chosen from: (i) hydroxy,
halogen, nitro, cyano, amino, Ci-dhaloalkyl, and Ci-dhaloalkoxy, and (ii) Cι-C6alkyl, d-dcycloalkyl, Cι-C6alkoxy, (Cι-C6alkoxy)Cι-C6alkyl, mono- and di-(Cι- C4alkyl)amino, mono- and di-(Cι-C4alkyl)amino(Cι-C4alkyl), and heterocycloalkyl(Co- C2alkyl); each of which (ii) is substituted with 0 to 3 substituents independently chosen from halogen, hydroxy, amino, nitro, cyano, Cι-C alkoxy, d-dcycloalkyl, and mono- and di-(Cι-C4alkyl)amino.
[0083] The invention further includes compounds and pharmaceutically acceptable forms of Formula 1 and Formula 1-A in which:
R2 is phenyl, pyridyl, or pyrimidinyl, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, halogen, Ci- C6alkyl, d-dcycloalkyl, Cι-C6alkoxy, Ci-dhaloalkyl, Ci-dhaloalkoxy, and mono- and di-(C 1 -C4alkyl)amino . Tlie Rs Variable
[0084] The invention includes compounds and pharmaceutically acceptable forms of Formula I and Formula 1-A in which:
R3 is hydrogen or Cι-C6alkyl, or R3 is C3-C7cycloalkyl(C0-C2alkyl), heterocycloalkyl(Co-C2alkyl), phenyl, phenyl, pyridyl, pyrimidinyl, pyrazinyl, imidazolyl, pyrrolyl, furanyl, thienyl, oxazolyl, or isoxazolyl, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, halogen, Cι-C6alkyl, d-dcycloalkyl, Cι-C6alkoxy, Ci-dhaloalkyl, Ci-dhaloalkoxy, and mono- and di-(Cι-C4alkyl)amino; or R3 is phenoxy phenyl, each of which phenyl rings is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, halogen, d-dalkyl, d-C7cycloalkyl, d-Qalkoxy, Ci-dhaloalkyl, Ci- dhaloalkoxy, and mono- and di-(Cι-C4alkyl)amino.
[0085] Further included are compounds and pharmaceutically acceptable forms of Formula I and Formula 1-A in which:
R3 is hydrogen, Cι-C6alkyl, C3-C7cycloalkyl(Co-dalkyl), phenyl, or phenoxyphenyl. In some preferred embodiments R3 is hydrogen or Cι-C4alkyl.
Formulas 6, 7, and 8
[0086] The invention pertains to compounds and pharmaceutically acceptable forms of Formula 6
(Formula 6) in which Ri, R2, R3, X, W, and Zi may carry any of the definitions set forth above for these variables.
[0087] The invention further pertains to compounds and pharmaceutically acceptable forms of Formula 7
(Formula 7) in which Ri, R2, R3, X, W, and Zi may carry any of the definitions set forth above for these variables.
[0088] The invention pertains to compounds and pharmaceutically acceptable forms of Formula 8
(Formula 8).
in which Ri, R2, R3, X, W, and Zi may carry any of the definitions set forth above for these variables.
[0089] The invention pertains to compounds and pharmaceutically acceptable forms of Formula 9 to 14:
(Formula 9) (Formula 10)
(Formula 12).
(Formula 11)
(Formula 13) (Formula 14)
[0090] Ri, R2, and R3 shown in Formula 9 to Formula 14 may carry any of the definitions set forth above for these variables.
[0091] In some preferred embodiments the invention includes compounds and pharmaceutically acceptable forms, in which:
Ri is bromo or Ci-dalkyl; or
Ri is phenyl substituted with 0 to 2 substituents independently chosen from fluoro, chloro, bromo, Ci-dalkyl, and Cι-C2alkoxy;
R2 is phenyl or benzyl, each of which is substituted with 0 to 3 substituents independently chosen from: (i) hydroxy, halogen, amino, Cι-C haloalkyl, and Ci- dhaloalkoxy; and (ii) Ci-Cδal yl, Cι-C6alkoxy, mono- and di-(Ci-C4alkyl)amino, mono- and di-(Cι-C4alkyl)amino(Cι-C4alkyl), piperazinyl(Co-Cι alkyl), piperidinyl(Co-Cιalkyl) and mo holinyl(Co-Cιalkyl); each of which (ii) is substituted with 0 to 3 substituents independently chosen from halogen, hydroxy, amino, Cι-C2alkoxy, and mono- and di- (Cι-C4alkyl)amino.
R3 is hydrogen or Cι-C4alkyl.
[0092] The definitions of the variables Ri, R2, R3, X, W, Zi, and Z2 given herein may be combined in any way that results in a stable compound of Formula I, 1, 1-A, or 2 to 14.
[0093] Certain compounds of Formula I described herein modulate ldnase and/or Hsp90 complex activity. Certain preferred compounds of Formula I are highly active inhibitors of Hsp90 complex activity.
[0094] Modulation of ldnase activity is determined by a biochemical assay such as the EphB4 biochemical assay of Example 8, or the c-Kit, TIE-2, and VEGF-R2 assays of Example 9.
[0095] Inhibition of Hsp90 complex activity results in reduced cell proliferation. Thus, modulation of Hsp90 complex activity is determined by a cell proliferation assay such as the tumor cell proliferation assay of Example 11. Hsp90 complex activity
inhibition may also be observed via Western blot, for example by the Western blot protocol of Example 10. In this protocol reduced level of Hsp90 substrate proteins, such as ErbB2, Raf, or Aid:, indicates inhibition of Hsp90 complex activity.
[0096] The invention includes compounds of Formula I, which exhibit an IC50 of 25 micromolar or less, and more preferably 10 micromolar or less in an in vitro assay of tumor cell proliferation (such as the assay of Example 11).
[0097] The invention includes a method of modulating binding of ATP to the Hsp90 complex, the method comprising contacting a cell or cells expressing Hsp90 complex with a compound of Formula I or any pharmaceutically acceptable form thereof according in an amount sufficient to detectably decrease the level of an Hsp90 complex substrate protein in vitro. Decreased level of Hsp90 complex substrate protein may be observed via Western blot, for example by the Western blot protocol of Example 10. The substrate may be ErbB2 or other Hsp90 complex substrate, such as Raf or Akt.
[0098] Modulation of ATP binding to Hsp90 complex may be in vivo or in vitro. Preferably the cell(s) expressing Hsp90 complex are present in a mammal. The mammal may be a human, companion animal, such as a cat or dog, livestock animal, or other mammal.
PHARMACEUTICAL PREPARATIONS
[0099] Compounds, salts, and any other pharmaceutically acceptable forms of the invention can be administered as the neat chemical, but are preferably administered as a pharmaceutical composition or formulation. Accordingly, the invention provides pharmaceutical formulations comprising a compound or pharmaceutically acceptable form of Formula I, together with one or more pharmaceutically acceptable carriers, excipients, adjuvants, diluents, or other ingredients.
[00100] Pharmaceutical carriers must be of sufficiently high purity and sufficiently low toxicity to render them suitable for administration to the animal being treated. The carrier can be inert or it can possess pharmaceutical benefits. The amount of carrier
employed in conjunction with the compound is sufficient to provide a practical quantity of material for administration per unit dose of the compound.
[00101] Exemplary pharmaceutically acceptable carriers or components thereof are sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose, and methyl cellulose; powdered tragacanth; malt; gelatin; talc; solid lubricants, such as stearic acid and magnesium stearate; calcium sulfate; synthetic oils; vegetable oils, such as peanut oil, cottonseed oil, sesame oil, olive oil, and corn oil; polyols such as propylene glycol, glycerine, sorbitol, mannitol, and polyethylene glycol; alginic acid; phosphate buffer solutions; emulsifiers, such as the TWEENS; wetting agents, such sodium lauryl sulfate; coloring agents; flavoring agents; tableting agents; stabilizers; antioxidants; preservatives; pyrogen-free water; isotonic saline; and phosphate buffer solutions.
[00102] Optional active agents may be included in a pharmaceutical composition, which do not substantially interfere with the activity of the compound of the present invention.
[00103] Effective concentrations of one or more of the compounds of the invention including pharmaceutically acceptable salts, esters or other derivatives thereof are mixed with a suitable pharmaceutical earner, excipients, adjuvant, or vehicle. In instances in which the compounds exhibit insufficient solubility, methods for solubilizing compounds may be used. Such methods are known to those of skill in this art, and include, but are not limited to, using cosolvents, such as dimethylsulfoxide (DMSO), using surfactants, such as TWEEN, or dissolution in aqueous sodium bicarbonate. Derivatives of the compounds, such as salts of the compounds or prodrugs of the compounds may also be used in formulating effective pharmaceutical compositions.
[00104] Upon mixing or addition of the compound(s) of the invention, the resulting mixture may be a solution, suspension, emulsion or the like. The form of the resulting mixture depends upon a number of factors, including the intended mode of administration and the solubility of the compound in the chosen carrier or vehicle. The
effective concentration sufficient for ameliorating the symptoms of the disease, disorder, or condition treated and may be empirically determined.
[00105] Compounds of general the invention may be administered orally, topically, parenterally, intravenously, by intramuscular injection, by inhalation or spray, sublingually, transdermally, via buccal administration, rectally, as an ophthalmic solution, or by other means, in dosage unit formulations.
[00106] Dosage formulations suitable for oral use, include, for example, tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents, such as sweetening agents, flavoring agents, coloring agents and preserving agents, in order to provide pharmaceutically elegant and palatable preparations. Oral formulations contain between 0.1 and 99% of a compound of the invention and usually at least about 5% (weight %) of a compound of the present invention. Some embodiments contain from about 25% to about 50% or from 5% to 75 % of a compound of invention.
[00107] Orally administered compositions also include liquid solutions, emulsions, suspensions, powders, granules, elixirs, tinctures, syrups, and the like. The pharmaceutically acceptable carriers suitable for preparation of such compositions are well known in the art. Oral formulations may contain preservatives, flavoring agents, sweetening agents, such as sucrose or saccharin, taste-masldng agents, and coloring agents.
[00108] Typical components of carriers for syrups, elixirs, emulsions and suspensions include ethanol, glycerol, propylene glycol, polyethylene glycol, liquid sucrose, sorbitol and water. Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent. Orally Administered Liquids formulations
[00109] Compounds of the invention can be incorporated into oral liquid preparations such as aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, for example. Moreover, formulations containing these compounds can be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations can contain conventional additives, such as suspending agents (e.g., sorbitol syrup, methyl cellulose, glucose/sugar, syrup, gelatin, hydroxyethyl cellulose, carboxymethyl cellulose, aluminum stearate gel, and hydrogenated edible fats), emulsifying agents (e.g., lecithin, sorbitan monsoleate, or acacia), non-aqueous vehicles, which can include edible oils (e.g., almond oil, fractionated coconut oil, silyl esters, propylene glycol and ethyl alcohol), and preservatives (e.g., methyl or propyl p- hydroxybenzoate and sorbic acid). Suspensions
[00110] For a suspension, typical suspending agents include methylcellulose, sodium carboxymethyl cellulose, AVICEL RC-591, tragacanth and sodium alginate; typical wetting agents include lecithin and polysorbate 80; and typical preservatives include methyl paraben and sodium benzoate.
[00111] Aqueous suspensions contain the active material(s) in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydropropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents; may be a naturally-occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol substitute, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan substitute. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n- propyl p-hydroxybenzoate.
[00112] Oily suspensions may be formulated by suspending the active ingredients in a vegetable oil, for example peanut oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide palatable oral preparations. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid. Emulsions
[00113] Pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, for example olive oil or peanut oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol, anhydrides, for example sorbitan monoleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monoleate. Dispersible powders
[00114] Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Tablets and Capsules
[00115] Tablets typically comprise conventional pharmaceutically compatible adjuvants as inert diluents, such as calcium carbonate, sodium carbonate, mannitol, lactose and cellulose; binders such as starch, gelatin and sucrose; disintegrants such as starch, alginic acid and croscarmelose; lubricants such as magnesium stearate, stearic acid and talc. Glidants such as silicon dioxide can be used to improve flow characteristics of the powder mixture. Coloring agents, such as the FD&C dyes, can be
added for appearance. Sweeteners and flavoring agents, such as aspartame, saccharin, menthol, peppermint, and fruit flavors, are useful adjuvants for chewable tablets. Capsules (including time release and sustained release formulations) typically comprise one or more solid diluents disclosed above. The selection of carrier components often depends on secondary considerations like taste, cost, and shelf stability.
[00116] Such compositions may also be coated by conventional methods, typically with pH or time-dependent coatings, such that the subject compound is released in the gastrointestinal tract in the vicinity of the desired topical application, or at various times to extend the desired action. Such dosage forms typically include, but are not limited to, one or more of cellulose acetate phthalate, polyvinylacetate phthalate, hydroxypropyl methylcellulose phthalate, ethyl cellulose, Eudragit coatings, waxes and shellac.
[00117] Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil. Injectable and P or enter al formulations
[00118] Pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleaginous suspension. This suspension may be foπnulated according to the known art using those suitable dispersing or wetting agents and suspending agents that have been mentioned above. The sterile injectable preparation may also be sterile injectable solution or suspension in a non-toxic parentally acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are useful in the preparation of injectables.
[00119] Compounds of the invention may be administered parenterally in a sterile medium. Parenteral administration includes subcutaneous injections, intravenous, intramuscular, intrathecal injection or infusion techniques. The compound or compounds of the invention, depending on the vehicle and concentration used, can either be suspended or dissolved in the vehicle. Advantageously, adjuvants such as local anesthetics, preservatives and buffering agents can be dissolved in the vehicle. In many compositions for parenteral administration the carrier comprises at least about 90% by weight of the total composition. Preferred carriers for parenteral administration include propylene glycol, ethyl oleate, pyrrolidone, ethanol, and sesame oil. Suppositories
[00120] Compounds of the invention may also be administered in the form of suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient that is solid at ordinary temperatures but liquid at rectal temperature and will therefore melt in the rectum to release the drug. Such materials include cocoa butter and polyethylene glycols. Topical formulations
[00121] Compounds of the invention may be formulated for local or topical application, such as for topical application to the skin and mucous membranes, such as in the eye, in the form of gels, creams, and lotions and for application to the eye. Topical compositions of the present invention may be in any form including, for example, solutions, creams, ointments, gels, lotions, milks, cleansers, moisturizers, sprays, skin patches, and the like.
[00122] Such solutions maybe foπnulated as 0.01% -10% isotonic solutions, pH about 5-7, with appropriate salts. Compounds of the invention may also be formulated for transdermal administration as a transdermal patch.
[00123] Topical compositions containing the active compound can be admixed with a variety of carrier materials well known in the art, such as, for example, water, alcohols, aloe vera gel, allantoin, glycerine, vitamin A and E oils, mineral oil, propylene glycol, PPG-2 myristyl propionate, and the like.
[00124] Other materials suitable for use in topical carriers include, for example, emollients, solvents, humectants, thickeners and powders. Examples of each of these types of materials, which can be used singly or as mixtures of one or more materials, are as follows: Emollients, such as stearyl alcohol, glyceryl monoricinoleate, glyceryl monostearate, propane- 1,2-diol, butane- 1, 3 -diol, mink oil, cetyl alcohol, iso-propyl isostearate, stearic acid, iso-butyl palmitate, isocetyl stearate, oleyl alcohol, isopropyl laurate, hexyl laurate, decyl oleate, octadecan-2-ol, isocetyl alcohol, cetyl palmitate, dimethylpolysiloxane, di-n-butyl sebacate, iso-propyl myristate, iso-propyl palmitate, isopropyl stearate, butyl stearate, polyethylene glycol, triethylene glycol, lanolin, sesame oil, coconut oil, arachis oil, castor oil, acetylated lanolin alcohols, petroleum, mineral oil, butyl myristate, isostearic acid, palmitic acid, isopropyl linoleate, lauryl lactate, myristyl lactate, decyl oleate, and myristyl myristate; propellants, such as propane, butane, iso- butane, dimethyl ether, carbon dioxide, and nitrous oxide; solvents, such as ethyl alcohol, methylene chloride, iso-propanol, castor oil, ethylene glycol monoethyl ether, diethylene glycol monobutyl ether, diethylene glycol monoethyl ether, dimethyl sulphoxide, dimethyl formamide, tetrahydrofuran; humectants, such as glycerin, sorbitol, sodium 2- pyrrolidone-5-carboxylate, soluble collagen, dibutyl phthalate, and gelatin; and powders, such as chalk, talc, fullers earth, kaolin, starch, gums, colloidal silicon dioxide, sodium polyacrylate, terra alkyl ammonium smectites, trialkyl aryl ammonium smectites, chemically modified magnesium aluminium silicate, organically modified montmorillonite clay, hydrated aluminium silicate, fumed silica, carboxyvinyl polymer, sodium carboxymethyl cellulose, and ethylene glycol monostearate.
[00125] Compounds of the invention may also be topically administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines. Other formulations
[00126] Other compositions useful for attaining systemic delivery of the subject compounds include sublingual, buccal and nasal dosage forms. Such compositions
typically comprise one or more of soluble filler substances such as sucrose, sorbitol and mannitol, and binders such as acacia, microcrystalline cellulose, carboxymethyl cellulose, and hydroxypropyl methylcellulose. Glidants, lubricants, sweeteners, colorants, antioxidants and flavoring agents disclosed above may also be included.
[00127] Compositions for inhalation typically can be provided in the form of a solution, suspension or emulsion that can be administered as a dry powder or in the form of an aerosol using a conventional propellant (e.g., dichlorodifluoromethane or trichloiOfluoromethane) . Additional components
[00128] The compositions of the present invention may also optionally comprise an activity enhancer. The activity enhancer can be chosen from a wide variety of molecules that function in different ways to enhance antimicrobial effects of compounds of the present invention. Particular classes of activity enhancers include skin penetration enhancers and absorption enhancers.
[00129] Pharmaceutical compositions of the invention may also contain additional active agents can be chosen from a wide variety of molecules, which can function in different ways to enhance the therapeutic effects of a compound of the present invention. These optional other active agents, when present, are typically employed in the compositions of the invention at a level ranging from about 0.01% to about 15%. Some embodiments contain from about 0.1% to about 10% by weight of the composition. Other embodiments contain from about 0.5% to about 5% by weight of the composition. Packaged Formulations
[00130] The invention includes packaged pharmaceutical formulations. Such packaged formulations include a pharmaceutical composition containing one or more compounds, salts, or other pharmaceutically acceptable forms thereof, of the invention in a container and instructions for using the composition to treat an animal (typically a human patient) suffering from a disease or disorder responsive to ldnase modulation or Hsp90 complex modulation, or prevent in a patient. Preferably the packaged
pharmaceutical formulation contains instructions for using the composition to treat a patient suffering from a disease or disorder responsive to Hsp90 complex modulation.
[00131] The invention includes providing prescribing information; for example, to a patient or health care provider, or as a label in a packaged pharmaceutical formulation. Prescribing information may include for example efficacy, dosage and administration, contraindication and adverse reaction information pertaining to the pharmaceutical formulation.
[00132] In all of the foregoing the compounds of the invention can be administered alone, as mixtures, or in combination with other active agents.
METHODS OF TREATMENT
[00133] The invention includes new imidazo[l,2-a]pyrazines. Certain compounds described herein are modulators of protein kinases, for example EphB4, Tie-2, c-Kit, and VEGF-R2 kinases, and/ or the Hsp90 complex. Certain preferred compounds described herein are highly active inhibitors of the Hsp90 complex. The compounds of the present invention are useful for the treatment of diseases and disorders responsive to ldnase modulation and/ or Hsp90 complex modulation. Prefeπed compounds described herein are useful for the treatment of diseases and disorders responsive to Hsp90 complex modulation.
[00134] Without wishing to be bound to any particular theory, it is believed that the interaction of the compounds of Formula I with one or more of several kinases or the Hsp90 complex results in the phaπnaceutical utility of these compounds. It is believed that the interaction of certain prefeπed compounds of Formula I with the Hsp90 complex results in the pharmaceutical utility of these prefeπed compounds.
[00135] Accordingly, the invention includes a method of treating a mammal, preferably a human, having a disease or disorder responsive to ldnase or Hsp90 complex modulation, comprising administrating to the mammal of an effective amount of a compound of Formula I.
[00136] Methods of treatment also include modulating kinase and/or Hsp90 complex activity, by inhibiting ATP binding or hydrolysis by a kinase or the Hsp90 complex or by some other mechanism, in vivo, in a patient suffering from a disease or disorder responsive to kinase or Hsp90 complex modulation, by administering a sufficient concentration of a compound of Formula I to inhibit kinase and/ or Hsp90 complex activity in vitro. By "sufficient concentration" of a compound administered to the patient is meant the concentration of the compound available in the patient's system to combat the disease or disorder. Such a concentration be ascertained experimentally, for example by assaying blood concentration of the compound, or theoretically, by calculating bioavailability.
[00137] In a prefeπed embodiment, the invention includes a method of treating a patient suffering from a disease or disorder responsive to Hsp90 complex modulation, wherein the disease or disorder is cancer, a neurodegenerative disorder, an autoimmune disease, or inflammation.
[00138] The invention provides methods of treatment in which a compound of the invention is the only active agent given to a patient and also includes methods of treatment in which a compound of Formula I is given to a patient with one or more active agents. Diseases and disorders responsive to kinase modulation
[00139] Certain compounds described herein are useful for treating a patient suffering from a disease or disorder responsive to ldnase modulation.
[00140] Protein Idnases, the largest family of human enzymes, are now considered to be the largest druggable target class. Encompassing well over 500 proteins (2% of the human genome), kinases play critical roles in signaling pathways controlling fundamental cellular processes such as proliferation, differentiation, and death (apoptosis). Abnormal ldnase activity has been implicated in a wide range of diseases, including multiple cancers and autoimmune and inflammatory diseases. The multifaceted role of kinases in key cell signaling pathways provides a significant opportunity to identify novel drugs targeting kinases and signaling pathways. Accordingly, there is intense industry-wide
interest in this target family, with kinase related research accounting for nearly 25% of the discovery programs at many pharmaceutical and biotechnology companies. The recently demonstrated efficacy of multiple ldnase inhibitors in the treatment of cancer including the FDA approval of the kinase inhibitor GLEEVEC (imatinib mesylate), a c- Kit, PDGFR, and Abl ldnase inhibitor, for the treatment of chronic myeloid leukemia, and the proof of clinical efficacy for AVASTIN, a VEGF modulator that inhibits angiogenesis, is testimony to the great clinical potential of kinase and other signal transduction inhibitors as therapeutics.
[00141] Kinases are implicated in a large variety of diseases, as certain mutations in protein kinases can lead to activation of pathways causing, for example, the production of tumors, while other mutations in protein kinases block pathways and prevent a response.
[00142] Altered PKA (cyclic AMP-dependent protein ldnase) expression is implicated in a variety of disorders and diseases including cancer, thyroid disorders, diabetes, atherosclerosis, and cardiovascular disease. Altered MAP (mitogen-activated protein) ldnase expression is implicated in a variety of disease conditions including cancer, inflammation, immune disorders, and disorders affecting growth and development. RTKs (receptor tyrosine Idnases), CDKs and STKs (serine/threonine Idnases) have all been implicated in a host of pathogenic conditions including, significantly, large number of diverse cancers. Others pathogenic conditions that have been associated with PTKs include, psoriasis, hepatic ciπhosis, diabetes, atherosclerosis, angiogenesis, restinosis, ocular diseases, rheumatoid arthritis and other inflammatory disorders, autoimmune disease, and a variety of renal disorders.
[00143] Within some embodiments the conditions, diseases and/or disorders that are affected using compounds of Formula I and compositions comprising such compounds include, but are not limited to, psoriasis, pathological angiogenesis, cancer (for example, chronic myelogenous leukemia, gastrointestinal stromal tumors, non-small cell lung cancer, breast cancer, ovarian cancer, recurrent ovarian cancer, prostate cancer such as hormonal refractory prostate cancer, kidney cancer, head and neck cancer, or
colorectal cancer), immunoregulation (graft rejection), atherosclerosis, rheumatoid arthritis, Parkinson's disease, Alzheimer's disease, diabetes (for example insulin resistance or diabetic retinopathy), septic shock, and the like.
[00144] Certain kinase inhibitory compounds play an active role in angiogenesis certain compounds described herein are useful for modulating angiogenesis. Angiogenesis, the formation of new blood vessels from preexisting ones, plays a critical role in many pathological settings, including cancer, chronic inflammation, diabetic retinopathy and macular degeneration. Angiogenesis is regulated by multiple cell- signaling pathways, including pathways controlled by cellular kinases. Blocking angiogenesis, through the modulation of cell kinases, therefore, represents an effective approach to the treatment of diseases such as cancer. Thus methods of treatment include administering a sufficient amount of a compound or form thereof of the invention to decrease the symptoms or slow the progression of these diseases or disorders by inhibiting the rate of angiogenesis in a tissue. Diseases and Disorders Responsive to Hsp90 Complex Modulation
[00145] Certain compounds described herein are useful for treating a patient suffering from a disease or disorder responsive to Hsp90 complex modulation.
[00146] The Hsp90 complex and its substrate proteins, including Akt, ErbB2, and Raf, have been implicated in a number of cancerous conditions. Thus Hsp90 complex inhibitors of the invention are particularly useful in the treatment of cancer, including, but not limited to, chronic myeloid leukemia, melanoma, breast, ovarian, brain, lung, thyroid, colorectal, prostate, and bladder cancer. Because of the role of Hsp90 in modulating the cellular stress response Hsp90 inhibitors of the invention are also useful in the treatment of heart disease, stroke, and neurodegenerative diseases including multiple sclerosis, Alzheimer's dementia, and ischemic optic neuropathy. Thus methods of treatment include administering a sufficient amount of a compound or form thereof of the invention to decrease the symptoms or slow the progression of these diseases or disorders. Combination Therapy
[00147] In addition to methods of treatment in which a compound of Formula I is the only active agent given to a patient, the invention further includes methods for combination drug therapy, in which a compound of the invention is given to a patient together with one or more other active agents. Thus in one embodiment the invention provides a method of treating cancer, which comprises administering to a mammal in need thereof an effective amount of a compound of Formula I together with a second active agent, which is useful for treating cancer. For example the second agent may be an antitumor agent. Treatment with the second active agent may be prior to, concomitant with, or following treatment with a compound of Formula I. In certain embodiments a compound of Formula I is combined with another active agent in a single dosage form. Suitable antitumor therapeutics that may be used in combination with a compound of Formula I include, but are not limited to chemotherapeutic agents, for example mitomycin C, carboplatin, taxol, cisplatin, paclitaxel, etoposide, doxorubicin, or a combination comprising at least one of the foregoing chemotherapeutic agents. Radiotherapeutic antitumor agents may also be used, alone or in combination with chemotherapeutic agents. Dosage Levels
[00148] Dosage levels of the order of from about 0.1 mg to about 140 mg per kilogram of body weight per day are useful in the treatment of the conditions listed above (about 0.5 mg to about 7 g per patient per day). The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. Dosage unit forms will generally contain between from about 1 mg to about 500 mg of an active ingredient.
[00149] Frequency of dosage may also vary depending on the compound used and the particular disease treated. However, for treatment of most infectious disorders, a dosage regimen of 4 times daily or less is prefeπed and a dosage regimen of 1 or 2 times daily is particularly prefeπed.
[00150] It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, and rate of excretion, drug combination and the severity of the particular disease in the patient undergoing therapy.
EXAMPLES
[00151] The invention is illustrated by the following non-limiting examples. Exemplary syntheses of compounds of the Formula I are included in this section. EXAMPLE 1. SYNTHESIS OF 1-O-TOLYL-3- {3-[8-(4-P-TOLYL-IMIDAZOL-1-YL)- IMIDAZO[1,2-A]PYRAZΓN-6-YL]-PHENYL}-UREA (Compound 6) Step 1. Preparation of 6,8-dibromoimidazo[l ,2-aJpyrazine (Compound 3)
EtVnFt
1 2 3
[00152] A mixture of bromoacetaldehyde diethyl acetal (1) (51 grams (g)), 48% hydrobromic acid (HBr) (11 milliliters (ml)), and water (11 ml) is heated at 120 °C for 1 hour (hr). The solution is cooled, poured into a mixture of sodium bicarbonate (NaHCO3) (60 g), and isopropyl alcohol (IPA) (200 ml), and stirred for 0.5 hr. The mixture is filtered, and the filtrate treated with 3,5-dibromo-2-aminopyrazine (2) (33 g) and heated under reflux for 16 hr. The suspension is cooled in ice, treated with 48%HBr (3 ml) and diethyl ether (60 ml) and filtered to give (3) (33 g) as the hydrobromide salt. Step 2. Preparation of 6-Bromo-8-(4-p-tolyl-imidazol-l-yl)-imidazo[l,2-a]pyrazine (Compound 4)
3 4
[00153] Sodium hydride (NaH) (144 milligrams (mg) of a 60% dispersion in mineral oil) is added to a solution of 4-p-tolyl-lH-imidazole (571 mg) inN,N,- dimethylformamide (DMF) (10 ml) and the mixture is stirred at room temperature (rt) for 0.5 hr. A solution of 6,8-dibromoimidazo[l,2-a]pyrazine (3) (1.0 g) in DMF (10ml) is added. The mixture is stiπed at room temperature (rt) for 16 hr. Water (50 ml) is added and the mixture is extracted with ethyl acetate (3x70 ml); extracts are washed with water (2 x 50 ml) and brine (1x50 ml), dried over magnesium sulfate (MgSO4), and evaporated in vacuo to give a waxy solid. The solid is sluπied with a little diethyl ether and filtered to give 6-Bromo-8-(4-p-tolyl-imidazol-l-yl)-imidazo[l,2-a]pyrazine (4) (1.08 g) as a light brown solid.
Step 3. Preparation ofS-[8-(4-ρ-Tolyl-imidazol-l-yl)-imidazo[l,2-a]pyrazin-6-yl]- phenylamine (Compound 5)
[00154] A mixture of 6-bromo-8-(4-p-tolyl-imidazol- 1 -yl)-imidazo[l ,2-a]pyrazine (4) (870mg), 3-aminophenylboronic acid hydrochloride (511mg),
tetralds(triphenylphosphine) palladium (Pd(PPli3) ) (142mg), 1 M aqueous sodium carbonate (Na2CO3) (7.4ml), and 1,2-dimethoxyethane (DME) (35ml) is heated at 90 °C for 16 hours. The mixture is cooled to rt, treated with water (50 ml) and extracted with ethyl acetate (3 x 80 ml). The extracts are washed with water (1 x 50 ml) and brine (1 x 50 ml), dried over MgSO4, and evaporated in vacuo to give a semi-solid which is triturated with diethyl ether/methanol (10:1) to give 3-[8-(4-p-Tolyl-imidazol-l-yl)- imidazo[l,2-a]pyrazin-6-yl]-phenylamine (5) (600mg) as a cream-colored solid. Step 4. Preparation of l-o-Tolyl-3-{3-[8-(4-p-tolyl-imidazol-l-yl)-imidazo[l ,2- aJpyrazin-6-ylJ-phenyl}-urea (Compound 6)
[00155] A solution of 3-[8-(4-p-tolyl-imidazol-l-yl)-imidazo[l,2-a]pyrazin-6-yl]- phenylamine (5) (50 mg), l-isocyanato-2 -methyl -benzene (18 mg), in dichloromethane (DCM) (3 ml) and DMF (0.5 ml) is stiπed at room temperature for 16 hr. The mixture is concentrated in vacuo, the residue sluπied with diethyl ether/methanol (20: 1), and filtered to give l-o-tolyl-3-{3-[8-(4-Jp-tolyl-imidazol-l-yl)-imidazo[l,2-a]pyrazin-6-yl]- phenyl}-urea (6) (40mg) as a cream solid.
EXAMPLE 2. PREPARATION OF 2-(4-CHLORO-PHENYL)-N- {3-[8-(2-PHENYL-IMIDAZOL- 1 - YL)-IMIDAZO[1 ,2-A]PYRAZIN-6-YL]-PHENYL} -ACETAMIDE
Toluene, DMF
[00156] Solid 3-[8-(2-Phenyl-imidazol-l-yl)-imidazo[l,2-a]p3π:azin-6-yl]- phenylamine (50 mg) (7) is added to an anhydrous 0.2 M solution of (4-Chloro-phenyl)- acetyl chloride in toluene (0.7 mL) at room temperature, and 0.25 ml of anliydrous DMF is subsequently added to solubilize the reagents. The reaction is wanned to 50 C and stiπed under N2 for 3 hours. The reaction is cooled to room temperature. Diethyl ether (15 ml) is then added slowly and the resulting tan solid 2-(4-Chloro-phenyl)-N-{3-[8-(2- phenyl-imidazol-l-yl)-imidazo[l,2-a]pyrazin-6-yl]-phenyl}-acetamide (60 mg) (8) is filtered and washed with diethyl ether and dried under vacuum. EXAMPLE 3. ADDITIONAL CELL PROLIFERATION INHIBITORS
[00157] The following compounds are synthesized via the procedure set forth in Examples 1 and 2. In some instances changes in starting materials and reaction conditions that will be readily apparent to those skilled in the art of organic synthesis may be required.
[00158] LC-MS data reported in this example is obtained as follows:
LC conditions: RP-HPLC is performed on an AGILENT 1100 Binary HPLC system. The column is a Restek Ultra IBD 5 μm 1.0 x 30 mm (Cat. #: 9175331).
The Mobile Phase contains component A, 0.2% Formic Acid/Water), and component B, Acetonitrile.
[00159] MS conditions: Electrospray MS is performed on a MICROMASS LCT equipped with a LockSpray source for accurate mass measurements. Spectra are acquired in positive ion mode from 100-1000 Da at an acquisition rate of 1 spectrum/0.9s with a 0. Is interscan delay. The instrument is tuned for a resolution of 5000 (FWHM). Every 5* scan is taken from the reference position of the Lockspray source. Leucine enkephalin (556.2771 [M+H]*) is used as the reference, or lock mass.
EXAMPLE 4. PREPARATION OF RADIOLABELED PROBE COMPOUNDS OF THE INVENTION
[00160] The compounds of the invention are prepared as radiolabeled probes by carrying out their synthesis using precursors comprising at least one atom that is a radioisotope. The radioisotope is preferably selected from of at least one of carbon (preferably 14C), hydrogen (preferably 3H), sulfur (preferably .35S), or iodine (preferably 125I). Radiolabeled probe compounds of the invention for use in positron emission tomography (PET) contain a positron emitting isotope such as C, N, O, or F. Such radiolabeled probes are conveniently synthesized by a radioisotope supplier specializing in custom synthesis of radiolabeled probe compounds. Such suppliers include Amersham Corporation, Arlington Heights, 111.; Cambridge Isotope Laboratories, Inc. Andover, Mass.; SRI International, Menlo Park, Calif.; Wizard Laboratories, West Sacramento, Calif.; ChemSyn Laboratories, Lexena, Kans.; American Radiolabeled Chemicals, Inc., St. Louis, Mo.; and Morave Biochemicals Inc., Brea, Calif.
[00161] Tritium labeled probe compounds are also conveniently prepared catalytically via platinum-catalyzed exchange in tritiated acetic acid, acid-catalyzed exchange in tritiated trifluoroacetic acid, or heterogeneous-catalyzed exchange with tritium gas. Tritium labeled probe compounds can also be prepared, when appropriate, by sodium borotritide reduction. Such preparations are also conveniently carried out as a custom radiolabeling by any of the suppliers listed in the preceding paragraph using the compound of the invention as substrate. EXAMPLE 5. RECEPTOR AUTO RADIOGRAPHY
[00162] Receptor autoradiography (receptor mapping) is carried out in vitro as described by Kuhar in sections 8.1.1 to 8.1.9 of Current Protocols in Pharmacology (1998) John Wiley & Sons, New York, using radiolabeled compounds of the invention prepared as described in the preceding Example. EXAMPLE 6. AKT-1 KINASE ASSAY
[00163] One standard AKT-1 Kinase Assay used to test compounds disclosed in this application is performed as follows.
[00164] Active recombinant N-terminus his-tagged AKT-1/PKBα kinase obtained from S/21 cells (UBI # 14-276; 50-100 ng; 19-38 nM; about 4.5-9 mU) is incubated in 25 millimolar (mM) Tris pH 7.6; 5 mM Beta-glycerophosphate; 2 mM dithiothreitol (DTT); 100 micromolar (μM) sodium vanadate; and 10 mM magnesium chloride (MgCl2). The final reaction volume is 40 microliters (μl). The reaction mixture is incubated in a 96- well Pierce REACTI-BIND streptavidin-coated high binding capacity coated white plate (Pierce # 15502) coated with saturating amounts of biotinylated Crosstide peptide (UBI #12-385; biotin-KGSGSGRPRTSSFAEG; 50 picomoles (pmoles); about 1.25 μM) and initiated with the addition of 2.5 microcurie (μCi) 32P-gamma-ATP (specific activity 3000 Ci/mmole; 10 mCi/ml; about 21 nanomolar (nM)). Compounds are initially tested in duplicate wells for determination of initial IC50 inhibition in half log serial dilutions starting at 100 uM with a final concentration of 2% dimethyl sulfoxide (DMSO). Following a 30 min (minutes) incubation at 30°C, the reaction is stopped by aspiration tested 4 x 100 ul washes with TBS plus 0.05% Tween-20 prior to addition of 100 μl scintillant and counting in a Beckman TopCount instrument.
[00165] Percent inhibition is calculated as [1-((AVE CPM compound - AVE CPMno peptide background )/(AVE CPM no compound MAX — AVE CPM no peptide background)))*'" 100] .
Staurosporine, a general ATP competitive kinase inhibitor is used as a reference compound. Staurosporine exhibits an IC50 of approximately 60-100 nM for AKT-1 in the current assay format. Approximate S/N ratios are 8-12 X with AVE CPM of Maximum about 15k and no peptide background about 1.5 K. Improved S/N ratios can be obtained using higher amounts of either AKT-1 kinase or P-gamma-ATP. Cold ATP is not added in current format but has been added at up to 200 μM in the presence of 5 μCi 32P- γATP resulting in S/N ratios of approximately 5-1 OX. EXAMPLE 7. SECOND AKT-1 KINASE ASSAY
[00166] Another standard AKT-1 Kinase Assay used to test compounds disclosed in this application may be performed as follows.
[00167] Materials include: 96-well isoplates (Perkin-Elmer Corp., Cat.# 1450- 514) Biotinylated crosstide (Upstate Corp, Cat.#12-385), PKBα/AKT-1 (Panvera Corp.,
Cat# R3878), Adenosine 5'-triphosphate, [gamma-32P] (Perkin Elmer Corp., Cat.# NEG302H001MC). and Streptavidin Coated Beads (Amersham Corp., Cat # RPNQ0007).
[00168] Kinase reaction buffer contains 3-[N-morpholino]propanesulfonic acid (MOPS) (4 mM), pH 7.2, beta-glycerol phosphate (5 mM), Ethylene glycol bis(2- aminoethylether)-N,N,N",N'-tetraaceticacid (EGTA) (1 mM), 0.2 mM sodium orthovanadate, 0.2 mM dithiothreitol, magnesium chloride (15 mM), crosstide (1.2 μM) and 135 ng/well AKT. Compounds in 2.5 μl of 100% DMSO are transferred to the assay plate, 37.5 μl of kinase in reaction buffer is added to the plate and 10 μl of a mixture of radioactive and non-radioactive ATP is added to achieve 5 μM total ATP and 0.2 μCi per well. The reactions are incubated at 24°C for 45 min. and terminated by the addition of 200 μl of a stop solution. The stop solution contains 250 μg of SPA beads, 50 μM ATP, 5 mM ethylenediaminetetraacetic acid (EDTA), and 0.11% Triton X-100 in IX PBS. The stopped reaction is incubated at 24 C for 30 min then centrifuged for 15 min at 800 rpms. Plates are counted in Microbeta Counter using the paralux counting method. EXAMPLE 8. ASSAY FOR EPHB KINASE ACTIVTY
[00169] The following is a procedure for a standard biochemical assay for EphB4 Kinase Activty.
[00170] Materials:
96-well, Vi area flat bottom, white polystyrene plates are purchased from Costar, cat #3693.
The cytoplasmic domain of recombinant EphB kinase (amino acids 596-987, Homo sapiens EphB4, GENBANK Accession No. AY056047.1) with a C-terminal 6X his tag is purified from S 9 cells. Purity of >95% is assessed by Sypro-Ruby staining of SDS gels.
PTK Biotinylated Peptide Substrate 2, is purchased from Promega, cat #V288A.
LANCE Eu-W1024 labeled anti-phosphotyrosine antibody (PT66) is purchased from Perkin-Elmer, cat #AD0068. Kinase Buffer is purchased from Cell Signaling cat #9802.
[00171] Dilutions of compounds are made in 100% DMSO at 20X the final desired concentration. Compounds in 100% DMSO are transferred (1.25 μL) to the 96 well assay plate. A 18.75 μL volume of master mix containing the final concentrations (in 25 ul) of 0.01% BSA, IX Cell Signaling Kinase Buffer, 0.5 μM PTK Biotinylated Peptide
Substrate 2, and 60 ng/well of EphB4 kinase is added to all wells, except the four negative
. . . ' control wells (which contain no kinase), and mixed. To initiate the reaction, 5 μL of 550 uM ATP is added to each well. (Final Concentration of ATP = 110 μM). The reactions are incubated for 1 hour at room temperature (RT). After incubation a quantity of 8.35 μL of a 4X SA-APC Detection Mix is added to each well. The final concentration of Eu- labelled PT66 antibody is 1 nM and the SA-APC is 20 nM (based on the SA moiety).
The reaction plates are incubated at RT for at least 15 minutes after SA-APC Detection
Mix addition. The reaction plates are read on an Envision plate reader (Perkin- Elmer) with 605nm Excitation and 605nm and 640nm Emission wavelengths. Values are corrected for the fluorescence in the absence of enzyme and inhibition curves are fit to the data using a Logit curve-fitting algorithm. IC50 values are determined from these inhibition curves.
EXAMPLE 9. BIOCHEMICAL ASSAY
[00172] The following assay is a standard biochemical assay used to test activity of compounds as inhibitors of c-Kit, VEGF-R2, and Tie2 kinase activity.
[00173] Test compounds are diluted 1:20 from an original 20 μM DMSO stock and incubated with recombinant c-Kit (10 ng), Tie-2 (6 ng), or VEGF-R2 (1 ng) enzyme (ProQinase GmbH, Germany), biotinylated peptide (PTK peptide 2, Promega) in Cell Signalling kinase buffer (c-Kit and Tie-2) or Upstate Kinase buffer (VEGF-R2) and 5 ul of ATP (final concentrations: 50 μM (50 μM for the VEGF-R2 assay, 60 μM for the Tie2 assay, and 150 μM for the c-Kit assay) for 60 minutes at room temperature. The final assay volume is 25 μl. After the 60 minute incubation Streptavidin-APC Detection Mix, which includes 1 nM LANCE Eu-W1024 labeled anti-phosphotyrosine antibody PT66 (Perkin-Elmer, cat #AD0068) and 20 nM SA-APC (based on the SA moiety), is
added. The reaction plates are incubated at room temperature for at least 15 minutes after SA-APC detection mix addition. The reaction plates are then read on an Envision plate reader (Perkin-Elmer) with 605nm excitation 615 nM and 640nm emission wavelengths.
[00174] For a negative control, i.e. a readout in which the kinases are not inhibited, the assay is run with without any test compound added. Staurosporine, a general kinase inhibitor, is used as a positive control.
[00175] IC50 values are determined from an 11 -point saturation binding curve for test compounds that show significant inhibition of one of the tyrosine kinases. In these assays concentration of test compound ranges from 10 μM to 20nM. Equilibrium binding parameters are determined by fitting the allosteric Hill equation to the measured values with the aid of the computer program, such as FitP (BIOSOFT, Ferguson, MO). EXAMPLE 10. WESTERN BLOT
[00176] Tumor cells, such as MCF-7 or HCT-15 cells (both from ATCC, Manassas, VA), are grown to -50-70% confluency and are subsequently incubated for 4- 48 hr at 37 °C in DMEM media containing 20 μM test compound. Cells are washed in ice-cold PBS, lysed, and spun at 10,000 x g for 10 minutes to removes cellular debris. Protein concentration of the cleared lysates is determined using a commercially available protein assay, such as the Piece BCA assay. Equal protein amounts, approximately 30 μl/ lane are loaded onto an SDS-PAGE gel. Proteins are transferred via electrophoresis to nitrocellulose membrane for western blotting. Blots are analyzed for depletion of an Hsp90 substrate protein, such as ErbB2 (Anti-ErbB2: Santa Cruz Biotechnology, Inc., #SC-284), Raf, or Akt, and increased levels of Hsp70 (Anti-HSP70, Transduction Labs #610608). An antibody against a protein that is not an Hsp90 client protein, such as PKA (Anti-PKA Transduction Labs #610980), is used as a loading control. Detection is via a horseradish peroxidase (HRP)-conjugated second antibody. EXAMPLE 11. TUMOR CELL MONOLAYER PROLIFERATION ASSAY:
[00177] Test compounds are diluted to 1% DMSO, final concentration, and incubated with 3-5 x 103 tumor cells (for example MCF-7 or HCT-15 cells) in a final volume of 200 μl for 5 days. CELLTITER 96 AQUEOUS ONE Solution Cell
Proliferation Assay (Promega, Madison WI), a colorimetric assay for determining the number of viable cells is used to quantitate cell growth. In this method, 10-20 μl MTS reagent is added to each well according to manufacturer's instructions, plates are incubated at 37°C and read at OD 490 nm. During the incubation period living cells covert the MTS reagent to a formazan product which absorbs at 490 nm. Thus the 490 nm absorbance is directly proportional to the number of living cells in culture.
[00178] For saturation binding analysis cell proliferation is response to a range of test compound concentrations is determined, for example 6 or 11 concentrations test compound concentrations, from 10 μM to 20 nM may be used. Equilibrium binding parameters are determined by fitting the allosteric Hill equation to the measured values. EXAMPLE 12. TEST RESULTS
[00179] All compounds described in Examples 1-3 were tested in the assay of Example 11 found to exhibit an IC50 of 25 micromolar or less. Certain compounds described herein exhibited an IC50 of 10 micromolar or less, in the assay of Example 11.
[00180] All cited references are incorporated herein in their entirety. While preferred embodiments have been shown and described, various modifications and substitutions may be made thereto without departing from the spirit and scope of the invention.
Claims
1. A compound having Formula 1 :
or pharmaceutically-acceptable form thereof, wherein:
Ri is hydrogen, halogen, Ci-C7alkyl, Cι-C6alkoxy, C3-C7cycloalkyl(C0-C2alkyl), heterocycloalkyl(C0-C2alkyl), sulfonamide, (C1-C6alkoxy)Cι-C6alkyl, ( - C6alkoxy)Cι-C6alkoxy, mono- or di-(Cι-C6alkyl)amino, or mono- or di-(Cι- C6alkyl)amino(Cι-C6alkyl); or i is phenyl or phenyl fused to a 5 to 7-membered heterocycloalkyl ring containing 1 or 2 heteroatoms chosen from N, O, and S, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, -CHO, halogen, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3- C7cycloalkyl, -Cealkoxy, -Cβhaloalkyl, Cι-C6haloalkoxy, Ci-Cβalkylthio, (C1-C6alkoxy)C1-C6alkyl, (C1-C6alkoxy)C1-C6alkoxy, mono- and di-(Cι- C6alkyl)amino, amino(Cι-C6alkyl), mono- and di-(C1-C6alkyl)amino(Cι-C6alkyl), Ca-Cδalkanoyl, and -C(O)R13 where R13 is -Cshaloalkyl, phenyl, heterocycloalkyl, or heteroaryl;
W is phenyl or a 5- or 6-membered heteroaryl containing from 1 to 4 heteroatoms independently chosen from nitrogen, oxygen, and sulfur; wherein W is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, -CHO, halogen, oxo, Cι-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-
C7cycloalkyl, Cι-C6alkoxy, Cι-C6haloalkyl, Ci-Cδhaloalkoxy, (Cι-C6alkoxy)Cι- C6alkyl, (Cι-C6alkoxy)C1-C6alkoxy, Ci-C6alkylthio, mono- and di-(Cι- C6alkyl)amino, amino(C1-C6alkyl), mono- and di-(C1-C6alkyl)amino(C1-C6alkyl), and C2-C6alkanoyl;
X is N or CH;
R2 is Cι-C7alkyl, C3-C7cycloalkyl(Co-C2alkyl), heterocycloalkyl(C0-C2alkyl), Q- C6alkoxy, (C1-C6alkoxy)C1-C6alkyl, or (C1-C6alkoxy)Cι-C6alkoxy; or
R2 is phenyl(C0-C2alkyl) or heteroaryl(C0-C2alkyl), each of which is substituted with 0 to 3 substituents independently chosen from
(i) hydroxy, halogen, nitro, cyano, amino, sulfonamide, -CHO, Ci-Cβhaloalkyl, and Cι-C6haloalkoxy,and
(ii) Ci-Cealkyl, C2-C6alkenyl, C2-C6alkynyl, Ca-Cγcycloalkyl, Cj-Cealkoxy, (Ci- Cealkoxy)Ci-C6alkyl, (Cι-C6alkoxy)Cι-C6alkoxy, Ci-Cόalkylthio, mono- and di- (Cι-C6allcyl)amino, amino(Cι-C6all yl), mono- and di-(Cι-C6alkyl)amino(Cι- Cβallcyl), C2-C6alkanoyl, heterocycloalkyl(Co-C2alkyl), and -C(O)Ri3; each of which (ii) is substituted with 0 to 3 substituents independently chosen from halogen, hydroxy, amino, nitro, cyano, Ci-Q alkoxy, C3-Cvcycloalkyl, and mono- and di~(Cι-C4allcyl)amino;
Z2 is
R8 and R9 are independently hydrogen, d-C6alkyl, Cι-C6alkoxy, or halogen; and n is 0, 1, or 2; Rio and Rπ are independently (iii) hydrogen or Cι-C6alkyl; or
(iv) phenyl or heteroaryl, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, -CHO, halogen, Cι-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3- C7cycloalkyl, Cι-C6alkoxy, Cι-C6haloalkyl, - haloalkoxy, (Ci- C6alkoxy)Cι-C6alkyl, (Cι-C6alkoxy)Cι-C6alkoxy, Cι-C6alkylthio, mono- and di-(Cι-C6alkyl)amino, amino(Cι-C6alkyl), mono- and di-(Ci- C6alkyl)amino(Cι-C6alkyl), C2-C6alkanoyl, and -C(O)Ri3j R3 is hydrogen or Ci-Cβalkyl, or
R3 is C3-C7cycloalkyl(C0-C2alkyl), heterocycloalkyl(Co-C2alkyl), phenyl, or heteroaryl, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, -CHO, halogen, -Cβalkyl, C2- C6alkenyl, C2-C6alkynyl, C3-C7cycloalkyl, Cι-C6alkoxy, Cι-C6haloalkyl, Ci- Cehaloalkoxy, (Cι-C6alkoxy)Cι-C6alkyl, (Cι-C6alkoxy)Cι-C6alkoxy, Ci- C6all ylthio, mono- and di-(Cι-C6alkyl)amino, amino(Cι-C6 alkyl), mono- and di- (Cι-C6alkyl)amino(Cι-C6all yl), C2-C6alkanoyl, and-C(O)Ri3; or R3 is phenoxy phenyl, each of which phenyl rings is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, -CHO, halogen, Cι-C6alkyl, C2-C6alkenyl, GrCealkynyl, C3-C cycloalkyl, Cι-C6alkoxy, Cι-C6haloalkyl, Ci-Cehaloalkoxy, (Cι-C6alkoxy)Cι-C6alkyl, (Cι-C6alkoxy)Cι- C6alkoxy, Cι-C6alkylthio, mono- and di-(Cι-C6alkyl)amino, amino(Cι-C6alkyl), mono- and di-(Cι-C6allcyl)amino(Cι-C6alkyl), C2-C6alkanoyl, and-C(O)Ri3.
2. A compound or form therof according to Claim 1, wherein
Ri is hydrogen, halogen, Ci-C7alkyl, Cι-C6alkoxy, C3-C7cycloalkyl(C0-C2alkyl), heterocycloalkyl(C0-C2alkyl), sulfonamide, (Cι-C6alkoxy)Cι-C6alkyl, (C\- C6alkoxy)Ci-C6alkoxy, mono- or di-(Cι-C6alkyl)amino, or mono- or di-( - C6alkyl)amino(Cι-C6alkyl); or
Ri is phenyl substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, -CHO, halogen, Cι-C6alkyl, C2-C6alkenyl, C2- Cealkynyl, C3-C cycloalkyl, Cι-C6alkoxy, Cι-C6haloalkyl, Cι-C6haloalkoxy, (C\- C6alkoxy)Ci-C6all yl, (Ci-C6alkoxy)Cι-C6alkoxy, Ci-Cδalkylthio, mono- and di- (Cι-C6alkyl)amino, amino(Cι-C6alkyl), mono- and di-(Cι-C6alkyl)amino(Cι- C6alkyl), and C2-C6alkanoyl;
W is phenyl or a 5- or 6-membered heteroaryl ring; substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, -CHO, halogen, oxo, Cι-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C7cycloalkyl, Q- Cealkoxy, Ci-Cδhaloalkyl, Cι-C6haloalkoxy, (Cι-C6alkoxy)Cι-C6alkyl, (Ci- C6alkoxy)Cι-C6alkoxy, Cι-C6alkylthio, mono- and di-(Cι-C6all yl)amino, amino(Cι-C6alkyl), mono- and di-(Cι-C6alkyl)amino(Cι-C6alkyl), and C2- C6alkanoyl;
X is N or CH;
R2 is Cι-C7alkyl, C3-C7cycloalkyl(C0-C2alkyl), heterocycloalkyl(Co-C2alkyl), Ci- C6alkoxy, (Cι-C6alkoxy)Cι-C6alkyl, or (Cι-C6alkoxy)Cι-C6alkoxy; or
R2 is phenyl(Co-C2alkyl) or 5- or 6-membered heteroaryl(C0-C2alkyl), each of which is substituted with 0 to 3 substituents independently chosen from (i) hydroxy, halogen, nitro, cyano, amino, sulfonamide, -CHO, Cι-C6haloalkyl, and Cι-C6haloalkoxy, and
(ii) Cι-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C7cycloalkyl, Cι-C6alkoxy, (Ci- C6alkoxy)Cι-C6alkyl, (Cι-C6alkoxy)Cι-C6alkoxy, Cι-C6alkylthio, mono- and di- (Cι-C6all yl)amino, amino(Cι-C6alkyl), mono- and di-(Cι-C6alkyl)amino(Cι-
C6alkyl), C2-C6alkanoyl, and heterocycloalkyl(C0-C2alkyl); each of which (ii) is substituted with 0 to 3 substituents independently chosen from halogen, hydroxy, amino, nitro, cyano, Cι-C4alkoxy, C3-C7cycloalkyl, and mono- and di-(Cι- C alkyl)amino;
Z2 is
R8 and Rg are independently hydrogen, Ci-C6alkyl, Cι-C6alkoxy, or halogen; and n is 0, 1, or 2; Rio and Rπ are independently (iii) hydrogen or Cι-C6alkyl; or
(iv) phenyl or a 5- or 6 membered heteroaryl ring, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, -CHO, halogen, Cι-C6alkyl, C2- Cealkenyl, C2-C6alkynyl, C3-Cycycloalkyl, Cι-C6alkoxy, Cι-C6haloalkyl, Ci-Cόhaloalkoxy, (Cι-C6alkoxy)Cι-C6alkyl, (Cι-C6alkoxy)Cι-C6alkoxy, Ci-C6alkylthio, mono- and di-(Cι-C6alkyl)amino, amino(Cι-C6alkyl), mono- and di-(Cι-C6allcyl)amino(Cι-C6alkyl), and C2-C6alkanoyl; R3 is hydrogen or Cι-C6alkyl, or
R3 is C3-C7cycloalkyl(C0-C2alkyl), heterocycloallcyl(C0-C2alkyl), phenyl, or a 5- or 6- membered heteroaryl, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, -CHO, halogen, Cι-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C7cycloalkyl, Cι-C6alkoxy, Cι-C6haloalkyl, Cι-C6haloalkoxy, (Cι-C6alkoxy)Cι-C6alkyl, (Cι-C6alkoxy)Cι- C6alkoxy, Cι-C6alkylthio, mono- and di-(Cι-C6alkyl)amino, amino(Cι-C6alkyl), mono- and di-(Cι-C6alkyl)amino(Cι-C6alkyl), and C2-C6alkanoyl; or
R3 is phenoxy phenyl, each of which phenyl rings is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, -CHO, halogen, Cι-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C7cycloalkyl, Cι-C6alkoxy, Cι-C6haloalkyl, Cι-C6haloalkoxy, (Cι-C6alkoxy)Cι-C6alkyl, (Cι-C6alkoxy)Cι- C6alkoxy, Cι-C6alkylthio, mono- and di-(Cι-C6alkyl)amino, amino(Cι-C6alkyl), mono- and di-(Cι-C6alkyl)amino(Cι-C6alkyl), and C2-C6alkanoyl.
3. A compound or form thereof according to Claim 1 or 2 wherein Ri is halogen, Cι-C7alkyl, Cι-C6alkoxy, C3-C7cycloalkyl(Co-C2alkyl), or heterocycloalkyl(C0-C2alkyl); or Ri is phenyl substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, -CHO, halogen, Cι-C6alkyl, C2-C6alkenyl, C2- C6alkynyl, C3-C7cycloalkyl, Cι-C6alkoxy, Cι-C6haloalkyl, Cι-C6haloalkoxy, ( - C6alkoxy)Cι-C6alkyl, (Cι-C6alkoxy)Cι-C6alkoxy, Cι-C6alkylthio, mono- and di- (Cι-C6alkyl)amino, amino(Cι-C6alkyl), mono- and di-(Cι-C6all<yl)amino(Cι- C6alkyl), and C2-C6alkanoyl.
4. A compound or form thereof according to Claim 3 wherein Ri is halogen or Cι-C7alkyl; or
Ri is phenyl substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, halogen, Ci-C6allcyl, C3-C7cycloalkyl, Cι-C6alkoxy, Ci- C2haloalkyl, Cι-C2haloalkoxy, and mono- and di-(Cι-C4alkyl)amino.
5. A compound or form thereof according to Claim 4 wherein
Ri is phenyl substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, halogen, Cι-C4alkyl, -Gjalkoxy, Cι-C2haloalkyl, Cj- C2haloalkoxy, and mono- and di-(Cι-C4alkyl)amino.
6. A compound or form thereof according to Claim 4 wherein Ri is bromo or Cι-C4alkyl; or
Ri is phenyl substituted with 0 to 2 substituents independently chosen from fluoro, chloro, bromo, Cι-C2alkyl, and Cι-C2alkoxy.
7. A compound or form thereof according to any one of Claims 1 to 6 wherein W is phenyl, pyridyl, pyrimidinyl, imidazolyl, pyrrolyl, pyrazolyl, furanyl, thienyl, oxazolyl, or isoxazolyl, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, -CHO, halogen, oxo, Cι-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C7cycloalkyl, Ci- C6alkoxy, Ci-Cβhaloalkyl, Cι-C6haloalkoxy, (Cι-C6alkoxy)Cι-C6alkyl, (Ci- C6alkoxy)Cι-C6alkoxy, Cι-C6alkylthio, mono- and di-(Cι-C6alkyl)amino, amino(Cι-C6alkyl), mono- and di-(Cι-C6alkyl)amino(Cι-C6alkyl), and C2- C6alkanoyl.
8. A compound or form thereof according to Claim 7 wherein
W is phenyl, pyridyl, pyrimidinyl, imidazolyl, pyrrolyl, pyrazolyl, furanyl, thienyl, oxazolyl, or isoxazolyl, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, halogen, oxo, Ci- C4alkyl, Cι-C alkoxy, Cι-C2haloalkyl, Cι-C2haloalkoxy, and mono- and di-(Cι- C4alkyl)amino.
9. A compound or form thereof according to Claim 8, wherein
W is imidazolyl, pyrrolyl, or pyrazolyl, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, cyano, halogen, oxo, - C4alkyl, Ci-Q alkoxy, trifluoromethyl, and trifluoromethoxy.
10. A compound or form thereof according to any one of Claims 1 to 6 of Formula 2
11. A compound or form thereof according to any one of Claims 1 to 6 of Formula 3
12. A compound or form thereof according to any one of Claims 1 to 6 of Formula 4:
13. A compound or form thereof according to any one of Claims 1 to 12, wherein X is N.
14. A compound or form thereof according to any one of Claims 1 to 12, wherein X is CH.
15. A compound or form thereof according to any one of Claims 1 to 14 wherein
Z2 is
R8 and R9 are independently hydrogen or Cι-C6alkyl; and n is 0, 1, or 2; and Rio and Rπ are independently hydrogen, Cι-C6allcyl, or phenyl.
16. A compound or form thereof according to Claim 15, wherein
Z2 is
17. A compound or form thereof according to Claim 16 wherein Rio and Rπ are both hydrogen.
18. A compound or form thereof according to any one of Claims 1 to 17 of Formula 6
19. A compound or form thereof according to any one of Claims 1 to 17 of Formula 7
20. A compound or form thereof according to any one of Claims 1 to 17 of Formula 8
21. A compound or form thereof according to any one of Claims 1 to 20 wherein
R2 is phenyl, pyridyl, pyrimidinyl, pyrazinyl, imidazolyl, pyrrolyl, furanyl, thienyl, oxazolyl, or isoxazolyl, each of which may be either directly attached or bound via a Cι-C2alkyl linker, and each of which is substituted with 0 to 3 substituents independently chosen from:
(i) hydroxy, halogen, nitro, cyano, amino, sulfonamide, -CHO, Cι-C6haloalkyl, and Cι-C6haloalkoxy, and
(ii) Cι-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C7cycloalkyl, Cι-C6alkoxy, (Ci- C6alkoxy)Cι-C6alkyl, (Cι-C6alkoxy)Cι-C6alkoxy, Cι-C6alkylthio, mono- and di- (Cι-C6alkyl)amino, amino(Cι-C6alkyl), mono- and di-(Cι-C6alkyl)amino(Cι- C6alkyl), C2-C6alkanoyl, and heterocycloalkyl(Co-C2alkyi); each of which (ii) is substituted with 0 to 3 substituents independently chosen from halogen, hydroxy, amino, nitro, cyano, C1-C alkoxy, C3-C7cycloalkyl, and mono- and di-( - C4alkyl)amino.
22. A compound or form thereof according to Claim 21 , wherein
R2 is phenyl(Co-C2alkyl), pyridyl (Co-Caalkyl), or pyτimidinyl(Co-C2alkyl), each of which is substituted with 0 to 3 substituents independently chosen from:
(i) hydroxy, halogen, nitro, cyano, amino, Cι-C2haloalkyl, and Cι-C2haloalkoxy, and
(ii) Cι-C6alkyl, C3-C7cycloalkyl, Cι-C6alkoxy, (Cι-C6alkoxy)Cι-C6alkyl, Q- C4alkylthio, mono- and di-(Cι-C4alkyl)amino, mono- and di-(Cι- C4alkyl)amino(Cι-C4alkyl), and heterocycloalkyl(Co-C2alkyl); each of which (ii) is substituted with 0 to 3 substituents independently chosen from halogen, hydroxy, amino, nitro, cyano, Cι-C4alkoxy, C3-C7cycloalkyl, and mono- and di- (C 1 -C4all yl) amino .
23. A compound or form thereof according to Claim 25, wherein
R2 is phenyl or benzyl, each of which is substituted with 0 to 3 substituents independently chosen from halogen, hydroxy, amino, Cι-C4alkyl, Cι-C4alkoxy, Cι-C4alkylthio, Cι-C2haloalkyl, and Cι-C2haloalkoxy.
24. A compound or form thereof according to any one of Claims 1 to 23, wherein
R3 is hydrogen or Cι-C6alkyl, or
R3 is C3-C7cycloalkyl, (C3-C7cycloalkyl)methyl, heterocycloalkyl, (heterocycloalkyl)Cι- Qjalkyl, phenyl, phenyl, pyridyl, pyrimidinyl, pyrazinyl, imidazolyl, pyrrolyl, furanyl, thienyl, oxazolyl, or isoxazolyl, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, halogen, Cι-C6alkyl, C3-C cycloalkyl, Cι-C6alkoxy, Cι-C2haloalkyl, Cι-C2haloalkoxy, and mono- and di-(Cι-C4all yl)amino; or
R3 is phenoxyphenyl, each of which phenyl rings is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, halogen, Cι-C6alkyl, C3-C7cycloalkyl, Cι-C6alkoxy, Cι-C2haloalkyl, Cι-C2haloalkoxy, and mono- and di-(Cι-C4alkyl)amino.
25. A compound or form thereof according to Claim 24, wherein
R3 is hydrogen, Cι-C6alkyl, C3-C7cycloalkyl(Co-Cιalkyl), phenyl, or phenoxyphenyl.
26. A compound or form thereof according to Claim 25, wherein R3 is hydrogen or Cι-C4alkyl.
7. A compound or form thereof according to Claim 1 of Formula 9
28. A compound or form thereof according to Claim 1 of Formula 10
29. A compound or form thereof according to Claim 1 of Formula 11
30. A compound or form thereof according to Claim 1 of Formula 12
31. A compound or form thereof according to Claim 1 of Formula 13
32. A compound or form thereof according to Claim 1 of Formula 14
33. A compound or form thereof according to Claim 30 to 32, wherein
Ri is bromo or Cι-C4alkyl; or
Ri is phenyl substituted with 0 to 2 substituents independently chosen from fluoro, chloro, bromo, Cι-C2alkyl, and Cι-C2alkoxy; R2 is phenyl or benzyl, each of which is substituted with 0 to 3 substituents independently chosen from:
(i) hydroxy, halogen, amino, Cι-C2haloalkyl, and Cι-C2haloalkoxy, and (ii) Ci-Cβalkyl, Cι-C6alkoxy, mono- and di-(Cι-C4alkyl)amino, mono- and di-(Cι- C4alkyl)amino(Cι-C4alkyl), piperazinyl(Co-Cιalkyl), piperidinyl(Co-Cιalkyl), and morpholinyl(Co-Cialkyl); each of which (ii) is substituted with 0 to 3 substituents independently chosen from halogen, hydroxy, amino, Cι-C2alkoxy, and mono- and di-(Cι-C4alkyl)amino; and R3 is hydrogen or Cι-C4alkyl.
34. A compound or form thereof according to any one of Claims 1 to 33, wherein the compound exhibits an IC50 of 25 micromolar or less in an in vitro assay of tumor cell proliferation.
35. A compound or form thereof according to any one of Claims 1 to 33, wherein the compound exhibits an IC5o of 10 micromolar or less in an in vitro assay of tumor cell proliferation.
36. A pharmaceutical composition, comprising a compound or form thereof according to any one of Claims 1 to 33, together with at least one pharmaceutically acceptable carrier or excipient.
37. A pharmaceutical composition according to Claim 36, wherein the composition is formulated as an injectable fluid, an aerosol, a cream, a gel, a tablet, a pill, a capsule, a syrup, ophthalmic solution, or a transdermal patch.
38. A packaged pharmaceutical composition, comprising
(a) a pharmaceutical composition according to Claim 36 in a container; and
(b) instructions for using the composition to treat a patient suffering from an disease or disorder responsive to Hsp90 complex modulation.
39. The packaged pharmaceutical composition of Claim 38 wherein the disease or disorder responsive to Hsp90 complex modulation is cancer, an autoimmune disease, or a neurodegenerative disease.
40. The packaged pharmaceutical composition of Claim 38 wherein the disease or disorder responsive to Hsp90 complex modulation is cancer.
41. The packaged pharmaceutical composition of Claim 38 wherein the disease or disorder responsive to Hsp90 complex modulation is autoimmune/inflammatory disease.
42. The packaged pharmaceutical composition of Claim 38 wherein the disease or disorder responsive to Hsp90 complex modulation is neurodegenerative disease.
43. A method of reducing medication error and enhancing therapeutic compliance of a patient being treated for a disease or disorder responsive to Hsp90 complex modulation, the method comprising providing a packaged pharmaceutical preparation according to Claim 38 wherein the instructions additionally include contraindication and adverse reaction information pertaining to the package pharmaceutical composition.
44. A method for modulating binding of ATP to Hsp90 complex, the method comprising contacting cells expressing Hsp90 complex with a compound according to any one of Claims 1 to 33 or form thereof in an amount sufficient to detectably decrease the level of an Hsp90 substrate protein in vitro.
45. A method for modulating the activity of Hsp90 complex, the method comprising contacting cells expressing Hsp90 complex with a compound according to any one of Claims 1 to 33 or form thereof in an amount sufficient to detectably decrease the level of an Hsp90 substrate protein in vitro.
46. The method of Claim 44 or Claim 45 wherein the substrate protein is ErbB2, Akt, or Raf.
47. The method of Claim 46 wherein the cells are present in a mammal.
48. The method of Claim 47 wherein the mammal is a human.
49. The method of Claim 47 wherein the mammal is a cat or dog.
50. A method for treating a patient having a disease or disorder responsive to Hsp90 complex modulation, comprising administering to the patient and effective amount of a compound or form thereof according to any one of Claims 1 to 33.
51. The method of Claim 50 wherein the patient is a human.
52. The method of Claim 50 wherein the patient is a cat or dog.
53. The method of Claim 50 wherein the disease or disorder responsive to Hsp90 complex modulation is cancer, an autoimmune disease, or a neurodegenerative disease.
54. The method of Claim 50 wherein the disease or disorder responsive to Hsp90 complex modulation is cancer.
55. The method of Claim 50 wherein the compound or form is administered orally.
56. The method of Claim 50 wherein the compound or form is administered intravenously, by intramuscularly, or parenterally.
57. A method for determining the presence or absence of Hsp90 complex in a sample comprising contacting the sample with a compound or form thereof according to any one of Claims 1 to 33 under conditions that permit binding of the compound or foπn to the Hsp90 complex, detecting a level of the compound or form bound to the Hsp90 complex, and therefrom determining the presence or absence of Hsp90 complex.
58. The method of Claim 57 wherein the compound or form thereof is radiolabelled.
59. The method of Claim 57, which additionally comprises separating unbound compound from bound compound; and determining the amount of bound compound in the sample.
60. A compound or form thereof according to Claim 1, wherein the compound is:
1 - {3 -[8-(4-Phenyl-imidazol- 1 -yl)-imidazo [ 1 ,2-a]pyrazin-6-yl] -phenyl} -3 -o-tolyl-urea; 1 -(4-Chloro-phenyl)-3- {3-[8-(4-phenyl-imidazol- 1 -yl)-imidazo[ 1 ,2-a]pyrazin-6-yl]- phenyl}-urea; 1 -(2-Methylsulfanyl-phenyl)-3 - {3 -[8-(2-phenyl-imidazol- 1 -yl)-imidazo [ 1 ,2-a]pyrazin-6- yl] -phenyl} -urea; l-{3-[8-(2-Phenyl-imidazol-l-yl)-imidazo[l,2-a]pyrazin-6-yl]-phenyl}-3-o-tolyl-urea; l-(4-Chloro-phenyl)-3-(3-{8-[4-(4-chloro-phenyl)-imidazol-l-yl]-imidazo[l,2-a]pyτazin-
6-yl } -phenyl)-urea; 1 -(3 - { 8- [4-(4-Chloro-phenyl)-imidazol- 1 -yl]-imidazo[ 1 ,2-a]pyrazin-6-yl} -phenyl)-3 -o- tolyl-urea; l-(4-Chloro-phenyl)-3-{3-[8-(4-p-tolyl-imidazol-l-yl)-imidazo[l,2-a]pyrazin-6-yl]- phenyl}-urea; l-o-Tolyl-3-{3-[8-(4-p-tolyl-imidazol-l-yl)-imidazo[l,2-a]pyrazin-6-yl]-phenyl}-urea; l-(4-Chloro-phenyl)-3-{3-[8-(4-methyl-imidazol-l-yl)-imidazo[l,2-a]pyrazin-6-yl]- phenyl}-urea; l-(3-Chloro-4-fluoro-phenyl)-3-(3-{8-[4-(4-chloiO-phenyl)-imidazol-l-yl]-imidazo[l,2- a]pyrazin-6-yl} -phenyl)-urea; l-(3-Chloro-4-fluoro-phenyl)-3-{3-[8-(4-phenyl-imidazol-l-yl)-imidazo[l,2-a]pyrazin-6- yl] -phenyl } -urea; l-(3-{8-[4-(4-Chloro-phenyl)-imidazol-l-yl]-imidazo[l,2-a]pyrazin-6-yl}-phenyl)-3-[4-
(4-methyl-piperazin- 1 -ylmethyl)-phenyl]-urea; l-(3-{8-[4-(4-Chloro-phenyl)-imidazol-l-yl]-imidazo[l,2-a]pyrazin-6-yl}-phenyl)-3-(4- morpholin-4-ylmethyl-phenyl)-urea; l-(3-{8-[4-(4-Chloro-phenyl)-imidazol-l-yl]-imidazo[l,2-a]pyrazin-6-yl}-phenyl)-3-{4-
[(3 -ethoxy-propylamino)-methyl] -phenyl} -urea; l-(4-Chloro-phenyl)-3-{3-[8-(3-phenyl-pyrazol-l-yl)-imidazo[l,2-a]pyrazin-6-yl]- phenyl}-urea;
l-(3-Chloro-4-fluoro-phenyl)-3-{3-[8-(3-phenyl-ρyrazol-l-yl)-imidazo[l,2-a]pyrazin-6- yl] -phenyl } -urea; 1 -(3 -Chloro-4-fluoro-phenyl)-3- {3-[8-(2-phenyl-imidazol- 1 -yl)-imidazo [ 1 ,2-a]pyrazin-6- yl] -phenyl} -urea; -Chloro-N- {3 - [8-(2-phenyl-imidazol- 1 -yl)-imidazo [ 1 ,2-a]pyrazin-6-yl]-phenyl} - benzamide; 3-Morpholin-4-ylmethyl-N-{3-[8-(2-phenyl-imidazol-l-yl)-imidazo[l,2-a]pyrazin-6-yl]- phenyl} -benzamide; -Morpholin-4-ylmethyl-N- {3-[8-(2-phenyl-imidazol- 1 -yl)-imidazo[ 1 ,2-a]pyrazin-6-yl]- phenyl} -benzamide; l-(3-Chloro-4-fluoro-phenyl)-3-{3-[8-(2-p-tolyl-imidazol-l-yl)-imidazo[l,2-a]pyrazin-6- yl] -phenyl } -urea; l-{3-[8-(2-p-Tolyl-imidazol-l-yl)-imidazo[l,2-a]pyrazin-6-yl]-phenyl}-3-(3- trifluoromethyl-phenyl)-urea; l-(4-Morpholin-4-ylmethyl-phenyl)-3-{3-[8-(2-phenyl-imidazol-l-yl)-imidazo[l,2- a]pyrazin-6-yl]-phenyl} -urea; 6-(4-Morpholin-4-ylmethyl-phenyl)-8-(2-phenyl-imidazol-l-yl)-imidazo[l,2-a]pyι-azine; l-(4-ChloiO-phenyl)-3-{3-[8-(2-o-tolyl-imidazol-l-yl)-imidazo[l,2-a]pyi-azin-6-yl]- phenyl}-urea; l-(3-Chloro-4-fluoiO-phenyl)-3-{3-[8-(2-o-tolyl-imidazol-l-yl)-imidazo[l,2-a]pyτazin-6- yl] -phenyl} -urea; 1 -(4-Chloro-phenyl)-3 -(3 - { 8-[2-(2-methoxy-phenyl)-imidazol- 1 -yl] -imidazo[ 1 ,2- a]pyrazin-6-yl} -phenyl)-urea; 1 -(4-Chloro-phenyl)-3 -(3 - { 8-[2-(2-fluoro-phenyl)-imidazol- 1 -yl]-imidazo [ 1 ,2-a]pyrazin-
6-yl} -phenyl)-urea; l-(3-Chloro-4-fluoro-phenyl)-3-(3-{8-[2-(2-fluoro-phenyl)-imidazol-l-yl]-imidazo[l,2- a]pyrazin-6-yl} -phenyl)-urea; 1 -(3 - { 8- [2-(2-Fluoro-phenyl)-imidazol- 1 -yl] -imidazo [ 1 ,2-a]pyrazin-6-yl} -phenyl)-3 -(3 - trifluoromethyl-phenyl)-urea;
l-(3-{8-[2-(2-Methoxy-phenyl)-imidazol-l-yl]-imidazo[l,2-a]pyrazin-6-yl}-phenyl)-3-
(3-xrifluoromethyl-phenyl)-urea; l-(4-Chloro-phenyl)-3-{3-[8-(2-isopropyl-imidazol-l-yl)-imidazo[l,2-a]pyrazin-6-yl]- phenyl}-urea; 1 -(3-Chloro-4-fluoro-phenyl)-3 - { 3 -[8-(2-isopropyl -imidazol- 1 -yl)-imidazo [ 1 ,2- a]pyrazin-6-yl]-phenyl} -urea; 1 - {3-[8-(4-Bromo-imidazol- 1 -yl)-imidazo[ 1 ,2-a]pyτazin-6-yl]-phenyl} -3 -(4-chloro- phenyl)-urea; 4-Fluoro-N- {3-[8-(2-phenyl-imidazol- 1 -yl)-imidazo[l ,2-a]pyrazin-6-yl]-phenyl} - benzamide; 3-Methoxy-N-{3-[8-(2-phenyl-imidazol-l-yl)-imidazo[l,2-a]p}τ:azin-6-yl]-phenyl}- benzamide 3-Methoxy-4-methyl-N-{3-[8-(2-phenyl-imidazol-l-yl)-imidazo[l,2-a]pyrazin-6-yl]- phenyl} -benzamide; N-{3-[8-(2-Phenyl-imidazol-l-yl)-imidazo[l,2-a]pyrazin-6-yl]-phenyl}-benzamide; 2,6-Dimethyl-N- { 3 - [8-(2-phenyl-imidazol- 1 -yl)-imidazo [ 1 ,2-a]pyrazin-6-yl]-phenyl } - benzamide; 4-Fluoro-N-{3-[8-(2-p-tolyl-imidazol-l-yl)-imidazo[l,2-a]pyrazin-6-yl]-phenyl}- benzamide; 3-Methoxy-N-{3-[8-(2-p-tolyl-imidazol-l-yl)-imidazo[l,2-a]pyrazin-6-yl]-phenyl}- benzamide; 3-Methoxy-4-methyl-N-{3-[8-(2-p-tolyl-imidazol-l-yl)-imidazo[l,2-a]pyrazin-6-yl]- phenyl} -benzamide; 2-(4-Chloro-phenyl)-N-{3-[8-(2-phenyl-imidazol-l-yl)-imidazo[l,2-a]pyrazin-6-yl]- phenyl} -acetamide; 2-(4-Chloro-phenyl)-N~(3 - { 8-[2-(4-chloro-phenyl)-imidazol- 1 -yl] -imidazo [ 1 ,2-a]pyrazin-
6-yl} -phenyl)-acetamide; N-(3- { 8-[2-(4-Chloro-phenyl)-imidazol- 1 -yl] -imidazo [1 ,2-a]pyrazin-6-yl} -phenyl)-2-(3 - trifluoromethyl-phenyl)-acetamide;
1 -(3 - { 8- [2-(4-Chloro-phenyl)-imidazol- 1 -yl] -imidazo [ 1 ,2-a]pyrazin-6-yl} -phenyl)-3 -(4- morpholin-4-ylmethyl-phenyl)-urea; 1 -(4-Chloro-benzyl)-3 -(3 - { 8-[2-(4-chloro-phenyl)-imidazol- 1 -yl]-imidazo [ 1 ,2-a]pyrazin-
6-yl}-phenyl)-urea; or l-(3-{8-[2-(4-Chloro-phenyl)-imidazol-l-yl]-imidazo[l,2-a]pyrazin-6-yl}-phenyl)-3-[4-
(4-methyl-piperazin- 1 -ylmethyl)-phenyl]-urea.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44637903P | 2003-02-10 | 2003-02-10 | |
US60/446,379 | 2003-02-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004072080A1 true WO2004072080A1 (en) | 2004-08-26 |
Family
ID=32869499
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/003922 WO2004072080A1 (en) | 2003-02-10 | 2004-02-10 | Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of hsp90 complex activity |
PCT/US2004/003923 WO2004072081A1 (en) | 2003-02-10 | 2004-02-10 | Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/003923 WO2004072081A1 (en) | 2003-02-10 | 2004-02-10 | Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity |
Country Status (2)
Country | Link |
---|---|
US (2) | US7189723B2 (en) |
WO (2) | WO2004072080A1 (en) |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005019220A2 (en) * | 2003-08-11 | 2005-03-03 | Cellular Genomics Inc. | Substituted imidazo[1,2-a]pyrazines as modulators of kinase activity |
US6919340B2 (en) | 2002-04-19 | 2005-07-19 | Cellular Genomics, Inc. | Imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof |
FR2884252A1 (en) * | 2005-04-08 | 2006-10-13 | Aventis Pharma Sa | NOVEL ISOINDOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME, PREPARATION THEREOF AND PHARMACEUTICAL USES THEREOF, IN PARTICULAR AS INHIBITORS OF CHAPERONE HSP90 PROTEIN ACTIVITY |
WO2006125101A2 (en) * | 2005-05-20 | 2006-11-23 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
FR2885904A1 (en) * | 2005-05-19 | 2006-11-24 | Aventis Pharma Sa | NOVEL FLUORENE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF |
US7160885B2 (en) | 2003-02-10 | 2007-01-09 | Cgi Pharmaceuticals, Inc. | Certain 6, 8-(heteroaryl or aryl) disubstituted imidazo[1,2-a]pyrazines as modulators of Hsp90 complex activity |
WO2007087716A1 (en) * | 2006-02-01 | 2007-08-09 | Aegera Therapeutics Inc. | Assay for identifying inhibitors of neuronal apoptotic pathways |
US7312341B2 (en) | 2002-09-09 | 2007-12-25 | Cgi Pharmaceuticals, Inc. | 6-aryl-imidazo[1,2-a] pyrazin-8-ylamines, method of making, and method of use thereof |
WO2008049994A1 (en) | 2006-10-24 | 2008-05-02 | Sanofi-Aventis | New fluorene derivatives, compositions containing the same and use thereof as inhibitors of the protein chaperone hsp 90 |
US7393848B2 (en) | 2003-06-30 | 2008-07-01 | Cgi Pharmaceuticals, Inc. | Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds |
US7405295B2 (en) | 2003-06-04 | 2008-07-29 | Cgi Pharmaceuticals, Inc. | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
US7625931B2 (en) | 2005-01-14 | 2009-12-01 | Cgi Pharmaceuticals, Inc. | Certain substituted diphenyl ureas, as modulators of kinase activity |
US7709468B2 (en) | 2005-09-02 | 2010-05-04 | Abbott Laboratories | Imidazo based heterocycles |
WO2011004132A1 (en) | 2009-07-10 | 2011-01-13 | Sanofi-Aventis | Novel hsp90-inhibiting indole derivatives, compositions containing said derivatives, and use thereof |
WO2011027081A2 (en) | 2009-09-03 | 2011-03-10 | Sanofi-Aventis | Novel derivatives of 5,6,7,8-tetrahydroindolizine inhibiting hsp90, compositions containing same, and use thereof |
WO2012052745A1 (en) | 2010-10-21 | 2012-04-26 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Combinations of pi3k inhibitors with a second anti -tumor agent |
JP2012524053A (en) * | 2009-04-16 | 2012-10-11 | セントロ ナシオナル デ インベスティガシオネス オンコロヒカス(セエネイオ) | Imidazopyrazines for use as kinase inhibitors |
US8440667B2 (en) | 2008-12-08 | 2013-05-14 | Gilead Connecticut, Inc. | Imidazopyrazine Syk inhibitors |
US8450321B2 (en) | 2008-12-08 | 2013-05-28 | Gilead Connecticut, Inc. | 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor |
US8455493B2 (en) | 2008-12-08 | 2013-06-04 | Gilead Connecticut, Inc. | Imidazopyrazine Syk inhibitors |
US8697699B2 (en) | 2008-02-13 | 2014-04-15 | Gilead Connecticut, Inc. | Imidazopyrazine SYK inhibitors |
US9290505B2 (en) | 2013-12-23 | 2016-03-22 | Gilead Sciences, Inc. | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors |
US9382256B2 (en) | 2013-07-30 | 2016-07-05 | Gilead Connecticut, Inc. | Formulation of Syk inhibitors |
US9562056B2 (en) | 2010-03-11 | 2017-02-07 | Gilead Connecticut, Inc. | Imidazopyridines Syk inhibitors |
US9657023B2 (en) | 2013-07-30 | 2017-05-23 | Gilead Connecticut, Inc. | Polymorph of Syk inhibitors |
US9687492B2 (en) | 2013-12-04 | 2017-06-27 | Gilead Sciences, Inc. | Methods for treating cancers |
US9707236B2 (en) | 2014-07-14 | 2017-07-18 | Gilead Sciences, Inc. | Combination methods for treating cancers |
US9968601B2 (en) | 2013-12-23 | 2018-05-15 | Gilead Sciences, Inc. | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors |
US9993554B2 (en) | 2010-10-21 | 2018-06-12 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Use of P13K Inhibitors for the Treatment of Obesity, Steatosis and ageing |
US11339168B2 (en) | 2019-02-22 | 2022-05-24 | Kronos Bio, Inc. | Crystalline forms of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as Syk inhibitors |
US11384082B2 (en) | 2017-08-25 | 2022-07-12 | Kronos Bio, Inc. | Hydrates of polymorphs of 6-(1H-indazol-6-YL)-N-(4-morpholinophenyl)-2,3-dihydroimidazo[1,2-A]pyrazin-8-amine bisemsylate as Syk inhibitors |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030031670A1 (en) * | 1999-11-08 | 2003-02-13 | Jack R. Wands | Diagnosis and treatment of malignant neoplasms |
US20050123545A1 (en) * | 1999-11-08 | 2005-06-09 | Wands Jack R. | Diagnosis and treatment of malignant neoplasms |
US6835370B2 (en) * | 1999-11-08 | 2004-12-28 | Rhode Island Hospital | Diagnosis and treatment of malignant neoplasms |
US20060183746A1 (en) * | 2003-06-04 | 2006-08-17 | Currie Kevin S | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
JP2008526988A (en) * | 2005-01-14 | 2008-07-24 | シージーアイ ファーマシューティカルズ,インコーポレーテッド | 1,3-Diaryl-substituted ureas as kinase activity modulators |
US7777040B2 (en) * | 2005-05-03 | 2010-08-17 | Cgi Pharmaceuticals, Inc. | Certain substituted ureas, as modulators of kinase activity |
US9002795B2 (en) * | 2006-01-26 | 2015-04-07 | Seagate Technology Llc | Object-based data storage device |
WO2007131034A1 (en) * | 2006-05-03 | 2007-11-15 | The Regents Of The University Of Michigan | Pyrimidone derivatives which are modulators of heat shock protein (hsp) 70 |
US7893058B2 (en) | 2006-05-15 | 2011-02-22 | Janssen Pharmaceutica Nv | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases |
JP2009538877A (en) | 2006-05-31 | 2009-11-12 | ガラパゴス・ナムローゼ・フェンノートシャップ | Triazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases |
US20090175852A1 (en) | 2006-06-06 | 2009-07-09 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
US8580519B2 (en) * | 2006-11-27 | 2013-11-12 | University Of Maryland, Baltimore | Use of plasma HSP90 related to malignancy |
NZ579635A (en) * | 2007-03-20 | 2011-07-29 | Curis Inc | Fused amino pyridine as hsp90 inhibitors |
JP4426600B2 (en) * | 2007-04-27 | 2010-03-03 | キヤノン株式会社 | How to use treatment solution |
US8148369B2 (en) | 2007-05-10 | 2012-04-03 | Janssen Pharmaceutica Nv | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases |
NZ594414A (en) * | 2009-01-16 | 2013-08-30 | Curis Inc | Fused amino pyridines for the treatment of brain tumors |
EA020847B1 (en) | 2009-10-30 | 2015-02-27 | Янссен Фармацевтика Нв | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS |
AR080754A1 (en) | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | IMIDAZO DERIVATIVES (1,2-A) PIRAZINA AND ITS USE AS PDE10 INHIBITORS |
JP6115962B2 (en) | 2011-06-27 | 2017-04-19 | ヤンセン ファーマシューティカ エヌ.ベー. | 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline derivatives |
JP6478908B2 (en) | 2012-05-25 | 2019-03-06 | バーグ エルエルシー | Method for treating metabolic syndrome by regulating heat shock protein (HSP) 90-β |
CN104411312B (en) | 2012-06-26 | 2018-03-06 | 詹森药业有限公司 | The combination for being used in treatment neurological or dysbolism use including PDE2 the inhibitor such as methyl of 1 aryl 4 [1,2,4] triazole [4,3 A] quinoxaline compounds and PDE10 inhibitor |
RU2667058C2 (en) | 2012-07-09 | 2018-09-14 | Янссен Фармацевтика Нв | Inhibitors of phosphodiesterase 10 enzyme |
CA2905509A1 (en) * | 2013-03-15 | 2014-09-18 | Memorial Sloan-Kettering Cancer Center | Hsp90-targeted cardiac imaging and therapy |
EP3415489A1 (en) | 2013-10-18 | 2018-12-19 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
SG10201806846RA (en) | 2014-02-13 | 2018-09-27 | Incyte Corp | Cyclopropylamines as lsd1 inhibitors |
SG10201908028SA (en) | 2014-02-13 | 2019-10-30 | Incyte Corp | Cyclopropylamines as lsd1 inhibitors |
WO2015123408A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
WO2015123437A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
EP3152307A4 (en) | 2014-06-06 | 2018-05-02 | Berg LLC | Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta |
WO2016007736A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyrazines as lsd1 inhibitors |
US9695168B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors |
US9695167B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors |
WO2016007727A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
TWI714567B (en) | 2015-04-03 | 2021-01-01 | 美商英塞特公司 | Heterocyclic compounds as lsd1 inhibitors |
WO2016209895A1 (en) * | 2015-06-26 | 2016-12-29 | Dow Global Technologies Llc | Imidazopyrazine derived compounds for electronic devices |
AU2016306555B2 (en) | 2015-08-12 | 2021-01-28 | Incyte Holdings Corporation | Salts of an LSD1 inhibitor |
CR20180553A (en) | 2016-04-22 | 2019-02-01 | Incyte Corp | FORMULATIONS OF AN LSD1 INHIBITOR |
EP3448859B1 (en) | 2017-03-20 | 2019-07-10 | Forma Therapeutics, Inc. | Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators |
WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
JP7450610B2 (en) | 2018-09-19 | 2024-03-15 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | Activation of pyruvate kinase R |
EP3853206B1 (en) | 2018-09-19 | 2024-04-10 | Novo Nordisk Health Care AG | Treating sickle cell disease with a pyruvate kinase r activating compound |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002060492A1 (en) * | 2001-01-30 | 2002-08-08 | Cytopia Pty Ltd | Methods of inhibiting kinases |
WO2003089434A2 (en) * | 2002-04-19 | 2003-10-30 | Cellular Genomics, Inc. | IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES METHOD OF MAKING AND METHOD OF USE THEREOF |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2607813B1 (en) | 1986-12-05 | 1989-03-31 | Montpellier I Universite | ALKYLAMINO-8 IMIDAZO (1,2-A) PYRAZINES AND DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
US5137876A (en) | 1990-10-12 | 1992-08-11 | Merck & Co., Inc. | Nucleoside antiviral and anti-inflammatory compounds and compositions and methods for using same |
DE4327027A1 (en) * | 1993-02-15 | 1994-08-18 | Bayer Ag | Imidazoazine |
DE4337609A1 (en) | 1993-11-04 | 1995-05-11 | Boehringer Ingelheim Kg | Novel pyrazinecarboxamide derivatives, their preparation and their use in medicines |
DE4337611A1 (en) * | 1993-11-04 | 1995-05-11 | Boehringer Ingelheim Kg | New benzoylguanidines, their preparation and their use in medicines |
FR2711993B1 (en) | 1993-11-05 | 1995-12-01 | Rhone Poulenc Rorer Sa | Drugs containing 7H-imidazol [1,2-a] pyrazine-8-one derivatives, new compounds and their preparation. |
FR2723373B1 (en) | 1994-08-02 | 1996-09-13 | Rhone Poulenc Rorer Sa | PURIFIED FORM OF STREPTOGRAMINS, ITS PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
WO1996034866A1 (en) | 1995-05-01 | 1996-11-07 | Fujisawa Pharmaceutical Co., Ltd. | Imidazo 1,2-a pyridine and imidazo 1,2-a pyridezine derivatives and their use as bone resorption inhibitors |
US5593997A (en) * | 1995-05-23 | 1997-01-14 | Pfizer Inc. | 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors |
SE9704404D0 (en) | 1997-11-28 | 1997-11-28 | Astra Ab | New compounds |
DE19948434A1 (en) | 1999-10-08 | 2001-06-07 | Gruenenthal Gmbh | Substance library containing bicyclic imidazo-5-amines and / or bicyclic imidazo-3-amines |
GB0018473D0 (en) | 2000-07-27 | 2000-09-13 | Merck Sharp & Dohme | Therapeutic agents |
DE10050663A1 (en) | 2000-10-13 | 2002-04-18 | Gruenenthal Gmbh | Use of amino-substituted imidazo(1,2-a)pyridine, imidazo(1,2-a)pyrimidine and imidazo(1,2-a)pyrazine derivatives as NO synthase inhibitors, e.g. in treatment of migraine and neurodegenerative diseases |
GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
WO2002076985A1 (en) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
CA2476681A1 (en) | 2002-02-19 | 2003-08-28 | Bruce N. Rogers | Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease |
WO2004022562A1 (en) | 2002-09-09 | 2004-03-18 | Cellular Genomics, Inc. | 6-ARYL-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF |
JP2006503838A (en) | 2002-09-23 | 2006-02-02 | シェーリング コーポレイション | A novel imidazopyrazine as a cyclin-dependent kinase inhibitor |
PE20050081A1 (en) * | 2002-09-23 | 2005-03-01 | Schering Corp | NEW IMIDAZOPYRAZINES AS INHIBITORS OF CYCLINE-DEPENDENT KINASES |
WO2004072080A1 (en) | 2003-02-10 | 2004-08-26 | Cellular Genomics, Inc. | Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of hsp90 complex activity |
US7157460B2 (en) * | 2003-02-20 | 2007-01-02 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
US7186832B2 (en) * | 2003-02-20 | 2007-03-06 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
US7405295B2 (en) * | 2003-06-04 | 2008-07-29 | Cgi Pharmaceuticals, Inc. | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
US7393848B2 (en) * | 2003-06-30 | 2008-07-01 | Cgi Pharmaceuticals, Inc. | Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds |
US7259164B2 (en) * | 2003-08-11 | 2007-08-21 | Cgi Pharmaceuticals, Inc. | Certain substituted imidazo[1,2-a]pyrazines, as modulators of kinase activity |
WO2005047290A2 (en) | 2003-11-11 | 2005-05-26 | Cellular Genomics Inc. | Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors |
-
2004
- 2004-02-10 WO PCT/US2004/003922 patent/WO2004072080A1/en unknown
- 2004-02-10 US US10/776,002 patent/US7189723B2/en active Active
- 2004-02-10 WO PCT/US2004/003923 patent/WO2004072081A1/en active Application Filing
- 2004-02-10 US US10/776,631 patent/US7160885B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002060492A1 (en) * | 2001-01-30 | 2002-08-08 | Cytopia Pty Ltd | Methods of inhibiting kinases |
WO2003089434A2 (en) * | 2002-04-19 | 2003-10-30 | Cellular Genomics, Inc. | IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES METHOD OF MAKING AND METHOD OF USE THEREOF |
Non-Patent Citations (1)
Title |
---|
DING ET AL: "A Combinatorial Scaffold Approach toward Kinase-Directed Heterocycle Libraries", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC, US, vol. 124, no. 8, 2002, pages 1594 - 1596, XP002210160, ISSN: 0002-7863 * |
Cited By (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6919340B2 (en) | 2002-04-19 | 2005-07-19 | Cellular Genomics, Inc. | Imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof |
US7312341B2 (en) | 2002-09-09 | 2007-12-25 | Cgi Pharmaceuticals, Inc. | 6-aryl-imidazo[1,2-a] pyrazin-8-ylamines, method of making, and method of use thereof |
US7160885B2 (en) | 2003-02-10 | 2007-01-09 | Cgi Pharmaceuticals, Inc. | Certain 6, 8-(heteroaryl or aryl) disubstituted imidazo[1,2-a]pyrazines as modulators of Hsp90 complex activity |
US7189723B2 (en) | 2003-02-10 | 2007-03-13 | Cgi Pharmaceuticals, Inc. | Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity |
US7405295B2 (en) | 2003-06-04 | 2008-07-29 | Cgi Pharmaceuticals, Inc. | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
US7393848B2 (en) | 2003-06-30 | 2008-07-01 | Cgi Pharmaceuticals, Inc. | Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds |
WO2005019220A3 (en) * | 2003-08-11 | 2005-03-24 | Cellular Genomics Inc | Substituted imidazo[1,2-a]pyrazines as modulators of kinase activity |
WO2005019220A2 (en) * | 2003-08-11 | 2005-03-03 | Cellular Genomics Inc. | Substituted imidazo[1,2-a]pyrazines as modulators of kinase activity |
US7259164B2 (en) | 2003-08-11 | 2007-08-21 | Cgi Pharmaceuticals, Inc. | Certain substituted imidazo[1,2-a]pyrazines, as modulators of kinase activity |
US7625931B2 (en) | 2005-01-14 | 2009-12-01 | Cgi Pharmaceuticals, Inc. | Certain substituted diphenyl ureas, as modulators of kinase activity |
FR2884252A1 (en) * | 2005-04-08 | 2006-10-13 | Aventis Pharma Sa | NOVEL ISOINDOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME, PREPARATION THEREOF AND PHARMACEUTICAL USES THEREOF, IN PARTICULAR AS INHIBITORS OF CHAPERONE HSP90 PROTEIN ACTIVITY |
JP2008534660A (en) * | 2005-04-08 | 2008-08-28 | アバンテイス・フアルマ・エス・アー | Novel isoindole derivatives, compositions containing them, their preparation and their pharmaceutical use, in particular as inhibitors of chaperone protein HSP90 activity |
WO2006108948A3 (en) * | 2005-04-08 | 2007-10-11 | Aventis Pharma Sa | Novel isoindole derivatives, compositions containing same, preparation thereof and pharmaceutical uses thereof in particular as inhibitors of chaperone protein hsp90 activities |
US8034939B2 (en) | 2005-04-08 | 2011-10-11 | Aventis Pharma S.A.. | Isoindole derivatives, compositions containing same, preparation thereof and pharmaceutical uses thereof in particular as inhibitors of chaperone protein Hsp90 activities |
EA019027B1 (en) * | 2005-05-19 | 2013-12-30 | Авентис Фарма С.А. | Fluorene derivatives, compositions containing said derivatives and the use thereof |
FR2885904A1 (en) * | 2005-05-19 | 2006-11-24 | Aventis Pharma Sa | NOVEL FLUORENE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF |
WO2006123061A3 (en) * | 2005-05-19 | 2007-01-11 | Aventis Pharma Sa | Fluorene derivatives, composition containing said derivatives and the use thereof |
US7674795B2 (en) | 2005-05-19 | 2010-03-09 | Aventis Pharma Sa | Fluorene derivatives, composition containing said derivatives and the use thereof |
KR101288696B1 (en) | 2005-05-19 | 2013-07-22 | 아벤티스 파마 소시에떼아노님 | Fluorene derivatives, composition containing said derivatives and the use thereof |
WO2006125101A3 (en) * | 2005-05-20 | 2007-03-29 | Array Biopharma Inc | Raf inhibitor compounds and methods of use thereof |
US7566716B2 (en) | 2005-05-20 | 2009-07-28 | Array Biopharma Inc. | Imidazopyrazines as Raf inhibitor compounds |
WO2006125101A2 (en) * | 2005-05-20 | 2006-11-23 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
US7709468B2 (en) | 2005-09-02 | 2010-05-04 | Abbott Laboratories | Imidazo based heterocycles |
WO2007087716A1 (en) * | 2006-02-01 | 2007-08-09 | Aegera Therapeutics Inc. | Assay for identifying inhibitors of neuronal apoptotic pathways |
WO2008049994A1 (en) | 2006-10-24 | 2008-05-02 | Sanofi-Aventis | New fluorene derivatives, compositions containing the same and use thereof as inhibitors of the protein chaperone hsp 90 |
US8163750B2 (en) | 2006-10-24 | 2012-04-24 | Sanofi-Aventis | Fluorene derivatives, compositions containing the same and use thereof as inhibitors of the protein chaperone HSP 90 |
US8697699B2 (en) | 2008-02-13 | 2014-04-15 | Gilead Connecticut, Inc. | Imidazopyrazine SYK inhibitors |
US9796718B2 (en) | 2008-12-08 | 2017-10-24 | Gilead Connecticut, Inc. | 6-(benzo[d]thiazol-5-yl)-n-(3,4-dimethoxyphenyl)imidazo[1,2-a]pyrazin-8-amine |
US8440667B2 (en) | 2008-12-08 | 2013-05-14 | Gilead Connecticut, Inc. | Imidazopyrazine Syk inhibitors |
US8450321B2 (en) | 2008-12-08 | 2013-05-28 | Gilead Connecticut, Inc. | 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor |
US8455493B2 (en) | 2008-12-08 | 2013-06-04 | Gilead Connecticut, Inc. | Imidazopyrazine Syk inhibitors |
US9120811B2 (en) | 2008-12-08 | 2015-09-01 | Gilead Connecticut, Inc. | 6-(1H-indazol-6-YL)-N-(4-morpholinophenyl)imidazo[1,4-A]pyrazin-8-amine for treating leukemia or lymphoma |
US10093684B2 (en) | 2008-12-08 | 2018-10-09 | Gilead Connecticut, Inc. | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors |
US9567348B2 (en) | 2008-12-08 | 2017-02-14 | Gilead Connecticut, Inc. | Substituted pyrazolo[1,5-a]pyrimidines as Syk inhibitors |
US8748607B2 (en) | 2008-12-08 | 2014-06-10 | Gilead Connecticut, Inc. | Imidazopyrizine syk inhibitors |
US8765761B2 (en) | 2008-12-08 | 2014-07-01 | Gilead Connecticut, Inc. | 6-(1H-indazol-6-yl)-N-{4-[2-methyl-1-(morpholin-4-yl)propan-2-yl]phenyl}imidazo[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a syk inhibitor |
US9212191B2 (en) | 2008-12-08 | 2015-12-15 | Gilead Connecticut, Inc. | 6-(2,3-dihydro-1H-pyrido-[2,3-b][1,4]oxazin-7-yl)-N-(4-morpholinophenyl)imidazo[1,2-a] pyrazin-8-amine as a spleen tyrosine kinase inhibitor |
US8796270B2 (en) | 2008-12-08 | 2014-08-05 | Gilead Connecticut, Inc. | N-[6-(1H-indazol-6-yl)imidazo[1,2-A]pyridin-8-yl]-6-(morpholin-4-yl)pyridazin-3-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor |
US8962835B2 (en) | 2008-12-08 | 2015-02-24 | Gilead Connecticut, Inc. | Imidazopyrazine Syk inhibitors |
JP2012524053A (en) * | 2009-04-16 | 2012-10-11 | セントロ ナシオナル デ インベスティガシオネス オンコロヒカス(セエネイオ) | Imidazopyrazines for use as kinase inhibitors |
US8778935B2 (en) | 2009-04-16 | 2014-07-15 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Imidazopyrazines for use as kinase inhibitors |
WO2011004132A1 (en) | 2009-07-10 | 2011-01-13 | Sanofi-Aventis | Novel hsp90-inhibiting indole derivatives, compositions containing said derivatives, and use thereof |
WO2011027081A2 (en) | 2009-09-03 | 2011-03-10 | Sanofi-Aventis | Novel derivatives of 5,6,7,8-tetrahydroindolizine inhibiting hsp90, compositions containing same, and use thereof |
US10842803B2 (en) | 2010-03-11 | 2020-11-24 | Kronos Bio, Inc. | Imidazopyridines Syk inhibitors |
US9562056B2 (en) | 2010-03-11 | 2017-02-07 | Gilead Connecticut, Inc. | Imidazopyridines Syk inhibitors |
US10092583B2 (en) | 2010-03-11 | 2018-10-09 | Gilead Connecticut, Inc. | Imidazopyridines Syk inhibitors |
WO2012052745A1 (en) | 2010-10-21 | 2012-04-26 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Combinations of pi3k inhibitors with a second anti -tumor agent |
US9993554B2 (en) | 2010-10-21 | 2018-06-12 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Use of P13K Inhibitors for the Treatment of Obesity, Steatosis and ageing |
US10266539B2 (en) | 2013-07-30 | 2019-04-23 | Gilead Connecticut, Inc. | Polymorph of Syk inhibitors |
US9918939B2 (en) | 2013-07-30 | 2018-03-20 | Gilead Connecticut, Inc. | Formulation of Syk inhibitors |
US9949932B2 (en) | 2013-07-30 | 2018-04-24 | Gilead Connecticut, Inc. | Formulation of syk inhibitors |
US9657023B2 (en) | 2013-07-30 | 2017-05-23 | Gilead Connecticut, Inc. | Polymorph of Syk inhibitors |
US9382256B2 (en) | 2013-07-30 | 2016-07-05 | Gilead Connecticut, Inc. | Formulation of Syk inhibitors |
US9974792B2 (en) | 2013-12-04 | 2018-05-22 | Gilead Sciences, Inc. | Methods for treating cancers |
US9687492B2 (en) | 2013-12-04 | 2017-06-27 | Gilead Sciences, Inc. | Methods for treating cancers |
US9968601B2 (en) | 2013-12-23 | 2018-05-15 | Gilead Sciences, Inc. | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors |
US10342794B2 (en) | 2013-12-23 | 2019-07-09 | Gilead Sciences, Inc. | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors |
US10828299B2 (en) | 2013-12-23 | 2020-11-10 | Kronos Bio, Inc. | Crystalline monomesylate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine |
US9290505B2 (en) | 2013-12-23 | 2016-03-22 | Gilead Sciences, Inc. | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors |
US11517570B2 (en) | 2013-12-23 | 2022-12-06 | Kronos Bio, Inc. | Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine |
US10080756B2 (en) | 2014-07-14 | 2018-09-25 | Gilead Sciences, Inc. | Combination methods for treating cancers |
US9707236B2 (en) | 2014-07-14 | 2017-07-18 | Gilead Sciences, Inc. | Combination methods for treating cancers |
US11384082B2 (en) | 2017-08-25 | 2022-07-12 | Kronos Bio, Inc. | Hydrates of polymorphs of 6-(1H-indazol-6-YL)-N-(4-morpholinophenyl)-2,3-dihydroimidazo[1,2-A]pyrazin-8-amine bisemsylate as Syk inhibitors |
US11339168B2 (en) | 2019-02-22 | 2022-05-24 | Kronos Bio, Inc. | Crystalline forms of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as Syk inhibitors |
Also Published As
Publication number | Publication date |
---|---|
US7189723B2 (en) | 2007-03-13 |
US7160885B2 (en) | 2007-01-09 |
US20050054648A1 (en) | 2005-03-10 |
US20050054649A1 (en) | 2005-03-10 |
WO2004072081A1 (en) | 2004-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7160885B2 (en) | Certain 6, 8-(heteroaryl or aryl) disubstituted imidazo[1,2-a]pyrazines as modulators of Hsp90 complex activity | |
US7259164B2 (en) | Certain substituted imidazo[1,2-a]pyrazines, as modulators of kinase activity | |
US10214533B2 (en) | N-acyl-(3-substituted)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders | |
US7405295B2 (en) | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds | |
CA2800079C (en) | Macrocyclic compounds as trk kinase inhibitors | |
EP2989103B1 (en) | N-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptor-mediated disorders | |
AU774867B2 (en) | Heteroaryl diazabicycloalkanes, their preparation and use | |
US20050288295A1 (en) | Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof | |
US7777040B2 (en) | Certain substituted ureas, as modulators of kinase activity | |
WO2005005429A1 (en) | Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds | |
JP2008530011A (en) | Raf inhibitor compounds and methods | |
TWI828712B (en) | Heterocyclic compounds as TRK inhibitors | |
TW201418255A (en) | 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes | |
EP2969000B1 (en) | New compounds | |
Zhan et al. | Design, synthesis, and biological evaluation of novel highly selective polo-like kinase 2 inhibitors based on the tetrahydropteridin chemical scaffold | |
CN111542522B (en) | Substituted pyrazolopyrimidines useful as kinase inhibitors | |
EP3750880A1 (en) | Pyrazine-2(1h)-ketone compound acting as fgfr inhibitor | |
EP3129378A1 (en) | Bromodomain-inhibiting compounds and pharmaceutical composition comprising same for preventing or treating a cancer | |
US20210269442A1 (en) | Fused ring derivative used as fgfr4 inhibitor | |
CN114423759B (en) | Fused heteroaryl derivatives, preparation method thereof and application thereof in medicines | |
CN107793371B (en) | Bromodomain recognition protein inhibitor and preparation method and application thereof | |
KR20230044416A (en) | Determination of indolo heptamyl oxime analogs as PARP inhibitors and method for their preparation | |
KR102513564B1 (en) | An azepane inhibitor of the menin-MLL interaction | |
RU2810215C2 (en) | Erbb receptor inhibitors | |
WO2023083292A1 (en) | Salt of pyrrolidine compound, crystal form thereof, and preparation method therefor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |